medicines in development for cancer
Post on 05-Feb-2017
218 Views
Preview:
TRANSCRIPT
Few things cause more fear and apprehension than a cancer diagnosis. But today—because of early detection and a steady stream of new and improved treatments—cancer increasingly can be managed and even beaten. But patients and their families are looking for more and bet-ter treatments, and America’s biopharmaceuti-cal research companies are responding.
Biopharmaceutical researchers are now work-ing on 981 medicines for cancer. Many are high-tech weapons to fight the disease, while some involve innovative research into using existing medicines in new ways.
Researchers’ deep commitment to patients and advancing science is at the core of the remark-able progress made in fighting cancer. In re-cent years we have seen significant declines in cancer deaths. The number of cancer survivors living in the United States has increased from 3 million in 1971 to nearly 12 million in 2008. The increase in survivors is attributed in large measure to earlier diagnosis and detection and better treatments and follow-up care.
America’s biopharmaceutical research com-panies are working on many new cutting-edge
approaches to fight cancer. They include:
• A medicine that interferes with the me-tabolism of cancer cells by depriving them of the energy provided by glucose.
• A medicine for acute myeloid leukemia (AML) that inhibits cancer cells with a mutation found in about a third of AML sufferers.
• A therapy that uses nanotechnology to target the delivery of medicines to cancer cells, potentially overcoming some limita-tions of existing treatments.
Despite recent progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart disease. In 2012, some 577,190 Americans are expected to die of cancer—more than 1,500 people a day. The hundreds of new medicines to treat cancer now being developed are our best hope for lessening the burden of cancer to patients, their families and society.
More Than 900 Medicines and Vaccines in Clinical Testing Offer New Hope in the Fight Against Cancer
Medicines in Development
CanCerpresented by america’s biopharmaceutical research companies
2012 RepoRt
111
66
121117
94
Lym
phom
a
Col
orec
tal C
ance
rLu
ng C
ance
r
Pros
tate
Can
cer
Brea
st C
ance
r
67
Skin
Can
cer
Medicines in Development
for Selected Cancer Types
More Than
1.6 million New Cases of Cancer Are Expected This Year
Medicines in Development Cancer 20122
**For more information about a specific medicine in this report, please call the telephone number listed.
Lung Cancer
Liver Cancer
Leukemia
Kidney Cancer
Head/Neck Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Brain Cancer
Bladder Cancer 9
62
66
111
8
25
35
120
36
121
Multiple Myeloma
Lymphoma 117
57
Ovarian Cancer 63
Cancer-Related Conditions
Stomach Cancer
Solid Tumors
Skin Cancer
Sarcoma
Prostate Cancer
Pancreatic Cancer
94
58
21
67
280
23
38
Unspecified Cancer
Other Cancers 102
72
* Some medicines are listed in more than one category.
Medicines in Development for Cancer*
Medicines in Development for Cancer
Bladder CanCer
product Name Sponsor Indication Development Status*
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ
second-line bladder cancer (see also breast, lung, ovarian, pancreatic, skin)
Phase II(908) 673-9000
AEZS-108 AEterna ZentarisBasking Ridge, NJ
(see also ovarian, prostate, other) Phase II(908) 626-5428
BC-819 (gene therapy)
BioCancell TherapeuticsJerusalem, Israel
(see also ovarian, pancreatic) Phase IIwww.biocancell.com
EN3488(mycobacterium cell wall-DNA complex)
Endo PharmaceuticalsChadds Ford, PA
non-muscle invasive bladder cancer(Fast Track)
Phase III(610) 558-9800
Medicines in Development Cancer 2012 3
Bladder CanCe
product Name Sponsor Indication Development Status
eoquin®
apaziquoneAllerganIrvine, CASpectrum PharmaceuticalsIrvine, CA
non-invasive bladder cancer(Fast Track)
Phase III(949) 788-6700
Folotyn®
pralatrexate(orphan Drug)
Allos TherapeuticsWestminster, CO
(see also breast, lung, lymphoma) Phase II(303) 426-6262
icrucumab(LY3012212/IMC-18F1)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
(see also breast, colorectal) Phase II(800) 545-5979
tesetaxel GentaBerkeley Heights, NJ
second-line bladder cancer (see also breast, prostate, skin, stomach)
Phase II(908) 286-9800
VB4-845 Viventia BiotechnologiesMississauga, Canada
(see also head/neck) Phase II(905) 362-2973
Brain CanCer
product Name Sponsor Indication Development Status
8H9 I-131 mAb United TherapeuticsSilver Spring, MD
(see also sarcoma, other) Phase I(301) 608-9292
ABT-888(veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also breast, colorectal, lung, lymphoma, ovarian, prostate, skin, other)
Phase I(847) 937-6100
AC480(pan-HER inhibitor)
Ambit BiosciencesSan Diego, CA
glioma(see also breast, lung)
Phase I(858) 334-2100
AEE788 Novartis PharmaceuticalsEast Hanover, NJ
glioblastoma Phase I/II(888) 669-6682
afatinib(BIBW2992)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
glioblastoma(see also breast, head/neck, lung)
Phase I/II(800) 243-0127
APN301(ch14.18 mAb/interleukin-2 fusion protein)
Apeiron BiologicsVienna, Austria
neuroblastoma in children(see also skin)
Phase II completedwww.apeiron-biologics.com
Medicines in Development for Cancer
Medicines in Development Cancer 20124
Brain CanCer
product Name Sponsor Indication Development Status
AR-67 Arno TherapeuticsFlemington, NJ
glioblastoma(see also leukemia, solid tumors)
Phase II(862) 703-7170
ARC-100 Archer BiosciencesNew York, NY
glioblastoma (recurrent)(see also breast, prostate, skin)--------------------------------------------------neuroblastoma (combination therapy)--------------------------------------------------medulloblastoma (combination therapy)
Phase II(646) 747-9090-------------------------------------------Phase I/II(646) 747-9090-------------------------------------------Phase I(646) 747-9090
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
glioblastoma(see also leukemia, lung, lymphoma, prostate, stomach)
Phase II(610) 408-0301
Avastin®
bevacizumabGenentechSouth San Francisco, CA
first-line glioblastoma multiforme (see also breast, colorectal, lung, ovarian, other)
Phase III(800) 626-3553
Azedra™metaiodobenzylguanidine I-131(orphan Drug)
Molecular Insights PharmaceuticalsCambridge, MA
neuroblastoma (pediatric) (Fast Track), paraganglioma, pheochromocytoma (Fast Track)
Phase II(617) 492-5554
bafetinib CytRx Los Angeles, CA
second-line brain cancer (see also leukemia, prostate)
Phase I(310) 826-5648
BKM120(PI3K inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
glioblastoma(see also breast, lung, other)
Phase I/II(888) 669-6682
ch14.18 mAb(orphan Drug)
United TherapeuticsSilver Spring, MD
neuroblastoma (children) Phase III(301) 608-9292
cilengitide(orphan Drug)
EMD SeronoRockland, MA
newly-diagnosed glioblastoma(combination therapy)(see also prostate)
Phase III(800) 283-8088
cintredekin besudotox(orphan Drug)
INSYS TherapeuticsPhoenix, AZ
glioma (adolescents and children)(Fast Track)
Phase I(602) 910-2617
Cotara®
monoclonal antibody TNT-1 (orphan Drug)
Peregrine PharmaceuticalsTustin, CA
recurrent glioblastoma(Fast Track)
Phase II(714) 508-6000
CPP-1X(eflornithine)
Cancer Prevention PharmaceuticalsTucson, AZ
neuroblastoma Phase I(520) 908-7774
Medicines in Development for Cancer
Medicines in Development Cancer 2012 5
Brain CanCer
product Name Sponsor Indication Development Status
crenolanib (CP-868-596)
AROG PharmaceuticalsDallas, TX
glioma (adults)(see also stomach)--------------------------------------------------glioma (pediatric)
Phase II(214) 594-0002-------------------------------------------Phase I(214) 594-0002
DCVax®-Brainbrain cancer vaccine(orphan Drug)
Northwest BiotherapeuticsBethesda, MD
glioblastoma Phase II(240) 497-9024
E7050 EisaiWoodcliff Lake, NJ
second-line glioblastoma (see also head/neck, liver, skin, solid tumors, stomach)
Phase I/II(888) 422-4743
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
glioma(see also skin, other)
Phase II(888) 422-4743
EPO-806(patupilone)
Novartis PharmaceuticalsEast Hanover, NJ
brain metastases from lung cancer(see also prostate)
Phase II(888) 669-6682
G-100 prophage cancer vaccine(vitespen)(orphan Drug)
AgenusLexington, MA
newly-diagnosed glioma Phase II(781) 674-4400
G-200 prophage cancer vaccine(vitespen)(orphan Drug)
AgenusLexington, MA
recurrent glioma Phase II(781) 674-4400
GliAtak™gene therapy(orphan Drug)
AdvantageneAuburndale, MA
glioma
--------------------------------------------------brain cancer (children)
Phase II(617) 916-5445-------------------------------------------Phase I(617) 916-5445
GMB-Vaxdendritic cell cancer vaccine
Activartis BiotechVienna, Austria
first-line glioblastoma Phase IIwww.activartis.com
GRN1005(LRP directed peptide-drugconjugate)
GeronMenlo Park, CA
brain metastases
--------------------------------------------------glioma
Phase II(650) 473-7700-------------------------------------------Phase I completed(650) 473-7700
GSK2118436(BRaf protein kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
brain metastases from melanoma(see also lung, skin)
Phase II(888) 825-5249
Hycamtin®
topotecanGlaxoSmithKlineRsch. Triangle Park, NC
metastatic brain cancer Phase III(888) 825-5249
Medicines in Development for Cancer
Medicines in Development Cancer 20126
Medicines in Development for Cancer
Brain CanCer
product Name Sponsor Indication Development Status
ICT-107(dendritic cell vaccine)(orphan Drug)
ImmunoCellular TherapeuticsWoodland Hills, CA
glioblastoma Phase II(818) 992-2907
Levulan® pDtaminolevulinic acid
DUSA PharmaceuticalsWilmington, MA
Phase II(978) 657-7500
lonafarnib MerckWhitehouse Station, NJ
glioblastoma Phase I(800) 672-6372
Lucanix®
belagenpumatucel-LNovaRxSan Diego, CA
glioma(see also lung)
Phase I(858) 522-8600
macitentan Actelion Pharmaceuticals USSouth San Francisco, CA
glioblastoma (combination therapy) Phase I(650) 624-6900
MEDI-575(anti-PDGFR-alpha mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
glioblastoma(see also lung)
Phase II(800) 236-9933(301) 398-0000
mibefradil(T-type calcium channel inhibitor)(orphan Drug)
Tau TherapeuticsCharlottesville, VA
glioblastoma Phase I(434) 974-6969
motexafin gadolinium PharmacyclicsSunnyvale, CA
glioblastoma (combination therapy) Phase II(408) 774-0330
nimotuzumab(orphan Drug)
YM Biosciences USALehigh Valley, PA
metastatic brain cancer, recurrent glioma (pediatric)(see also breast, prostate)
Phase II(610) 560-0600
olaratumab(LY3012207)
Eli LillyIndianapolis, INImClone SystemsBridgewater, NJ
glioblastoma(see also ovarian)
Phase II(800) 545-5979
opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
glioma, glioblastoma(see also lung, ovarian, stomach, other)
Phase II(800) 215-2355
perifosine AEterna ZentarisBasking Ridge, NJ
refractory metastatic glioma(see also colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Phase II(908) 626-5428
Medicines in Development Cancer 2012 7
Medicines in Development for Cancer
Brain CanCer
product Name Sponsor Indication Development Status
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
recurrent glioblastoma(see also leukemia, lymphoma, solid tumors)
Phase II(510) 647-4000
Poly-ICLC(orphan Drug)
OncovirWashington, DC
anaplastic astrocytoma (adolescents and children), glioblastoma (adolescents and children)
Phase IIwww.oncovir.com
PX-866 OncothyreonSeattle, WA
second-line glioblastoma (see also head/neck, lung, prostate)
Phase II(206) 801-2100
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
glioma(see also colorectal, head/neck, lung, ovarian, pancreatic, sarcoma,skin, solid tumors)
Phase I/II(403) 670-7377
rindopepimut(orphan Drug)
Celldex TherapeuticsNeedham, MA
first-line glioblastoma (Fast Track)--------------------------------------------------second-line glioblastoma (Fast Track)
Phase III(781) 433-0771-------------------------------------------Phase II(781) 433-0771
SB-313-xTZ Sangamo BiosciencesRichmond, CA
glioblastoma Phase I(510) 970-6000
SBG Biotec PharmaconTromsø, Norway
neuroblastoma (pediatric) Phase I/II completedwww.biotec.no
SL-701(brain cancer vaccine)
Stemline TherapeuticsNew York, NY
glioma (adults)
--------------------------------------------------glioma (children)
Phase I/II(212) 831-1111-------------------------------------------Phase I/II(212) 831-1111
SpRYCeL®
dasatinibBristol-Myers SquibbPrinceton, NJ
glioblastoma(see also breast, pancreatic, prostate, other)
in clinical trials(800) 332-2056
tarceva®
erlotinib(orphan Drug)
GenentechSouth San Francisco, CAOSI PharmaceuticalsFarmingdale, NY
late-stage brain metastases, recurrent ependymoma (children), glioblastoma(see also breast, head/neck, leukemia, liver, lung, other)
Phase II(800) 626-3553(631) 962-0600
terameprocol Erimos PharmaceuticalsHouston, TX
glioma (intravenous)(see also cervical, head/neck, solid tumors, other)
Phase I/II(713) 541-2000
TGF-ß R1 inhibitor(LY2157299)
Eli LillyIndianapolis, IN
(see also liver) Phase II(800) 545-5979
Medicines in Development Cancer 20128
Brain CanCer
product Name Sponsor Indication Development Status
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
astrocytoma(see also leukemia, multiple myeloma, pancreatic, sarcoma)
Phase II(650) 474-8200
Toca 511/Toca FC(cytosine deaminase gene therapy)
TocagenSan Diego, CA
glioblastoma Phase I/II(858) 412-8400
trans-sodium crocetinate (TSC)(orphan Drug)
Diffusion PharmaceuticalsCharlottesville, VA
gliobastoma Phase I/II(434) 220-0718
TVI-Brain-1(cellular immunotherapyvaccine)
TVAX BiomedicalLenexa, KS
glioma Phase II(913) 492-2221
VAL-083 Del Mar PharmaceuticalsVancouver, Canada
grade IV malignant glioma Phase I/II(604) 629-5989
VB-111 VBL TherapeuticsOr Yehuda, Israel
glioblastoma(see also other)
Phase I/IIwww.vblrx.com
Xeloda®
capecitabineGenentechSouth San Francisco, CA
newly-diagnosed glioma (adolescents and children)(see also colorectal, liver, stomach)
Phase I(800) 626-3553
Zelboraf®vemurafenib
GenentechSouth San Francisco, CAPlexxikonBerkeley, CA
brain metastases(see also colorectal, other)
Phase II(800) 626-3553
Breast CanCer
product Name Sponsor Indication Development Status
18F-fluorothymidine MerckWhitehouse Station, NJ
breast cancer (diagnosis) Phase II(800) 672-6372
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ
first-line metastatic breast cancer(see also bladder, lung, ovarian,pancreatic, skin)
Phase II(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, colorectal, lung, lymphoma, ovarian, prostate, skin, other)
Phase II(847) 937-6100
AC480(pan-HER inhibitor)
Ambit BiosciencesSan Diego, CA
(see also brain, lung) Phase I(858) 334-2100
Medicines in Development for Cancer
Medicines in Development Cancer 2012 9
Breast CanCer
product Name Sponsor Indication Development Status
acolbifene(4th-generation SERM)
EndoCeuticsQuebec, Canada
Phase II(418) 653-0033
AE37 peptide vaccine Antigen ExpressWorcester, MA
(see also ovarian) Phase II(508) 852-8783
afatinib(BIBW2992)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
second-line metastatic breast cancer(see also brain, head/neck, lung)--------------------------------------------------first-line breast cancer
Phase III(800) 243-0127-------------------------------------------Phase II(800) 243-0127
afimoxifene ASCEND TherapeuticsHerndon, VA
breast cancer (prevention) Phase II(703) 471-4744
Afinitor®
everolimusNovartis PharmaceuticalsEast Hanover, NJ
HER2-positive breast cancer(see also kidney, lymphoma)
Phase III(888) 669-6682
AFP464 KiraxBonita Springs, FL
Phase II(239) 444-5400
amrubicin CelgeneSummit, NJ
late-stage breast cancer (see also lung)
Phase I/II(908) 673-9000
ARC-100 Archer BiosciencesNew York, NY
(see also brain, prostate, skin) Phase II(646) 747-9090
ARRY-380(HER2 inhibitor)
Array BioPharmaBoulder, CO
Phase I(877) 633-2436
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
breast cancer (monotherapy)(see also colorectal, lung, multiple myeloma, stomach)--------------------------------------------------breast cancer (combination therapy)
Phase II(888) 669-6682
-------------------------------------------Phase I/II(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 201210
Breast CanCer
product Name Sponsor Indication Development Status
Avastin®
bevacizumabGenentechSouth San Francisco, CA
adjuvant HER2-negative breast can-cer, adjuvant HER2-positive breast cancer, adjuvant triple negative breast cancer(see also brain, colorectal, lung, ovarian, other)
Phase III(800) 626-3553
AZD8931(erbB kinase inhibitor)
AstraZenecaWilmington, DE
advanced breast cancer (combination therapy)(see also solid tumors)
Phase II(800) 236-9933
BAY 86-5044 (lonaprisan)
Bayer HealthCare PharmaceuticalsWayne, NJ
metastatic breast cancer Phase II completed(888) 842-2937
BIIB 2024 Biogen IdecCambridge, MA
(see also stomach) Phase II completed(617) 679-2000
BKM120(PI3K inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
second-line breast cancer(see also brain, lung, other)
Phase I/II(888) 669-6682
breast cancer vaccine (dendritic cell vaccine)
Quantum ImmunologicsTampa, FL
Phase I/II(866) 213-4594
brostallicin Cell TherapeuticsSeattle, WA
triple-negative breast cancer Phase I(800) 215-2355
BTSCAN Molecular Targeting TechnologiesWest Chester, PA
breast cancer (diagnosis) Phase I(610) 738-7938
BZL-101 BionovoEmeryville, CA
Phase I(510) 601-2000
cabozantinib(XL184)
ExelixisSouth San Francisco, CA
(see also kidney, lung, ovarian, prostate, other)
Phase II(650) 837-7000
cancer vaccine MabVax TherapeuticsSan Diego, CA
(see also sarcoma) Phase I(858) 259-9405
CDX-011(glembatumumab vedotin)
Celldex TherapeuticsNeedham, MA
breast cancer (Fast Track)(see also skin)
Phase II(781) 433-0771
CV-301(cancer vaccine)
BN ImmunoTherapeuticsMountain View, CA
metastatic breast cancer Phase II(650) 681-4660
D-1MT NewLink GeneticsAmes, IA
second-line metastatic breast cancer(see also solid tumors)
Phase I/II(515) 296-5555
Medicines in Development for Cancer
Medicines in Development Cancer 2012 11
Breast CanCer
product Name Sponsor Indication Development Status
dalotuzumab(MK-0646)
MerckWhitehouse Station, NJ
second-line breast cancer (combination therapy)(see also lung, pancreatic, other)--------------------------------------------------first-line breast cancer
Phase II(800) 672-6372
-------------------------------------------Phase I(800) 672-6372
DPX-0907 ImmunovaccineHalifax, Canada
(see also ovarian, prostate) Phase I(902) 492-1819
eniluracil Adherex TechnologiesRsch. Triangle Park, NC
metastatic breast cancer(combination therapy)
Phase II(919) 636-4530
entinostat Syndax PharmaceuticalsWaltham, MA
(see also colorectal, kidney, leukemia, lung, lymphoma)
Phase II(781) 419-1400
etirinotecan pegol (NKTR-102)
Nektar TherapeuticsSan Francisco, CA
metastatic breast cancer(see also colorectal, ovarian, solid tumors)
Phase III(855) 482-6587
EZN-2208(PEG-SN38, firtecan pegol)
Enzon PharmaceuticalsPiscataway, NJ
metastatic breast cancer(see also colorectal, solid tumors)
Phase II(973) 980-4500
Faslodex®
fulvestrantAstraZenecaWilmington, DE
first-line advanced breast cancer Phase III(800) 236-9933
folate binding protein (E39) vaccine
Galena BiopharmaLake Oswego, OR
(see also ovarian, other) Phase I(855) 855-4253
Folotyn®pralatrexate
Allos TherapeuticsWestminster, CO
(see also bladder, lung, lymphoma) Phase II(303) 426-6262
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
(see also colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach)
Phase II(781) 274-8200
ganitumab(AMG 479)
AmgenThousand Oaks, CA
combination therapy(see also colorectal, lung, pancreatic, sarcoma)
Phase II(800) 772-6436
GDC-0980(PI3 kinase/mTOR dual inhibitor)
GenentechSouth San Francisco, CA
hormone receptor-positive breast cancer(see also lymphoma, solid tumors)
Phase II(800) 626-3553
GSK2302024A(WT1 antigen-specific cancerimmunotherapeutic)
GlaxoSmithKlineRsch. Triangle Park, NC
neoadjuvant breast cancer Phase I/II(888) 825-5249
GVAX® Breastcancer vaccine
BioSante PharmaceuticalsLincolnshire, IL
Phase I(847) 478-0500
Medicines in Development for Cancer
Medicines in Development Cancer 201212
Breast CanCer
product Name Sponsor Indication Development Status
HER2 antigen-specific cancerimmunotherapeutic
GlaxoSmithKlineRsch. Triangle Park, NC
Phase II(888) 825-5249
icrucumab(LY3012212/IMC-18F1)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
metastatic breast cancer(see also bladder, colorectal)
Phase II(800) 545-5979
imetelstat GeronMenlo Park, CA
metastatic breast cancer(combination therapy)(see also leukemia, lung, multiple myeloma)
Phase II(650) 473-7700
IMT-1012 immunotherapeuticvaccine
ImmunotopeDoylestown, PA
(see also ovarian) Phase I(215) 253-4180
indibulin(ZIO-301)
ZIOPHARM OncologyNew York, NY
late-stage breast cancer Phase I/II(646) 214-0700
iniparib(BSI-201)
Sanofi USBridgewater, NJ
neoadjuvant breast cancer(see also lung, ovarian)
Phase II(800) 981-2491
KW-2450 Kyowa Hakko Kirin PharmaPrinceton, NJ
first-line breast cancer, second-line breast cancer
Phase I/II(609) 919-1100
LFA102(anti-prolactin receptor anti-body)
Novartis PharmaceuticalsEast Hanover, NJXOMABerkeley, CA
(see also prostate) Phase I(888) 669-6682
LGK974(WNT signaling pathway inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also skin) Phase I(888) 669-6682
linifanib Abbott LaboratoriesAbbott Park, IL
breast cancer (combination therapy)(see also colorectal, kidney, liver, lung)
Phase II(847) 937-6100
liposome encapsulated paclitaxel (LEP-ETU)
Insys TherapeuticsPhoenix, AZ
Phase II(602) 910-2617
litronesib(LY2523355)
Eli LillyIndianapolis, IN
metastatic breast cancer(see also lung)
Phase II(800) 545-5979
LOR-2040 Lorus TherapeuticsToronto, Canada
metastatic breast cancer(see also colorectal, kidney, leukemia, prostate)
Phase II(416) 798-1200
Lymphoseek®
Tc-99m tilmanoceptNavidea PharmaceuticalsDublin, OH
breast cancer (diagnosis)(see also head/neck, skin)
application submitted(614) 793-7500
Medicines in Development for Cancer
Medicines in Development Cancer 2012 13
Breast CanCer
product Name Sponsor Indication Development Status
maraciclatide GE HealthcareWaukesha, WI
breast cancer (diagnosis) in clinical trialswww.gehealthcare.com
MK-0752(notch signaling pathway inhibitor)
MerckWhitehouse Station, NJ
early-stage breast cancer, late-stage breast cancer(see also other)
Phase I(800) 672-6372
MK-2206(c-akt inhibitor)
MerckWhitehouse Station, NJ
HER2-positive breast cancer(see also other)
Phase I(800) 672-6372
MM-111 Merrimack PharmaceuticalsCambridge, MA
breast cancer (combination therapy) Phase I/II(617) 441-1000
MM-302(anti-HER2 antibody doxorubicin conjugate)
Merrimack PharmaceuticalsCambridge, MA
Phase I(617) 441-1000
motesanib AmgenThousand Oaks, CA
(see also colorectal, lung, other) Phase I/II(800) 772-6436
MVA-BN® HeR2(HER-2/neu-based MVA vaccine)
BN ImmunoTherapeuticsMountain View, CA
Phase I(650) 681-4660
Myocet™doxorubicin liposomal
Sopherion TherapeuticsPrinceton, NJ
first-line breast cancer (combination therapy) (Fast Track)
Phase III(609) 986-2020
NeuVax™cancer vaccine E75
Galena BiopharmaLake Oswego, OR
early-stage breast cancer(prevention of relapse)(see also prostate)
Phase III(855) 855-4253
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
(see also colorectal, head/neck, kidney, leukemia, liver, lung, multiple myeloma, ovarian, other)
Phase III(888) 842-2937
nimotuzumab YM Biosciences USALehigh Valley, PA
(see also brain, prostate) Phase I(610) 560-0600
NK-012 Nippon KayakuTokyo, Japan
(see also lung) Phase IIwww.nipponkayaku.co.jp
OBP-301 Oncolys BiopharmaTokyo, Japan
(see also head/neck, liver, lung) Phase Iwww.oncolys.com
OGX-427 OncoGenex PharmaceuticalsBothell, WA
(see also lung, ovarian) Phase I(425) 686-1500
Medicines in Development for Cancer
Medicines in Development Cancer 201214
Breast CanCer
product Name Sponsor Indication Development Status
onartuzumab GenentechSouth San Francisco, CA
metastatic breast cancer (combination therapy)(see also colorectal, lung)
Phase II(800) 626-3553
OPT-822/OPT-821 Optimer BiotechnologySan Diego, CA
Phase II/III(858) 909-0736
PB-272 (neratinib) Puma BiotechnologyLos Angeles, CA
second-line breast cancer, neoadjuvant breast cancer
Phase II(424) 248-6500
pertuzumab GenentechSouth San Francisco, CA
first-line metastatic breast cancer
--------------------------------------------------second-line late-stage breast cancer
application submitted(800) 626-3553-------------------------------------------Phase II(800) 626-3553
pertuzumab companion diagnostic(HER2 FISH pharmDx™)
DakoGlostrup, DenmarkGenentechSouth San Francisco, CA
breast cancer (diagnostic) Phase IIIwww.dako.com(800) 626-3553
pertuzumab companiondiagnostic(HercepTest™)
DakoGlostrup, DenmarkGenentechSouth San Francisco, CA
breast cancer (diagnosis) Phase IIIwww.dako.com(800) 626-3553
pixantrone Cell TherapeuticsSeattle, WA
breast cancer (Fast Track)(see also lymphoma)
Phase II(800) 215-2355
PTC299 PTC TherapeuticsSouth Plainfield, NJ
(see also solid tumors, other) Phase I/II(908) 222-7000
Quinamed®
amonafideCephalonFrazer, PA
(see also ovarian, prostate) Phase II(610) 344-0200
ramucirumab(IMC-1121B)
Eli LillyIndianapolis, INImClone SystemsBridgewater, NJ
metastatic breast cancer(see also colorectal, stomach)
Phase III(800) 545-5979
Reximmune-C®
personalized cancer vaccineEpeius BiotechnologiesSan Marino, CA
Phase I/II(626) 441-6695
Rexin-G® Epeius BiotechnologiesSan Marino, CA
metastatic breast cancer(see also pancreatic, sarcoma)
Phase I/II(626) 441-6695
Medicines in Development for Cancer
Medicines in Development Cancer 2012 15
Breast CanCer
product Name Sponsor Indication Development Status
ridaforolimus ARIAD PharmaceuticalsCambridge, MAMerckWhitehouse Station, NJ
metastatic breast cancer(see also kidney, lung, prostate, sarcoma, other)
Phase II(800) 672-6372
rucaparib Clovis OncologyBoulder, CO
(see also ovarian) Phase II(303) 625-5000
sagopilone Bayer HealthCare PharmaceuticalsWayne, NJ
(see also ovarian, prostate) Phase II completed(888) 842-2937
samarium SM-153 lexidronaminjection
EUSA PharmaLanghorne, PA
(see also multiple myeloma, prostate, sarcoma, other)
Phase II(800) 833-3533
SAR245408 (XL147)(oral PI3K inhibitor)
Sanofi USBridgewater, NJExelixis South San Francisco, CA
(see also other) Phase II(800) 981-2491(650) 837-7000
SAR245409 (XL765)(PI3K/mTOR inhibitor)
Sanofi USBridgewater, NJExelixis South San Francisco, CA
(see also lymphoma) Phase II(800) 981-2491(650) 837-7000
SAR256212 (MM-121)(anti-ErbB3 mAb)
Merrimack PharmaceuticalsCambridge, MASanofi USBridgewater, NJ
(see also lung, ovarian) Phase II(800) 981-2491
SF1 (sonodynamic therapy) SonneMedBoston, MA
advanced breast cancer Phase I/IIwww.sonnemed.com
SpRYCeL®
dasatinibBristol-Myers SquibbPrinceton, NJ
(see also brain, pancreatic, prostate, other)
in clinical trials(800) 332-2056
SR 16234 SRI InternationalMenlo Park, CA
Phase II(650) 859-2000
tarceva®
erlotinibGenentechSouth San Francisco, CAOSI PharmaceuticalsFarmingdale, NY
(see also brain, head/neck, leukemia, liver, lung, other)
Phase II(800) 626-3553(631) 962-0600
tesetaxel GentaBerkeley Heights, NJ
first-line breast cancer (see also bladder, prostate, skin, stomach)
Phase II(908) 286-9800
Medicines in Development for Cancer
Medicines in Development Cancer 201216
Breast CanCer
product Name Sponsor Indication Development Status
thermoDox®
doxorubicin liposomalCelsionLawrenceville, NJ
recurrent breast cancer(see also colorectal, liver)
Phase I/II(609) 896-9100
tigatuzumab(anti-DR5 antibody)
Daiichi SankyoParsippany, NJ
(see also colorectal, liver, lymphoma, ovarian, pancreatic)
Phase II(973) 944-2600
tivozanib(ASP4130/AV-951)
Astellas Pharma USDeerfield, ILAVEO PharmaceuticalsCambridge, MA
breast cancer (combination therapy)(see also colorectal, kidney)
Phase I/II(800) 695-4321(617) 299-5000
TKI258(dovitinib)
Novartis PharmaceuticalsEast Hanover, NJ
metastatic breast cancer(see also kidney, multiple myeloma, prostate, skin, other)
Phase II(888) 669-6682
trabectedin Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
metastatic breast cancer (see also ovarian, prostate, sarcoma)
Phase III(800) 817-5286
trastuzumab-DM1(RG3502)
GenentechSouth San Francisco, CA
Phase III(800) 626-3553
trastuzumab-DM1 companion diagnostic(HercepTest™)
DakoGlostrup, DenmarkGenentechSouth San Francisco, CA
breast cancer (diagnosis) Phase IIIwww.dako.com(800) 626-3553
trastuzumab-DM1 companion diagnostic(HER2 FISH pharmDx™)
DakoGlostrup, DenmarkGenentechSouth San Francisco, CA
breast cancer (diagnosis) Phase IIIwww.dako.com(800) 626-3553
TRC 105(ENG protein inhibitor)
TRACON PharmaceuticalsSan Diego, CA
(see also ovarian, prostate, other) Phase I/II(858) 550-0780
trebananib (AMG386)
AmgenThousand Oaks, CA
(see also colorectal, kidney, liver, ovarian, stomach, other)
Phase II(800) 772-6436
tykerb®
lapatinibGlaxoSmithKlineRsch. Triangle Park, NC
inflammatory breast cancer (see also colorectal, head/neck, stomach)--------------------------------------------------adjuvant breast cancer, first-line metastatic breast cancer--------------------------------------------------neoadjuvant breast cancer
application submitted(888) 825-5249
-------------------------------------------Phase III(888) 825-5249-------------------------------------------Phase II(888) 825-5249
upamostat (WX-671)
WilexMunich, Germany
Phase IIwww.wilex.de
Medicines in Development for Cancer
Medicines in Development Cancer 2012 17
Breast CanCer
product Name Sponsor Indication Development Status
varlitinib ASLAN PharmaceuticalsSingapore
Phase IIwww.aslanpharma.com
VeriStrat®companion diagnostic testEGFR-TKI
BiodesixBoulder, CO
advanced breast cancer (diagnosis-outcome test in HER2-overexpressing tumors)
Phase III(303) 417-0500
YM155(sepantronium)
Astellas Pharma USDeerfield, IL
(see also lymphoma) Phase II(800) 695-4321
Zolinza®
vorinostatMerckWhitehouse Station, NJ
(see also leukemia, lung, lymphoma, multiple myeloma, other)
Phase II(800) 672-6273
Zytiga®
abirateroneJanssen BiotechHorsham, PA
second-line metastatic breast cancer(see also prostate)
Phase II(800) 526-7736
CerviCal CanCer
product Name Sponsor Indication Development Status
ADXS-HPV AdvaxisPrinceton, NJ
cervical cancer, cervical intraepithelial neoplasia
Phase II(609) 452-9813
PM-00104 PharmaMarMadrid, Spain
(see also sarcoma, other) Phase IIwww.pharmamar.com
PV701(replication-competent oncolytic virus)
Wellstat BiologicsGaithersburg, MD
(see also colorectal) Phase II(240) 683-2500
terameprocol Erimos PharmaceuticalsHouston, TX
cervical intraepithelial neoplasia (intravaginal)(see also brain, head/neck, solid tumors, other)
Phase II(713) 541-2000
V503(HPV virus-like particle (VLP) vaccine)
MerckWhitehouse Station, NJ
prevention of cervical cancer, prevention of vulvovaginal cancer
Phase III(800) 672-6372
V505(HPV vaccine)
MerckWhitehouse Station, NJ
prevention of cervical cancer Phase II completed(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 201218
CerviCal CanCer
product Name Sponsor Indication Development Status
verpasep caltespen(cancer vaccine)
Akela PharmaAustin, TX
cervical intraepithelial neoplasia Phase I completed(512) 834-0449
VGX-3100(DNA cancer vaccine)
Inovio PharmaceuticalsBlue Bell, PA
cervical intraepithelial neoplasia Phase II(877) 446-6846
ColoreCtal CanCer
product Name Sponsor Indication Development Status
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, lung, lymphoma, ovarian, prostate, skin, other)
Phase II(847) 937-6100
Aptocine™talaporfin
Light Sciences OncologyBellevue, WA
metastatic colorectal cancer Phase III(425) 957-8900
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
second-line colorectal cancer (combination therapy)(see also breast, lung, multiplemyeloma, stomach)
Phase I(888) 669-6682
Avastin®
bevacizumabGenentechSouth San Francisco, CA
metastatic colorectal cancer (treatment beyond progression) (see also brain, breast, lung, ovarian, other)
Phase III(800) 626-3553
AVX701(CEA cancer immunotherapy)
AlphaVaxRsch. Triangle Park, NC
colorectal cancer prevention in patients with advanced or metastatic CEA-expressing malignancies
Phase I/II(919) 595-0400
belinostat Spectrum PharmaceuticalsHenderson, NV
colorectal cancer (combination therapy)(see also leukemia, liver, lung, lymphoma, ovarian, other)
Phase I/II(702) 835-6300
brivanib(VEGFR/FGFR kinase inhibitor)
Bristol-Myers SquibbPrinceton, NJ
metastatic colorectal cancer(see also liver, sarcoma)
Phase II(800) 332-2056
CPX-1(irinotecan/floxuridine)
Celator PharmaceuticalsPrinceton, NJ
Phase II completed(609) 243-0123
CT-011 CureTechYavne, Israel
first-line metastatic colorectal cancer (combination therapy)(see also leukemia, lymphoma)
Phase IIwww.curetechbio.com
E7820 EisaiWoodcliff Lake, NJ
Phase II(888) 422-4743
Medicines in Development for Cancer
Medicines in Development Cancer 2012 19
ColoreCtal CanCer
product Name Sponsor Indication Development Status
efatutazone Daiichi SankyoParsippany, NJ
metastatic colorectal cancer(see also lung, other)
Phase II(973) 944-2600
EGEN-001 EGENHuntsville, AL
(see also ovarian, other) Phase I/II(256) 512-0077
EGFR antagonist companion diagnostic
QIAGENValencia, CA
colorectal cancer (diagnosis) application submittedwww.qiagen.com
encapsulated cell therapy(macrobeads)
Rogosin InstituteNew York, NY
refractory metastatic colorectal cancer(see also pancreatic, prostate)
Phase II(212) 746-1566
entinostat Syndax PharmaceuticalsWaltham, MA
metastatic colorectal cancer(combination therapy)(see also breast, kidney, leukemia, lung, lymphoma)
Phase II(781) 419-1400
eRBItUX®
cetuximabBristol-Myers SquibbPrinceton, NJEli LillyIndianapolis, IN
first-line colorectal cancer(see also stomach)
in clinical trials(800) 332-2056(800) 545-5979
etirinotecan pegol(NKTR-102)
Nektar TherapeuticsSan Francisco, CA
second-line colorectal cancer(see also breast, ovarian, solid tumors)
Phase II/III(855) 482-6587
EZN-2208(PEG-SN38, firtecan pegol)
Enzon PharmaceuticalsPiscataway, NJ
metastatic colorectal cancer(see also breast, solid tumors)
Phase II(973) 980-4500
FANG™ Vaccineautologous tumor cell vaccine
GradalisCarrollton, TX
(see also ovarian, skin) Phase II(214) 442-8100
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
refractory, metastatic colorectal cancer(see also breast, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach)
Phase II(781) 274-8200
ganitumab(AMG 479)
AmgenThousand Oaks, CA
second-line metastatic colorectal cancer (combination therapy)(see also breast, lung, pancreatic, sarcoma)
Phase II(800) 772-6436
GI-4000(cancer vaccine)
GlobeImmuneLouisville, CO
(see also lung, pancreatic) Phase II(303) 625-2700
Medicines in Development for Cancer
Medicines in Development Cancer 201220
ColoreCtal CanCer
product Name Sponsor Indication Development Status
GM-CT-01 Galectin TherapeuticsNewton, MA
colorectal cancer (combination therapy)
Phase II(617) 559-0033
GS-6624(monoclonal antibody)
Gilead SciencesFoster City, CA
(see also pancreatic) Phase II(800) 445-3235
GVAX® Colorectalcancer vaccine
BioSante PharmaceuticalsLincolnshire, IL
Phase I(847) 478-0500
icrucumab(LY3012212/IMC-18F1)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
(see also bladder, breast) Phase II(800) 545-5979
IMO-2055(TLR9 agonist)
Idera PharmaceuticalsCambridge, MA
(see also head/neck, lung) Phase I(617) 679-5000
Imprime pGG® BiotheraEagan, MN
(see also leukemia, lung, skin) Phase III(651) 675-0300
JX-594 (pexastimogene devacirepvec)
Jennerex BiotherapeuticsSan Francisco, CA
(see also liver) Phase I/II(415) 281-8886
KRN-330 Kyowa Hakko Kirin PharmaPrinceton, NJ
colorectal cancer (combination therapy)--------------------------------------------------colorectal cancer (monotherapy)
Phase I/II(609) 919-1100-------------------------------------------Phase I(609) 919-1100
labetuzumab I-131(IMMU-111)
ImmunomedicsMorris Plains, NJ
Phase II(973) 605-8200
labetuzumab-SN-38(IMMU-130)
ImmunomedicsMorris Plains, NJ
Phase I(973) 605-8200
LGX818(RAF inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
metastatic colorectal cancer(see also skin)
Phase I(888) 669-6682
linifanib Abbott LaboratoriesAbbott Park, IL
second-line colorectal cancer(see also breast, kidney, liver, lung)
Phase II(847) 937-6100
LOR-2040 Lorus TherapeuticsToronto, Canada
metastatic colorectal cancer(see also breast, kidney, leukemia, prostate)
Phase II(416) 798-1200
motesanib AmgenThousand Oaks, CA
(see also breast, lung, other) Phase I(800) 772-6436
Medicines in Development for Cancer
Medicines in Development Cancer 2012 21
ColoreCtal CanCer
product Name Sponsor Indication Development Status
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
metastatic colorectal cancer (see also breast, head/neck, kidney, leukemia, liver, lung, multiple myeloma, ovarian, other)
Phase II(888) 842-2937
NPC-1C(ensituximab)
Neogenix OncologyRockville, MD
metastatic colorectal cancer(see also pancreatic)
Phase I(301) 917-6893
onartuzumab GenentechSouth San Francisco, CA
(see also breast, lung) Phase II(800) 626-3553
oncoVAX®
active specific immunotherapyVaccinogenFrederick, MD
(Fast Track) Phase I/II(301) 668-8400
perifosine AEterna ZentarisBasking Ridge, NJ
refractory metastatic colorectal cancer (combination therapy)(Fast Track)(see also brain, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Phase III(908) 626-5428
PHY906 PhytoCeuticaNew Haven, CT
(see also liver, pancreatic, cancer-related)
Phase I/II(203) 777-3462
picoplatin Ponaird PharmaceuticalsSeattle, WA
(see also lung, ovarian, prostate) Phase II(206) 281-7001
polyclonal antibody stimulator Cancer AdvancesDurham, NC
(see also pancreatic, stomach) Phase II(919) 361-2162
PV701(replication-competent oncolytic virus)
Wellstat BiologicsGaithersburg, MD
(see also cervical) Phase II(240) 683-2500
ramucirumab(IMC-1121B)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
(see also breast, stomach) Phase III(800) 545-5979
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
metastatic colorectal cancer (Fast Track)(see also kidney, lung, solid tumors, stomach)
Phase III(888) 842-2837
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
(see also brain, head/neck, lung, ovarian, pancreatic, sarcoma,skin, solid tumors)
Phase I(403) 670-7377
Medicines in Development for Cancer
Medicines in Development Cancer 201222
ColoreCtal CanCer
product Name Sponsor Indication Development Status
RG7160(EGFR inhibitor)
RocheNutley, NJ
second-line metastatic colorectal cancer (combination therapy)
Phase II(973) 235-5000
RG7414(EGFL7 inhibitor)
GenentechSouth San Francisco, CA
(see also lung) Phase II(800) 626-3553
RIGScan™tumor-specific, radio-labeled monoclonal antibody targeting agent
Navidea BiopharmaceuticalsDublin, OH
metastatic colorectal cancer (diagnosis)
application submitted(800) 793-0079
robatumumab MerckWhitehouse Station, NJ
(see also sarcoma, solid tumors) Phase II completed(800) 672-6372
Sym004 SymphogenLyngby, Denmark
metastatic colorectal cancer Phase IIwww.symphogen.com
TAS-102 Taiho Pharma U.S.A.Princeton, NJ
Phase I(609) 750-5300
telatinib ACT BiotechSan Francisco, CA
(see also stomach) Phase I(415) 230-3900
TF2(pretargeted radioimmuno-therapy)
ImmunomedicsMorris Plains, NJ
colorectal cancer Phase I(973) 605-8200
thermoDox®
doxorubicin liposomalCelsionLawrenceville, NJ
adjuvant inoperable/unresectable, metastatic colorectal cancer(see also breast, liver)
Phase II(609) 896-9100
tigatuzumab(anti-DR5 antibody)
Daiichi SankyoParsippany, NJ
(see also breast, liver, lymphoma, ovarian, pancreatic)
Phase I(973) 944-2600
tivantinib (ARQ 197)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
(see also kidney, liver, lung, pancreatic, sarcoma, other)
Phase I/II(781) 994-0300(973) 944-2600
tivozanib(ASP4130/AV-951)
Astellas Pharma USDeerfield, ILAVEO PharmaceuticalsCambridge, MA
colorectal cancer (combination therapy)(see also breast, kidney)
Phase II(800) 695-4321(617) 299-5000
trebananib (AMG386)
AmgenThousand Oaks, CA
(see also breast, kidney, liver, ovarian, stomach, other)
Phase II(800) 772-6436
tykerb®
lapatinibGlaxoSmithKlineRsch. Triangle Park, NC
metastatic colorectal cancer(see also breast, head/neck, stomach)
Phase II(888) 825-5249
Medicines in Development for Cancer
Medicines in Development Cancer 2012 23
ColoreCtal CanCer
product Name Sponsor Indication Development Status
Vectibix®
panitumumabAmgenThousand Oaks, CA
first-line and second-line colorectal cancer (see also head/neck)
application submitted(800) 772-6436
Xeloda®
capecitabineGenentechSouth San Francisco, CA
first-line and second-line metastatic colorectal cancer (combination therapy)(see also brain, liver, stomach)
application submitted(800) 626-3553
Zaltrap™aflibercept
Regeneron PharmaceuticalsTarrytown, NYSanofi USBridgewater, NJ
second-line metastatic colorectal cancer(see also prostate)
application submitted(914) 345-7400(800) 981-2491
Zelboraf®vemurafenib
GenentechSouth San Francisco, CAPlexxikonBerkeley, CA
(see also brain, other) Phase I(800) 626-3553
Head/neCk CanCer
product Name Sponsor Indication Development Status
ACE-041(dalantercept)
Acceleron PharmaCambridge, MA
(see also multiple myeloma) Phase II(617) 649-9200
afatinib(BIBW2992)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
second-line head/neck cancer(see also breast, brain, lung)
Phase II(800) 243-0127
AP5346 Access PharmaceuticalsDallas, TX
Phase II(214) 905-5100
E7050 EisaiWoodcliff Lake, NJ
(see also brain, liver, skin, solid tumors, stomach)
Phase I/II(888) 422-4743
foretinib(GSK1363089)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also kidney, liver, lung) Phase II completed(888) 825-5249
GL-0810(orphan Drug)
GliknikBaltimore, MD
Phase Iwww.gliknik.com
GL-0817(orphan Drug)
GliknikBaltimore, MD
(see also multiple myeloma) Phase Iwww.gliknik.com
HF-10 Takara BioShiga, Japan
Phase Iwww.takara-bio.com
Medicines in Development for Cancer
Medicines in Development Cancer 201224
Head/neCk CanCer
product Name Sponsor Indication Development Status
IMO-2055(TLR9 agonist)
Idera PharmaceuticalsCambridge, MA
second-line head and neck cancer(combination therapy)(see also colorectal, lung)
Phase II(617) 679-5000
IRX-2 IRX TherapeuticsNew York, NY
(Fast Track) Phase II(212) 582-1199
Lymphoseek®
Tc-99m tilmanoceptNavidea PharmaceuticalsDublin, OH
head and neck cancer (diagnosis)(see also breast, skin)
Phase III(614) 793-7500
Multikine®
leukocyte interleukin(orphan Drug)
CEL-SCIVienna, VA
first-line head and neck cancer Phase III(703) 506-9460
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, colorectal, kidney, leukemia, liver, lung, multiple myeloma, ovarian, other)
Phase II(888) 842-2937
OBP-301 Oncolys BiopharmaTokyo, Japan
(see also breast, liver, lung) Phase Iwww.oncolys.com
PX-866 OncothyreonSeattle, WA
head and neck cancer (combination therapy)(see also brain, lung, prostate)
Phase II(206) 801-2100
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
metastatic head and neck cancer (combination therapy)(see also brain, colorectal, lung, ovarian, pancreatic, sarcoma, skin, solid tumors)
Phase III(403) 670-7377
RG7597(EGFR antagonist)
GenentechSouth San Francisco, CA
Phase II(800) 626-3553
seliciclib(CYC202)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
nasopharyngeal cancer (see also solid tumors)
Phase II(908) 517-7330
tarceva®
erlotinibGenentechSouth San Francisco, CAOSI PharmaceuticalsFarmingdale, NY
first-line head/neck cancer (combination therapy)(see also brain, breast, leukemia,liver, lung, other)
Phase II(800) 626-3553(631) 962-0600
TAS-106 Taiho Pharma U.S.A.Princeton, NJ
Phase II(609) 750-5300
Medicines in Development for Cancer
Medicines in Development Cancer 2012 25
Head/neCk CanCer
product Name Sponsor Indication Development Status
terameprocol Erimos PharmaceuticalsHouston, TX
head and neck cancer (intratumoral)(see also brain, cervical, solid tumors, other)
Phase I(713) 541-2000
tNFerade™golnerminogene pradenovec
GenVecGaithersburg, MD
(see also prostate, skin, stomach) Phase I/II completed(877) 943-6832
tykerb®
lapatinibGlaxoSmithKlineRsch. Triangle Park, NC
head and neck squamous cell carcinoma (resectable disease)(see also breast, colorectal, stomach)
Phase III(888) 825-5249
VB4-845(orphan Drug)
Viventia BiotechnologiesMississauga, Canada
(Fast Track)(see also bladder)
Phase II(905) 362-2973
Vectibix®
panitumumabAmgenThousand Oaks, CA
first-line head and neck cancer(see also colorectal)--------------------------------------------------second-line head and neck cancer
Phase III(800) 772-6436-------------------------------------------Phase II(800) 772-6436
kidney CanCer
product Name Sponsor Indication Development Status
Afinitor®
everolimusNovartis PharmaceuticalsEast Hanover, NJ
hepatocellular carcinoma(see also breast, lymphoma)
Phase II(888) 669-6682
AGS-003(personalized dendritic cell vaccine)
Argos TherapeuticsDurham, NC
renal cancer (combination therapy)(Fast Track)--------------------------------------------------metastatic renal cancer (monotherapy)
Phase II(919) 287-6300-------------------------------------------Phase II(919) 287-6300
AMG 172 AmgenThousand Oaks, CA
Phase I(800) 772-6436
anti-PD1 (BMS-936558)
Bristol-Myers SquibbPrinceton, NJ
renal cell carcinoma(see also lung, skin)
Phase II(800) 332-2056
BNC105 BionomicsThebarton, Australia
Phase IIwww.bionomics.com.au
cabozantinib(XL184)
ExelixisSouth San Francisco, CA
renal cell carcinoma(see also breast, lung, ovarian, prostate, other)
Phase I(650) 837-7000
Medicines in Development for Cancer
Medicines in Development Cancer 201226
kidney CanCer
product Name Sponsor Indication Development Status
CVX 060 (PF-04856884)(Ang2 antagonist)
PfizerNew York, NY
renal cell carcinoma(see also solid tumors)
Phase II(860) 732-5156
CYT107(interleukin-7)
CytherisRockville, MD
(see also skin) Phase I(301) 231-0451
entinostat Syndax PharmaceuticalsWaltham, MA
(see also breast, colorectal, leukemia, lung, lymphoma)
Phase I/II(781) 419-1400
foretinib(GSK1363089)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also head/neck, liver, lung) Phase II(888) 825-5249
IMA901(cancer vaccine)
immatics biotechnologiesTüebingen, Germany
renal cancer Phase IIIwww.immatics.com
Inlyta®
axitinib(orphan Drug)
PfizerNew York, NY
advanced renal cell carcinoma in treatment-naive patients(see also liver, other)
Phase III(860) 732-5156
Istodax®
romidepsinCelgeneSummit, NJ
renal cancer(see also pancreatic, prostate, other)
Phase II(908) 673-9000
LBH589 (panobinostat)
Novartis PharmaceuticalsEast Hanover, NJ
renal cancer(see also leukemia, multiple myeloma, prostate, solid tumors)
Phase II(888) 669-6682
linifanib Abbott LaboratoriesAbbott Park, IL
renal cancer (see also breast, colorectal, liver, lung)
Phase II(847) 937-6100
LOR-2040(orphan Drug)
Lorus TherapeuticsToronto, Canada
metastatic renal cancer(see also breast, colorectal, leukemia, prostate)
Phase II(416) 798-1200
naptumomab estafenatox Active BiotechLund, Sweden
(see also lung, pancreatic) Phase I completedwww.activebiotech.com
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
renal cell carcinoma (adjuvant therapy)(see also breast, colorectal, head/neck, leukemia, liver, lung, multiple myeloma, ovarian, other)
Phase III(888) 842-2937
oncophage®
vitespen(orphan Drug)
AgenusLexington, MA
renal cell carcinoma (Fast Track) Phase II(781) 674-4400
OSI-027(TORC1/TORC2 inhibitor)
OSI PharmaceuticalsFarmingdale, NY
renal cancer(see also lymphoma)
Phase II(631) 962-0600
Medicines in Development for Cancer
Medicines in Development Cancer 2012 27
kidney CanCer
product Name Sponsor Indication Development Status
perifosine AEterna ZentarisBasking Ridge, NJ
metastatic renal cancer(see also brain, colorectal, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Phase II(908) 626-5428
Redectane®
girentuximab I-124 companion diagnostic
WilexMunich, Germany
renal cancer (diagnosis) Phase III completedwww.wilex.de
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
renal cancer(see also colorectal, lung, solid tumors, stomach)
Phase II(888) 842-2837
Rencarex®
girentuximab(orphan Drug)
WilexMunich, Germany
clear cell renal cell carcinoma(Fast Track)
Phase IIIwww.wilex.de
ridaforolimus ARIAD PharmaceuticalsCambridge, MAMerckWhitehouse Station, NJ
(see also breast, lung, prostate, sarcoma, other)
Phase I(800) 672-6372
SGN-75(vorsetuzumab mafodotin)
Seattle GeneticsBothell, WA
renal cancer(see also lymphoma)
Phase I(425) 527-4000
Sutent®sunitinib(orphan Drug)
PfizerNew York, NY
renal cell carcinoma (adjuvant therapy)
Phase III(860) 732-5156
tivantinib (ARQ 197)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
(see also colorectal, liver, lung, pancreatic, sarcoma, other)
Phase II(781) 994-0300(973) 944-2600
tivozanib(ASP4130/AV-951)
Astellas Pharma USDeerfield, ILAVEO PharmaceuticalsCambridge, MA
first-line renal cancer (see also breast, colorectal)
--------------------------------------------------renal cancer(combination therapy)
Phase III(800) 695-4321(617) 299-5000-------------------------------------------Phase I(800) 695-4321(617) 299-5000
TKI258(dovitinib)
Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, multiple myeloma, prostate, skin, other)
Phase III(888) 669-6682
torisel®temsirolimus(orphan Drug)
PfizerNew York, NY
renal cell carcinoma Phase III(860) 732-5156
trebananib (AMG386)
AmgenThousand Oaks, CA
renal cancer(see also breast, colorectal, liver, ovarian, stomach, other)
Phase II(800) 772-6436
Medicines in Development for Cancer
Medicines in Development Cancer 201228
kidney CanCer
product Name Sponsor Indication Development Status
TVI-Kidney-1(cellular immunotherapyvaccine)
TVAX BiomedicalLenexa, KS
renal cell carcinoma Phase II completed(913) 492-2221
veglin (VEGF antisense)
VasGene TherapeuticsLos Angeles, CA
(see also lung, skin) Phase I(323) 221-7818
Votrient™pazopanib
GlaxoSmithKlineRsch. Triangle Park, NC
(see also ovarian, other) Phase III(888) 825-5249
leukemia
product Name Sponsor Indication Development Status
ABIO-0501 (TALL104)
Abiogen PharmaPisa, Italy
chronic myeloid leukemia (CML) Phase IIwww.abiogen.it
AC220(quizartinib)
Ambit BiosciencesSan Diego, CAAstellas Pharma USDeerfield, IL
second-line and third-line acute myeloid leukemia (AML) (monotherapy)(see also solid tumors)--------------------------------------------------acute lymphocytic leukemia (ALL) (combination therapy), first-line AML
Phase II(858) 334-2100(800) 695-4321
-------------------------------------------Phase I(858) 334-2100(800) 695-4321
AC430(JAK2 inhibitor)
Ambit BiosciencesSan Diego, CA
Phase I(858) 334-2100
Adcetris™brentuximab vedotin
Millennium PharmaceuticalsCambridge, MASeattle GeneticsBothell, WA
(see also lymphoma) Phase II(800) 390-5663(425) 527-4000
AEG35156(XIAP inhibitor)
Aegera TherapeuticsMontreal, Canada
AML(see also lymphoma)--------------------------------------------------chronic lymphocytic leukemia (CLL)
Phase II(514) 288-5532-------------------------------------------Phase I/II(514) 288-5532
AFX-9154 Afecta PharmaceuticalsIrvine, CA
in clinical trials(949) 253-4688
Medicines in Development for Cancer
Medicines in Development Cancer 2012 29
leukemia
product Name Sponsor Indication Development Status
AGS-005 Argos TherapeuticsDurham, NC
CLL Phase I/II(919) 287-6300
ALD-151 AldagenDurham, NC
Phase I(919) 484-2571
ALXN6000(samalizumab)
Alexion PharmaceuticalsCheshire, CT
CLL(see also multiple myeloma)
Phase I/II completed(203) 272-2596
aminopterin Syntrix BiosystemsAuburn, WA
ALL Phase II completed(253) 833-8009
anti-CD22/CD19 mAb-toxinconjugate
Abiogen PharmaPisa, Italy
ALL Phase Iwww.abiogen.com
AR-42 Arno TherapeuticsFlemington, NJ
CLL(see also lymphoma, multiple myeloma)
Phase I/II(862) 703-7170
AR-67 Arno TherapeuticsFlemington, NJ
myelodysplastic syndromes(see also brain, solid tumors)
Phase II(862) 703-7170
Arranon®
nelarabine(orphan Drug)
GlaxoSmithKlineRsch. Triangle Park, NC
first-line ALL(see also lymphoma)--------------------------------------------------second-line ALL
Phase III(888) 669-6682-------------------------------------------Phase I/II(888) 669-6682
ARRY-520(KSP inhibitor)
Array BioPharmaBoulder, CO
AML(see also multiple myeloma, solid tumors)
Phase II(877) 633-2436
Arzerra®
ofatumumab(orphan Drug)
GlaxoSmithKlineRsch. Triangle Park, NC
first-line CLL (combination therapy)(see also lymphoma)
Phase III(888) 825-5249
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
CLL(see also brain, lung, lymphoma, prostate, stomach)
Phase II(610) 408-0301
AT-406/Debio-1143 Ascenta TherapeuticsMalvern, PADebiopharmLausanne, Switzerland
AML(see also lymphoma)
Phase I(610) 408-0301www.debiopharm.com
Medicines in Development for Cancer
Medicines in Development Cancer 201230
leukemia
product Name Sponsor Indication Development Status
AT7519(CDK inhibitor)
Astex PharmaceuticalsDublin, CA
CLL(see also lymphoma, multiple myeloma, solid tumors)
Phase II(925) 560-0100
AT9283(aurora/Jak2 inhibitor)(orphan Drug)
Astex PharmaceuticalsDublin, CA
AML(see also lymphoma, multiple myeloma, solid tumors)
Phase I/II(925) 560-0100
AVL-292(Btk inhibitor)
CelgeneSummit, NJ
second-line CLL (combination therapy)(see also lymphoma, unspecified)
Phase I(908) 673-9000
AZD1208(Pim kinase inhibitor)
AstraZenecaWilmington, DE
AML Phase I(800) 236-9933
bafetinib(orphan Drug)
CytRx Los Angeles, CA
second-line CLL (see also brain, prostate)--------------------------------------------------ALL, CML
Phase II(310) 826-5648-------------------------------------------Phase I(310) 826-5648
Bcl-2 inhibitor(ABT-199/GDC-0199)
Abbott LaboratoriesAbbott Park, ILGenentechSouth San Francisco, CA
CLL(see also lymphoma)
Phase I(847) 937-6100(800) 626-3553
belinostat Spectrum PharmaceuticalsHenderson, NV
AML(see also colorectal, liver, lung, lymphoma, ovarian, other)
Phase I/II(702) 835-6300
BI-811283(aurora kinase B inhibitor)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
AML(see also solid tumors)
Phase I/II(800) 243-0127
BI-836826 Boehringer IngelheimPharmaceuticalsRidgefield, CT
CLL Phase I(800) 243-0127
bosutinib PfizerNew York, NY
previously treated CML application submitted(860) 732-5156
cenersen(orphan Drug)
EleosOmaha, NE
AML Phase II completed(402) 393-3034
Ceplene®
histamine dihydrochloride injection(orphan Drug)
EpiCeptTarrytown, NY
AML application submitted(914) 606-3500
Medicines in Development for Cancer
Medicines in Development Cancer 2012 31
leukemia
product Name Sponsor Indication Development Status
CLL immunotherapeutic vaccine MaxCyteGaithersburg, MD
CLL Phase I/II(301) 944-1700
Clolar®
clofarabine injection (orphan Drug)
GenzymeCambridge, MA
AML (adults) Phase III(617) 252-7500
CNDO-109(tumor activated NK cells)
Coronado BiosciencesBurlington, MA
AML Phase I(781) 238-6621
CPX-351(cytarabine/daunorubicin)(orphan Drug)
Celator PharmaceuticalsPrinceton, NJ
AML Phase II(609) 243-0123
CT-011 CureTechYavne, Israel
second-line AML (combination therapy)(see also colorectal, lymphoma)
Phase IIwww.curetechbio.com
CWP232291 JW PharmaceuticalSeoul, South Korea
AML Phase I
Dacogen®
decitabineEisaiWoodcliff Lake, NJ
AML
--------------------------------------------------pediatric AML
application submitted(888) 422-4743-------------------------------------------Phase II(888) 422-4743
danusertib Nerviano Medical SciencesNerviano, Italy
CML Phase IIwww.nervianoms.com
DCC-2036 Deciphera PharmaceuticalsLawrence, KS
ALL, CML
--------------------------------------------------AML
Phase I/II(785) 830-2100-------------------------------------------Phase I(785) 830-2100
DCDS-4501A GenentechSouth San Francisco, CA
CLL(see also lymphoma)
Phase I(800) 626-3553
DCDT-2980S GenentechSouth San Francisco, CA
recurrent CLL(see also lymphoma)
Phase I(800) 626-3553
elacyt™elacytarabine(orphan Drug)
Clavis PharmaOslo, Norway
late-stage AML(Fast Track)--------------------------------------------------early-stage AML
Phase IIIwww.clavispharma.com-------------------------------------------Phase IIwww.clavispharma.com
Medicines in Development for Cancer
Medicines in Development Cancer 201232
leukemia
product Name Sponsor Indication Development Status
elesclomol Synta PharmaceuticalsLexington, MA
AML(see also lung, ovarian)
Phase I(781) 274-8200
entinostat Syndax PharmaceuticalsWaltham, MA
(see also breast, colorectal, kidney, lung, lymphoma)
Phase II(781) 419-1400
epratuzumab(orphan Drug)
ImmunomedicsMorris Plains, NJUCBAtlanta, GA
ALL in children (combination therapy)(see also lymphoma)
Phase II(973) 605-8200
forodesine(orphan Drug)
BioCryst PharmaceuticalsDurham, NC
CLL(see also lymphoma)
Phase II(919) 859-1302
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
ALL, AML, CML(see also breast, colorectal, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach)--------------------------------------------------myelodysplastic syndromes
Phase I/II(781) 274-8200
-------------------------------------------Phase I(781) 274-8200
GNKG-168 SBI BiotechTokyo, Japan
CLL Phase Iwww.sbibiotech.jp
GRNVAC1(dendritic cell vaccine)
Argos TherapeuticsDurham, NCGeronMenlo Park, CA
AML(see also prostate)
Phase II(650) 473-7700
GS-1101(PI3K delta inhibitor)
Gilead SciencesFoster City, CA
second-line CLL (see also lymphoma)
Phase III(800) 445-3235
GSK2110183(protein kinase B inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also multiple myeloma) Phase II(888) 825-5249
GSK2130579A(WT1 antigen-specific cancer immunotherapeutic)
GlaxoSmithKlineRsch. Triangle Park, NC
AML Phase II(888) 825-5249
GVAX® Leukemiacancer vaccine(orphan Drug)
BioSante PharmaceuticalsLincolnshire, IL
AML, CML Phase II(847) 478-0500
HuM195-Ac-225(lintuzumab Ac-225)
Actinium PharmaceuticalsNewark, NJ
AML Phase I(973) 344-6500
Medicines in Development for Cancer
Medicines in Development Cancer 2012 33
leukemia
product Name Sponsor Indication Development Status
HuM195-Bi-213(lintuzumab Bi-213)
Actinium PharmaceuticalsNewark, NJ
AML Phase I/II(973) 344-6500
HuM195/rGel(lintuzumab-gelonin conjugate)
Targa TherapeuticsSan Diego, CA
AML, CML, myelodysplasticsyndromes
Phase I(858) 483-6600
ibrutinib(PCI-32765)
Janssen BiotechHorsham, PAPharmacyclicsSunnyvale, CA
CLL(see also lymphoma, multiple myeloma)
Phase I/II(800) 526-7736(408) 774-0330
imatinib sublingual Kedem PharmaceuticalsMesa, AZ
CML in clinical trials(604) 324-4244
imetelstat GeronMenlo Park, CA
CLL(see also breast, lung, multiple myeloma)
Phase I/II(650) 473-7700
Imprime pGG® BiotheraEagan, MN
CLL(see also colorectal, lung, skin)
Phase I/II(651) 675-0300
INNO-305(WT-1 vaccine)
CytRxLos Angeles, CA
AML, myelodysplastic syndromes(see also solid tumors)
Phase I(310) 826-5648
inotuzumab ozogamicin PfizerNew York, NY
ALL(see also lymphoma)
Phase I(860) 732-5156
ISF35(recombinant immunotherapeutic vaccine)
MemgenSan Diego, CA
CLL (monotherapy)(see also lymphoma)--------------------------------------------------refractory metastatic CLL (combination therapy)
Phase II(858) 524-5400-------------------------------------------Phase I(858) 524-5400
JNJ-26481585(quisinostat)
Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
myelodysplastic syndromes, metastatic leukemia(see also lymphoma)
Phase I(800) 817-5286
JVRS-100(lipid-DNA complex vaccine)
Colby PharmaceuticalSan Jose, CA
Phase I(650) 333-3152
KX2-391 Kinex PharmaceuticalsBuffalo, NY
AML in the elderly(see also prostate)
Phase I(716) 898-8626
Medicines in Development for Cancer
Medicines in Development Cancer 201234
leukemia
product Name Sponsor Indication Development Status
LBH589 (panobinostat)
Novartis PharmaceuticalsEast Hanover, NJ
ALL, AML, myelodysplastic syndromes(see also kidney, multiple myeloma, prostate, solid tumors)
Phase II(888) 669-6682
LDE225(erismodegib)
Novartis PharmaceuticalsEast Hanover, NJ
CML (combination therapy)(see also pancreatic, solid tumors, skin)
Phase I(888) 669-6682
lestaurtinib(orphan Drug)
CephalonFrazer, PA
AML Phase II(610) 344-0200
leukemia DNA vaccine Inovio PharmaceuticalsBlue Bell, PAUniversity of SouthamptonSouthampton, United Kingdom
AML, CML Phase II(877) 446-6846
LG740(activated T-cells)
LentigenGaithersburg, MDUniversity of PennsylvaniaPhiladelphia, PA
ALL, B-cell prolymphocytic leukemia, CLL(see also lymphoma)
Phase I(301) 527-4200
LOR-2040(orphan Drug)
Lorus TherapeuticsToronto, Canada
AML (combination therapy)(see also breast, colorectal, kidney, prostate)--------------------------------------------------CML, myelodysplastic syndromes
Phase II(416) 798-1200
-------------------------------------------Phase I (416) 798-1701
lurbinectedin PharmaMarMadrid, Spain
(see also solid tumors) Phase Iwww.pharmamar.com
Marqibo®
vincristine liposomal(orphan Drug)
Talon TherapeuticsSan Mateo, CA
relapsed or refractory Philadelphia chromosome-negative ALL (Fast Track)(see also lymphoma, skin, other)--------------------------------------------------ALL in the elderly (Fast Track)
application submitted(650) 588-6404
-------------------------------------------Phase III(650) 588-6404
milatuzumab ImmunomedicsMorris Plains, NJ
CLL (monotherapy)(see also lymphoma, multiple myeloma)
Phase I/II(973) 605-8200
MK-7956(dinaciclib)(orphan Drug)
MerckWhitehouse Station, NJ
CLL(see also lymphoma)
Phase II(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 35
leukemia
product Name Sponsor Indication Development Status
MK-8242 MerckWhitehouse Station, NJ
AML(see also solid tumors)
Phase I(800) 672-6372
mocetinostat(MGCD0103, HDAC inhibitor)
MethylGeneMontreal, Canada
CLL(see also lymphoma, solid tumors)
Phase II completed(514) 337-3333
Mozobil®plerixafor
GenzymeCambridge, MA
AML Phase I(617) 252-7500
navitoclax(ABT-263)
Abbott LaboratoriesAbbott Park, IL
first-line CLL (combination therapy)(see also lung, lymphoma)--------------------------------------------------CLL, lymphoid leukemia
Phase II(847) 937-6100-------------------------------------------Phase I(847) 937-6100
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
AML, myelodysplastic syndromes(see also breast, colorectal, head/neck, kidney, liver, lung, multiple myeloma, ovarian, other)
Phase I/II(888) 842-2937
obatoclax(orphan Drug)
CephalonFrazer, PA
CLL(see also lung, lymphoma, multiple myeloma)
Phase I/II completed(610) 344-0200
obinutuzumab(GA101/RG7159)
Biogen IdecWeston, MAGenentechSouth San Francisco, CA
first-line CLL (combination therapy)(see also lymphoma)
Phase III(781) 464-2000(800) 626-3553
omapro™omacetaxine(orphan Drug)
CephalonFrazer, PA
second-line CML(see also solid tumors)--------------------------------------------------AML, myelodysplastic syndromes
application submitted(610) 344-0200-------------------------------------------Phase II(610) 344-0200
ON 013105 Onconova TherapeuticsNewtown, PA
ALL(see also lymphoma)
Phase I(267) 759-3680
oral azacitidine(orphan Drug)
CelgeneSummit, NJ
myelodysplastic syndromes(Fast Track) (see also lung, lymphoma, solid tumors)--------------------------------------------------AML, CML
Phase II(908) 673-9000
-------------------------------------------Phase I(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 201236
leukemia
product Name Sponsor Indication Development Status
oral clofaribine GenzymeCambridge, MA
myelodysplastic syndromes Phase I(617) 252-7500
OVI-123(orphan Drug)
OncoVista Innovative TherapiesSan Antonio, TX
TdT-positive leukemia Phase I(210) 677-6000
OXi4503 OXiGENESouth San Francisco, CA
AML, myelodysplastic syndromes Phase I(650) 635-7000
perifosine AEterna ZentarisBasking Ridge, NJ
refractory metastatic CLL(see also brain, colorectal, kidney, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Phase II(908) 626-5428
PKC412(midostaurin)
Novartis PharmaceuticalsEast Hanover, NJ
AML Phase III(888) 669-6682
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
recurrent or refractory AML(see also brain, lymphoma, solid tumors)
Phase I/II(510) 647-4000
ponatinib(orphan Drug)
ARIAD PharmaceuticalsCambridge, MA
Philadelphia-positive ALL, CML
--------------------------------------------------AML
Phase II(617) 494-0400-------------------------------------------Phase I(617) 494-0400
PR104 ProactaLa Jolla, CA
AML Phase I/II(858) 642-0386
Revlimid®
lenalidomide(orphan Drug)
CelgeneSummit, NJ
CLL, myelodysplastic syndromes(see also lymphoma)
Phase III(908) 673-9000
rigosertib(orphan Drug)
Onconova TherapeuticsNewtown, PA
myelodysplastic syndromes (intravenous)(see also lymphoma, ovarian, pancreatic)--------------------------------------------------CLL
--------------------------------------------------AML
--------------------------------------------------myelodysplastic syndromes (oral)
Phase III(267) 759-3680
-------------------------------------------Phase II(267) 759-3680-------------------------------------------Phase I/II(267) 759-3680-------------------------------------------Phase I(267) 759-3680
Medicines in Development for Cancer
Medicines in Development Cancer 2012 37
leukemia
product Name Sponsor Indication Development Status
sapacitabine (CYC682)(orphan Drug)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
first-line AML (see also lung, solid tumors)--------------------------------------------------CLL (combination therapy),myelodysplastic syndromes
Phase III(908) 517-7330-------------------------------------------Phase II(908) 517-7330
SB989 (pracinostat)
S*BIOOakland, CA
myelodysplastic syndromes(see also solid tumors, other)
Phase I(650) 730-2860
SB1518 (pacritinib)
S*BIOOakland, CA
myelodysplastic syndromes
--------------------------------------------------myeloid leukemia
Phase II(650) 730-2860-------------------------------------------Phase I/II(650) 730-2860
SF1126(orphan Drug)
Semafore PharmaceuticalsIndianapolis, IN
CLL(see also multiple myeloma, solid tumors)
Phase I(317) 876-3075
SGI110(DNMT inhibitor)
Astex PharmaceuticalsDublin, CA
AML, myelodysplastic syndromes Phase I/II(925) 560-0100
SL-401(recombinant fusion protein)(orphan Drug)
Stemline TherapeuticsNew York, NY
AML, myelodysplastic syndromes Phase I/II(646) 502-2310
tamibarotene(orphan Drug)
CytRxLos Angeles, CA
acute promyelocytic leukemia (APL) (Fast Track)(see also lung)--------------------------------------------------APL (combination therapy)
Phase II(310) 826-5648
-------------------------------------------Phase I(310) 826-5648
tarceva®
erlotinibGenentechSouth San Francisco, CAOSI OncologyFarmingdale, NY
myelodysplastic syndromes(see also brain, breast, head/neck, liver, lung, other)
Phase II(800) 626-3553(631) 962-0600
tasigna®
nilotinib(orphan Drug)
Novartis PharmaceuticalsEast Hanover, NJ
CML (adolescents and children), ALL (adolescents and children)(see also skin, stomach)
Phase II(888) 669-6682
temodar®
temozolomideMerckWhitehouse Station, NJ
AML(see also lung)
Phase II(800) 672-6372
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
(see also brain, multiple myeloma, pancreatic, sarcoma)
Phase I(650) 474-8200
thiarabine Access PharmaceuticalsDallas, TX
(see also lymphoma) Phase I/II(215) 904-5100
Medicines in Development for Cancer
Medicines in Development Cancer 201238
leukemia
product Name Sponsor Indication Development Status
TL-32711(birinapant)
TetraLogic PharmaceuticalsMalvern, PA
AML(see also solid tumors)
Phase I/II(610) 889-9900
tosedostat(orphan Drug)
Chroma TherapeuticsOxon, United Kingdom
AML Phase IIwww.chromatherapeutics.com
trametinib GlaxoSmithKlineRsch. Triangle Park, NC
relapsed or refractory leukemia(see also brain, lung, lymphoma, multiple myeloma, pancreatic, skin)
Phase III(888) 825-5249
treanda®
bendamustineCephalonFrazer, PA
ALL in children, AML in children(see also lymphoma, multiple myeloma)
Phase I/II(610) 344-0200
treosulfan MedacWedel, Germany
ALL, AML, myelodysplastic syndromes
Phase IIwww.medac.de
TRU-016(humanized anti-CD37 therapeutic)
Emergent BioSolutionsRockville, MD
CLL(see also lymphoma)
Phase II(301) 795-1800
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
second-line T-cell prolymphocytic leukemia (see also lymphoma, other, cancer-related)
Phase II(800) 390-5663
veltuzumab(orphan Drug)
ImmunomedicsMorris Plains, NJ
CLL(see also lymphoma)
Phase I/II(973) 605-8200
Vidaza®
azacitidine(orphan Drug)
CelgeneSummit, NJ
AML in the elderly(see also lymphoma)
Phase III(908) 673-9000
vosaroxin(orphan Drug)
Sunesis PharmaceuticalsSouth San Francisco, CA
second-line AML(Fast Track)(see also ovarian)--------------------------------------------------AML in the elderly
Phase III(650) 266-3739
-------------------------------------------Phase II(650) 266-3739
XmAb® 5574(MOR208, anti-CD19 mAb)
MorphoSysPlanegg, GermanyXencorMonrovia, CA
recurrent CLL Phase Iwww.morphosys.com(626) 305-5900
Zolinza®
vorinostatMerckWhitehouse Station, NJ
AML, myelodysplastic syndromes(see also breast, lung, lymphoma, multiple myeloma, other)
Phase II(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012 39
liver CanCer
product Name Sponsor Indication Development Status
ALN-VSP Alnylam PharmaceuticalsCambridge, MA
Phase I(617) 551-8200
bavituximab Peregrine PharmaceuticalsTustin, CA
(see also lung, pancreatic) Phase I/II(715) 508-6000
BAY 86-9766(MEK inhibitor)
Ardea BiosciencesSan Diego, CABayer HealthCare PharmaceuticalsWayne, NJ
first-line liver cancer (combination therapy)(see also pancreatic)
Phase II(888) 842-2937
belinostat Spectrum PharmaceuticalsHenderson, NV
inoperable/unresectable liver cancer(see also colorectal, leukemia, lung, lymphoma, ovarian, other)
Phase I/II(702) 835-6300
BIIB 022 Biogen IdecCambridge, MA
(see also lung) Phase I completed(617) 679-2000
brivanib(VEGFR/FGFR kinase inhibitor)
Bristol-Myers SquibbPrinceton, NJ
first-line liver cancer, liver cancer (TACE)(see also colorectal, sarcoma)
Phase III(800) 332-2056
cixutumumab(LY3012217/IMC-A12)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
(see also lung) Phase II(800) 545-5979
darinaparsin(ZIO-101)
ZIOPHARM OncologyNew York, NY
(see also lymphoma, multiple myeloma, solid tumors)
Phase II(646) 214-0700
DC Bead®
doxorubicin-eluting beadsBayer HealthCare PharmaceuticalsWayne, NJBiocompatiblesSurrey, United Kingdom
Phase II(888) 842-2937
E7050 EisaiWoodcliff Lake, NJ
(see also brain, head/neck, skin, solid tumors, stomach)
Phase I/II(888) 422-4743
foretinib(GSK1363089)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also head/neck, kidney, lung) Phase I(888) 825-5249
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
(see also breast, colorectal, leukemia, lung, multiple myeloma, pancreatic, prostate, skin, stomach)
Phase II(781) 274-8200
Inlyta®
axitinibPfizerNew York, NY
(see also kidney, other) Phase II(860) 732-5156
irinotecan eluting beads Biocompatibles InternationalSurrey, United Kingdom
liver metastases from colorectal cancer
Phase IIwww.biocompatibles.com
Medicines in Development for Cancer
Medicines in Development Cancer 201240
liver CanCer
product Name Sponsor Indication Development Status
JX-594 (pexastimogene devacirepvec)(orphan Drug)
Jennerex BiotherapeuticsSan Francisco, CA
(see also colorectal) Phase II(415) 281-8886
lansoprazole (orphan Drug)
Apricus BiosciencesSan Diego, CA
first-line liver cancer Phase II(858) 220-8041
linifanib Abbott LaboratoriesAbbott Park, IL
first-line liver cancer (monotherapy)(see also breast, colorectal, kidney, lung)
Phase III(847) 937-6100
mapatumumab Human Genome SciencesRockville, MD
liver cancer (combination therapy)(see also lung, multiple myeloma)
Phase II(301) 309-8504
MB07133(HepDirect HepB inhibitor)
Ligand PharmaceuticalsLa Jolla, CA
inoperable/unresectable liver cancer Phase I/II completed(858) 550-7500
melphalan drug delivery system Delcath SystemsNew York, NY
inoperable/unresectable liver cancer application submitted(212) 489-2100
muparfostat (PI-88) Progen PharmaceuticalsQueensland, Australia
liver cancer (Fast Track)(see also skin)
Phase IIIwww.progen.com.au
Nexavar®
sorafenib(orphan Drug)
Bayer HealthCare PharmaceuticalsWayne, NJ
heptocellular carcinoma (adjuvant therapy)(see also breast, colorectal, head/neck, kidney, leukemia, lung, multiple myeloma, ovarian, other)
Phase III(888) 842-2937
NV-1020 CatherexPhiladelphia, PA
Phase I/II completed
OBP-301 Oncolys BiopharmaTokyo, Japan
(see also breast, head/neck, lung) Phase Iwww.oncolys.com
PEG arginine deiminase (ADI-PEG 20)
Polaris PharmaceuticalsSan Diego, CA
hepatocellular carcinoma(see also prostate, skin, other)
Phase III(858) 452-6688
PHY906 PhytoCeuticaNew Haven, CT
(see also colorectal, pancreatic, cancer-related)
Phase I/II completed(203) 777-3462
PV-10(rose bengal sodium)(orphan Drug)
Provectus PharmaceuticalsKnoxville, TN
liver cancer, liver metastases(see also skin)
Phase I(866) 594-5999
RG7686 RocheNutley, NJ
metastatic liver cancer(combination therapy)
Phase II(973) 235-5000
Medicines in Development for Cancer
Medicines in Development Cancer 2012 41
liver CanCer
product Name Sponsor Indication Development Status
tarceva®
erlotinibGenentechSouth San Francisco, CAOSI PharmaceuticalsFarmingdale, NY
first-line inoperable/unresectable liver cancer (combination therapy)(see also brain, breast, head/neck, leukemia, lung, other)--------------------------------------------------second-line liver cancer (combination therapy)
Phase III(800) 626-3553(631) 962-0600
-------------------------------------------Phase II(800) 626-3553(631) 962-0600
TGF-ß R1 inhibitor(LY2157299)
Eli LillyIndianapolis, IN
(see also brain) Phase II(800) 545-5979
thermoDox®
doxorubicin liposomal(orphan Drug)
CelsionLawrenceville, NJ
first-line inoperable/unresectable liver cancer (Fast Track)(see also breast, colorectal)
Phase III(609) 896-9100
tigatuzumab(anti-DR5 antibody)
Daiichi SankyoParsippany, NJ
(see also breast, colorectal, lymphoma, ovarian, pancreatic)
Phase II(973) 944-2600
tivantinib (ARQ 197) ArQuleWoburn, MADaiichi SankyoParsippany, NJ
second-line liver cancer (see also colorectal, kidney, lung, pancreatic, sarcoma, other)--------------------------------------------------liver cancer (combination therapy)
Phase II(781) 994-0300(973) 944-2600------------------------------------------Phase I(781) 994-0300(973) 944-2600
trebananib (AMG386)
AmgenThousand Oaks, CA
(see also breast, colorectal, kidney, ovarian, stomach, other)
Phase II(800) 772-6436
Xeloda®
capecitabineGenentechSouth San Francisco, CA
biliary cancer (combination therapy)(see also brain, colorectal, stomach)
Phase II(800) 626-3553
Zadaxin®
thymalfasin alfa 1(orphan Drug)
SciClone PharmaceuticalsFoster City, CA
(see also skin) Phase II/III(650) 358-3456
Medicines in Development for Cancer
Medicines in Development Cancer 201242
lung CanCer
product Name Sponsor Indication Development Status
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ
first-line non-small-cell lung cancer (NSCLC)(see also bladder, breast, ovarian, pancreatic, skin)
application submitted(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
NSCLC(see also brain, breast, colorectal, lymphoma, ovarian, prostate, skin, other)
Phase II(847) 937-6100
AC480(pan-HER inhibitor)
Ambit BiosciencesSan Diego, CA
NCSLC(see also brain, breast)
Phase I(858) 334-2100
Actimid®
pomalidomideCelgeneSummit, NJ
small-cell lung cancer (SCLC)(see also lymphoma, multiple myeloma, pancreatic)
Phase I/II(908) 673-9000
afatinib(BIBW2992)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
first-line NSCLC(see also brain, breast, head/neck)--------------------------------------------------second-line NSCLC (Fast Track)
Phase III(800) 243-0127-------------------------------------------Phase II/III(800) 243-0127
Alimta®
pemetrexedEli LillyIndianapolis, IN
first-line and maintenance NSCLC Phase III(800) 545-5979
AMG888/U3-1287(anti-HER3 antibody)
AmgenThousand Oaks, CADaiichi SankyoParsippany, NJ
NSCLC Phase II(800) 772-6436(973) 944-2600
amrubicin(orphan Drug)
CelgeneSummit, NJ
SCLC (Fast Track)(see also breast)--------------------------------------------------first-line SCLC
Phase III(908) 673-9000-------------------------------------------Phase II(908) 673-9000
amuvatinib(MP470)
Astex PharmaceuticalsDublin, CA
SCLC (combination therapy)(see also lymphoma)
Phase II(925) 560-0100
anti-PD1 (BMS-936558)
Bristol-Myers SquibbPrinceton, NJ
(see also kidney, skin) Phase II(800) 332-2056
AP26113 ARIAD PharmaceuticalsCambridge, MA
NSCLC Phase I(617) 494-0400
apricoxib(TG01)
Tragara PharmaceuticalsSan Diego, CA
second-line NSCLC (combination therapy)(see also pancreatic)
Phase II(858) 350-6900
Medicines in Development for Cancer
Medicines in Development Cancer 2012 43
lung CanCer
product Name Sponsor Indication Development Status
astuprotimut-R(MAGE-A3 antigen-specific cancer immunotherapeutic)
GlaxoSmithKlineRsch. Triangle Park, NC
adjuvant NSCLC (see also skin)
Phase III(888) 825-5249
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
NSCLC (combination therapy), SCLC (combination therapy) (see also brain, leukemia, lymphoma, prostate, stomach)
Phase II(610) 408-0301
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
third-line NSCLC(see also breast, colorectal, multiple myeloma, stomach)--------------------------------------------------second-line late-stage NSCLC(combination therapy)
Phase II(888) 669-6682
-------------------------------------------Phase I/II(888) 669-6682
Avastin®
bevacizumabGenentechSouth San Francisco, CA
adjuvant NSCLC (see also brain, breast, colorectal, ovarian, other)
Phase III(800) 626-3553
bavituximab Peregrine PharmaceuticalsTustin, CA
first-line NSCLC, second-line NSCLC(see also liver, pancreatic)
Phase II(715) 508-6000
belinostat Spectrum PharmaceuticalsHenderson, NV
mesothelioma(see also colorectal, leukemia, liver, lymphoma, ovarian, other)--------------------------------------------------NSCLC
--------------------------------------------------SCLC
Phase II completed(702) 835-6300
-------------------------------------------Phase I/II(702) 835-6300-------------------------------------------Phase I(702) 835-6300
BIIB 022 Biogen IdecCambridge, MA
NSCLC(see also liver)
Phase I completed(617) 679-2000
BKM120(PI3K inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
late-stage NSCLC (see also brain, breast, other)
Phase II(888) 669-6682
cabozantinib(XL184)
ExelixisSouth San Francisco, CA
NSCLC(see also breast, kidney, ovarian, prostate, other)
Phase I/II(650) 837-7000
CBP-501(peptide mimetic)
CanBasShizouka, Japan
mesothelioma (combination therapy), first-line NSCLC (combination therapy)(see also solid tumors)
Phase IIwww.canbas.co.jp
Medicines in Development for Cancer
Medicines in Development Cancer 201244
lung CanCer
product Name Sponsor Indication Development Status
CC-223(mTOR inhibitor)
CelgeneSummit, NJ
NSCLC(see also lymphoma, multiple myeloma)
Phase I(908) 673-9000
CEP-9722(PARP inhibitor)
CephalonFrazer, PA
NSCLC (combination therapy)(see also lymphoma)
Phase II(610) 344-0200
Chk1 inhibitor(LY2603618)
Eli LillyIndianapolis, IN
NSCLC(see also pancreatic)
Phase II(800) 545-5979
cixutumumab(LY3012217/IMC-A12)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
NSCLC(see also liver)
Phase II(800) 545-5979
CLR1404-I-124 Novelos TherapeuticsMadison, WI
NSCLC (diagnosis) Phase I/II(608) 441-8120
CLR1404-I-131 Novelos TherapeuticsMadison, WI
NSCLC (diagnosis) Phase I/II(608) 441-8120
CO-1686(EGFR inhibitor)
Clovis OncologyBoulder, CO
second-line NSCLC Phase I/II(303) 625-5000
custirsen(OGX-001/TV-1011)
OncoGenex PharmaceuticalsBothell, WATeva PharmaceuticalsTikva, Israel
first-line NSCLC(see also prostate)
Phase II(425) 686-1500
dacomitinib(PF-00299804)
PfizerNew York, NY
NSCLC(see also solid tumors)
Phase III(860) 732-5156
dalotuzumab(MK-0646)
MerckWhitehouse Station, NJ
recurrent NSCLC (combination therapy)(see also breast, pancreatic, other)
Phase II(800) 672-6372
EC20(technetium Tc-99m etarfolatide)
EndocyteWest Lafayette, IN
NSCLC (diagnosis)(see also ovarian)
Phase IIwww.endocyte.com
EC145(vintafolide)
EndocyteWest Lafayette, INMerckWhitehouse Station, NJ
NSCLC(see also ovarian)
Phase IIwww.endocyte.com(800) 672-6372
efatutazone Daiichi SankyoParsippany, NJ
NSCLC(see also colorectal, other)
Phase II(973) 944-2600
elesclomol Synta PharmaceuticalsLexington, MA
NSCLC(see also leukemia, ovarian)
Phase I/II(781) 274-8200
Medicines in Development for Cancer
Medicines in Development Cancer 2012 45
lung CanCer
product Name Sponsor Indication Development Status
emepepimut-S EMD SeronoRockland, MAOncothyreonSeattle, WA
NSCLC (Fast Track)(see also prostate)
Phase III(800) 283-8088
entinostat Syndax PharmaceuticalsWaltham, MA
NSCLC (combination therapy)(see also breast, colorectal, kidney, leukemia, lymphoma)
Phase II(781) 419-1400
ficlatuzumab(AV-299)
AVEO PharmaceuticalsCambridge, MA
NSCLC (combination therapy)(see also solid tumors)
Phase II(617) 299-5000
Folotyn®
pralatrexateAllos TherapeuticsWestminster, CO
NSCLC(see also bladder, breast, lymphoma)
Phase II(303) 426-6262
foretinib(GSK1363089)
GlaxoSmithKlineRsch. Triangle Park, NC
NSCLC (see also head/neck, kidney, liver)
Phase I/II(888) 825-5249
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
second-line NSCLC (combination therapy)(see also breast, colorectal, leukemia, liver, multiple myeloma, pancreatic, prostate, skin, stomach)--------------------------------------------------SCLC
Phase II/III(781) 274-8200
-------------------------------------------Phase II(781) 274-8200
ganitumab(AMG 479)
AmgenThousand Oaks, CA
first-line SCLC (combination therapy)(see also breast, colorectal, pancreatic, sarcoma)
Phase I/II(800) 772-6436
GI-4000(cancer vaccine)
GlobeImmuneLouisville, CO
NSCLC(see also colorectal, pancreatic)
Phase I(303) 625-2700
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
NSCLC (combination therapy)(see also prostate, skin, other)
Phase II(888) 669-6682
GSK2118436(BRaf protein kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
BRAF mutation-positive disease NSCLC(see also brain, skin)
Phase II(888) 825-5249
Halaven®
eribulinEisaiWoodcliff Lake, NJ
NSCLC(see also prostate, sarcoma)
Phase III(888) 422-4743
HS-110(cancer vaccine)
Heat BiologicsChapel Hill, NC
late-stage NSCLC (combination therapy)
Phase I(919) 240-7133
Medicines in Development for Cancer
Medicines in Development Cancer 201246
lung CanCer
product Name Sponsor Indication Development Status
HyperAcute® Lunglung cancer immunotherapy
NewLink GeneticsAmes, IA
metastatic NSCLC Phase II(515) 296-5555
IDM-2101(multi-epitope cancer vaccine)
Biotech SynergySan Diego, CA
NSCLC Phase II(858) 459-6689
imetelstat GeronMenlo Park, CA
late-stage NSCLC(see also breast, leukemia, multiple myeloma)
Phase II(650) 473-7700
IMO-2055(TLR9 agonist)
Idera PharmaceuticalsCambridge, MA
(see also colorectal, head/neck) Phase I(617) 679-5000
Imprime pGG® BiotheraEagan, MN
NSCLC(see also colorectal, leukemia, skin)
Phase II(651) 675-0300
iniparib(BSI-201)
Sanofi USBridgewater, NJ
squamous NSCLC(see also breast, ovarian)--------------------------------------------------non-squamous NSCLC
Phase III(800) 981-2491-------------------------------------------Phase II(800) 981-2491
Iressa®
gefitinibAstraZenecaWilmington, DE
first-line EGFR mutation-positiveNSCLC
Phase III(800) 236-9933
ISIS-EIF4ERx Isis PharmaceuticalsCarlsbad, CA
late-stage NSCLC (combination therapy)(see also prostate)
Phase II(800) 679-4747
JNJ-26854165(Hdm2 inhibitor)
Johnson & Johnson Pharmaceutical Research & DevelopmentRaritan, NJ
NSCLC(see also prostate, solid tumors)
Phase I(800) 817-5286
Karenitecin®
BNP1350BioNumerik PharmaceuticalsSan Antonio, TX
NSCLC(see also ovarian, solid tumors)
Phase II(210) 614-1701
KD019(SSKI inhibitor)
Kadmon PharmaceuticalsWarrendale, PA
late-stage NSCLC Phase III(724) 778-6100
KD032(ras/mTOR inhibitor)
Kadmon PharmaceuticalsWarrendale, PA
NSCLC(see also pancreatic)
Phase II completed(724) 778-6100
linifanib Abbott LaboratoriesAbbott Park, IL
NSCLC(see also breast, colorectal, kidney, liver)
Phase II(847) 937-6100
litronesib(LY2523355)
Eli LillyIndianapolis, IN
NSCLC(see also breast)
Phase II(800) 545-5979
Medicines in Development for Cancer
Medicines in Development Cancer 2012 47
lung CanCer
product Name Sponsor Indication Development Status
lorvotuzumab mertansine(IMGN901)(orphan Drug)
ImmunoGenWaltham, MA
SCLC(see also multiple myeloma)
Phase II(781) 895-0600
Lucanix®
belagenpumatucel-LNovaRxSan Diego, CA
NSCLC (Fast Track)(see also brain)
Phase III(858) 522-8600
mapatumumab Human Genome SciencesRockville, MD
NSCLC (combination therapy)(see also liver, multiple myeloma)
Phase II(301) 309-8504
MEDI-575(anti-PDGFR-alpha mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
NSCLC(see also brain)
Phase II(800) 236-9933(301) 398-0000
MGCD265(multi-kinase inhibitor)
MethylGeneMontreal, Canada
NSCLC (combination therapy) Phase I/II(514) 337-3333
MORAb-003(farletuzumab)
EisaiWoodcliff Lake, NJ
NSCLC(see also ovarian)
Phase II(888) 422-4743
MORAb-009(amatuximab)
EisaiWoodcliff Lake, NJ
mesothelioma Phase II(888) 422-4743
motesanib AmgenThousand Oaks, CA
NSCLC(see also breast, colorectal, other)
Phase III(800) 772-6436
naptumomab estafenatox Active BiotechLund, Sweden
NSCLC (Fast Track)(see also kidney, pancreatic)
Phase I completedwww.activebiotech.com
navitoclax(ABT-263)
Abbott LaboratoriesAbbott Park, IL
NSCLC, SCLC(see also leukemia, lymphoma)
Phase II(847) 937-6100
necitumumab(IMC-11F8)
Bristol-Myers SquibbPrinceton, NJEli LillyIndianapolis, INImClone SystemsBridgewater, NJ
NSCLC Phase III(800) 332-2056(800) 545-5979
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
NSCLC(see also breast, colorectal, head/neck, kidney, leukemia, liver, multiple myeloma, ovarian, other)
Phase III(888) 842-2937
Medicines in Development for Cancer
Medicines in Development Cancer 201248
lung CanCer
product Name Sponsor Indication Development Status
NGR-hTNF(orphan Drug)
MolMedMilan, Italy
second-line mesothelioma Phase IIIwww.molmed.com
NK-012 Nippon KayakuTokyo, Japan
SCLC(see also breast)
Phase IIwww.nipponkayaku.co.jp
NTX-010 NeotropixMalvern, PA
SCLC(see also other)
Phase IIwww.neotropix.com
obatoclax CephalonFrazer, PA
first-line SCLC(see also leukemia, lymphoma, multiple myeloma)
Phase II(610) 344-0200
OBP-301 Oncolys BiopharmaTokyo, Japan
mesothelioma(see also breast, head/neck, liver)
Phase Iwww.oncolys.com
OGX-427 OncoGenex PharmaceuticalsBothell, WA
NSCLC(see also breast, ovarian)
Phase I(425) 686-1500
ombrabulin (AVE8062)
Sanofi USBridgewater, NJ
first-line NSCLC (see also ovarian, sarcoma)
Phase II(800) 981-2491
onartuzumab GenentechSouth San Francisco, CA
metastatic NSCLC(see also breast, colorectal)
Phase III(800) 626-3553
oncoprex™(TUSC2/FUS1 gene therapy)
GenprexAustin, TX
NSCLC Phase I(512) 597-5900
opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
NSCLC(see also brain, ovarian, stomach, other)
Phase III(800) 215-2355
oral azacitidine CelgeneSummit, NJ
NSCLC(see also leukemia, lymphoma, solid tumors)
Phase I(908) 673-9000
OSI-906(IGF-1R/1R tyrosinase kinase inhibitor)
OSI PharmaceuticalsFarmingdale, NY
NSCLC(see also ovarian, other)
Phase II(631) 962-0600
P2045 Bryan OncorSomerville, MA
NSCLC, SCLC Phase I completed
palifosfamide(ZIO-201)
ZIOPHARM OncologyNew York, NY
SCLC(see also sarcoma, solid tumors)
Phase I(646) 214-0700
Medicines in Development for Cancer
Medicines in Development Cancer 2012 49
lung CanCer
product Name Sponsor Indication Development Status
pegdinetanib (VEGFR-2 adnectin)(BMS-844203)
Bristol-Myers SquibbPrinceton, NJ
NSCLC Phase II(800) 332-2056
perifosine AEterna ZentarisBasking Ridge, NJ
NSCLC(see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Phase I/II(908) 626-5428
picoplatin(orphan Drug)
Ponaird PharmaceuticalsSeattle, WA
second-line SCLC(Fast Track)(see also colorectal, ovarian, prostate)
Phase II(206) 281-7001
plinabulin (NPI-2358)
Nereus PharmaceuticalsSan Diego, CA
NSCLC Phase II(858) 587-4090
PRAME antigen-specific cancer immunotherapeutic (recombinant)
GlaxoSmithKlineRsch. Triangle Park, NC
NSCLC(see also skin)
Phase I(888) 825-5349
PT107(allogeneic tumor cell vaccine)
Pique TherapeuticsDurham, NC
NSCLC Phase II(919) 806-4395
PX-866 OncothyreonSeattle, WA
NSCLC (combination therapy)(see also brain, head/neck, prostate)
Phase II(206) 801-2100
ranpirnase Tamir BiotechnologyMonmouth Junction, NJ
NSCLC Phase II(732) 823-1003
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
NSCLC(see also colorectal, kidney, solid tumors, stomach)
Phase I(888) 842-2837
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
NSCLC (combination therapy)(see also brain, colorectal, head/neck, ovarian, pancreatic, sarcoma, skin, solid tumors)
Phase II(403) 670-7377
retaspimycin Infinity PharmaceuticalsCambridge, MA
NSCLC Phase II(617) 453-1000
RG7414(EGFL7 inhibitor)
GenentechSouth San Francisco, CA
NSCLC(see also colorectal)
Phase II(800) 626-3553
Medicines in Development for Cancer
Medicines in Development Cancer 201250
lung CanCer
product Name Sponsor Indication Development Status
RG7599(antibody drug conjugate)
GenentechSouth San Francisco, CA
NSCLC(see also ovarian)
Phase I(800) 626-3553
ridaforolimus ARIAD PharmaceuticalsCambridge, MAMerckWhitehouse Station, NJ
NSCLC(see also breast, kidney, prostate, sarcoma, other)
Phase II(800) 672-6372
sapacitabine (CYC682)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
NSCLC(see also leukemia, solid tumors)
Phase II(908) 517-7330
SAR256212 (MM-121)(anti-ErbB3 mAb)
Merrimack PharmaceuticalsCambridge, MASanofi USBridgewater, NJ
NSCLC(see also breast, ovarian)
Phase II(800) 981-2491
talactoferrin alfa (oral)(orphan Drug)
AgennixPrinceton, NJ
NSCLC(Fast Track)
Phase III(609) 524-1000
tamibarotene CytRxLos Angeles, CA
NSCLC(see also leukemia)
Phase II(310) 826-5648
tarceva®
erlotinibGenentechSouth San Francisco, CAOSI PharmaceuticalsFarmingdale, NY
adjuvant NSCLC (see also brain, breast, head/neck, leukemia, liver, other)
Phase III(800) 626-3553(631) 962-0600
tavocept®dimesna
BioNumerik PharmaceuticalsSan Antonio, TX
(see also cancer-related) Phase III(210) 614-1701
Tc-99m ethylenedicysteine glucosamine(EC-G)
Cell PointCentennial, CO
NSCLC (diagnosis) Phase II/III(303) 689-9693
telcyta™canfosfamide
TelikPalo Alto, CA
third-line NSCLC (see also lymphoma, ovarian)
Phase III completed(650) 845-7700
temodar®
temozolomideMerckWhitehouse Station, NJ
SCLC(see also leukemia)
Phase II(800) 672-6372
tivantinib (ARQ 197)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
NSCLC(see also colorectal, kidney, liver, pancreatic, sarcoma, other)
Phase III(781) 994-0300(973) 944-2600
Medicines in Development for Cancer
Medicines in Development Cancer 2012 51
lung CanCer
product Name Sponsor Indication Development Status
topotecan liposomes injection Talon TherapeuticsSan Mateo, CA
SCLC(see also ovarian)
Phase I(650) 599-6404
trametinib GlaxoSmithKlineRsch. Triangle Park, NC
second-line NSCLC (see also leukemia, lymphoma, multiple myeloma, pancreatic, skin)
Phase II(888) 825-5249
Vargatef™intedanib
Boehringer IngelheimPharmaceuticalsRidgefield, CT
second-line late-stage NSCLC (combination therapy)(see also ovarian)
Phase III(800) 243-0127
veglin (VEGF antisense)
VasGene TherapeuticsLos Angeles, CA
mesothelioma(see also kidney, skin)
Phase I(323) 221-7818
volociximab Abbott LaboratoriesAbbott Park, IL Biogen IdecWeston, MA
NSCLC Phase II(847) 937-6100(781) 464-2000
Xalkori®crizotinib(orphan Drug)
PfizerNew York, NY
first-line ALK-positive NSCLC, second-line ALK-positive NSCLC(see also solid tumors)--------------------------------------------------NSCLC (combination therapy)
Phase III(860) 732-5156
-------------------------------------------Phase I/II(860) 732-5156
YeRVoY®
ipilimumabBristol-Myers SquibbPrinceton, NJ
NSCLC, SCLC(see also prostate, skin)
in clinical trials(800) 332-2056
Zolinza®
vorinostat(orphan Drug)
MerckWhitehouse Station, NJ
mesothelioma(see also breast, leukemia, lymphoma, multiple myeloma, other)
Phase III(800) 672-6273
Zybrestat™fosbretabulin
OXiGENESouth San Francisco, CA
first-line NSCLC(see also ovarian)
Phase II(650) 635-7000
Medicines in Development for Cancer
Medicines in Development Cancer 201252
lympHoma
product Name Sponsor Indication Development Status
abexinostat(HDAC inhibitor)
PharmacyclicsSunnyvale, CA
lymphoma(see also sarcoma)
Phase I/II(408) 774-0330
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, colorectal, lung, ovarian, prostate, skin, other)
Phase I/II(847) 937-6100
Actimid®
pomalidomideCelgeneSummit, NJ
Waldenström’s macroglobulinemia(see also lung, multiple myeloma, pancreatic)
Phase I(908) 673-9000
Adcetris™brentuximab vedotin
Millennium PharmaceuticalsCambridge, MASeattle GeneticsBothell, WA
post-transplant Hodgkin’s lymphoma relapse prevention(see also leukemia)--------------------------------------------------relapsed/refractory CD30-positive non-Hodgkin’s lymphoma, relapsed/refractory anaplastic large-cell lymphoma--------------------------------------------------first-line anaplastic large-cell lymphoma, first-line Hodgkin’s lymphoma
Phase III(800) 390-5663(425) 527-4000-------------------------------------------Phase II(800) 390-5663(425) 527-4000
-------------------------------------------Phase I(800) 390-5663(425) 527-4000
Adcetris™ Companion Diagnosticbrentuximab vedotin companion diagnostic
Millennium PharmaceuticalsCambridge, MASeattle GeneticsBothell, WAVentana Medical SystemsTucson, AZ
cutaneous T-cell lymphoma (diagnosis), T-cell lymphoma (diagnosis)
in clinical trials(617) 679-7000(425) 527-4000(800) 227-2155
AEG35156(XIAP inhibitor)
Aegera TherapeuticsMontreal, Canada
B-cell lymphoma(see also leukemia)
Phase I/II(514) 288-5532
AEZS-112 AEterna Zentaris Basking Ridge, NJ
(see also solid tumors) Phase I(908) 626-5428
Afinitor®
everolimusNovartis PharmaceuticalsEast Hanover, NJ
mantle cell lymphoma(see also breast, kidney)
Phase II(888) 669-6682
AFM13 Affimed TherapeuticsHeidelberg, Germany
second-line Hodgkin’s disease Phase Iwww.affimed.com
Alocrest™vinorelbine liposomal
Talon TherapeuticsSan Mateo, CA
non-Hodgkin’s lymphoma(see also solid tumors)
Phase I(650) 588-6404
Medicines in Development for Cancer
Medicines in Development Cancer 2012 53
lympHoma
product Name Sponsor Indication Development Status
AME-133v (ocaratuzumab)
MENTRIK BiotechDallas, TX
non-Hodgkin’s lymphoma Phase II completed(214) 593-0500
Amplimexon®
imexonAmpliMedTucson, AZ
second-line non-Hodgkin’s lymphoma Phase II(520) 529-1000
amuvatinib(MP470)
Astex PharmaceuticalsDublin, OH
(see also lung) Phase I(925) 560-0100
anti-CD22 mAb Abiogen PharmaPisa, Italy
B-cell lymphoma Phase Iwww.abiogen.com
Aplidin®
plitidepsinPharmaMarMadrid, Spain
(see also multiple myeloma, solid tumors)
Phase Iwww.pharmamar.com
AR-12 Arno TherapeuticsFlemington, NJ
(see also solid tumors) Phase I(862) 703-7170
AR-42 Arno TherapeuticsFlemington, NJ
(see also leukemia, multiple myeloma)
Phase I/II(862) 703-7170
Arranon®
nelarabine(orphan Drug)
GlaxoSmithKlineRsch. Triangle Park, NC
first-line T-cell lymphoma(see also leukemia)--------------------------------------------------second-line T-cell lymphoma
Phase III(888) 669-6682-------------------------------------------Phase I/II(888) 669-6682
Arzerra®
ofatumumabGlaxoSmithKlineRsch. Triangle Park, NC
second-line diffuse large B-cell lymphoma, second-line follicular lymphoma(see also leukemia)--------------------------------------------------Waldenström’s macroglobulinemia
Phase III(888) 825-5249
-------------------------------------------Phase II(888) 825-5249
ASP3026 Astellas Pharma USDeerfield, IL
late-stage B-cell lymphoma(see also solid tumors)
Phase I(800) 695-4321
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
non-Hodgkin’s lymphoma(see also brain, leukemia, lung, prostate, stomach)
Phase II(610) 408-0301
AT-406/Debio-1143 Ascenta TherapeuticsMalvern, PADebiopharmLausanne, Switzerland
lymphoma (see also leukemia)
Phase I(610) 408-0301www.debiopharm.com
Medicines in Development for Cancer
Medicines in Development Cancer 201254
lympHoma
product Name Sponsor Indication Development Status
AT7519(CDK inhibitor)
Astex PharmaceuticalsDublin, CA
mantle cell lymphoma(see also leukemia, multiple myeloma, solid tumors)
Phase II(925) 560-0100
AT9283(aurora/Jak2 inhibitor)
Astex PharmaceuticalsDublin, CA
non-Hodgkin’s lymphoma(see also leukemia, multiple myeloma, solid tumors)
Phase I(925) 560-0100
autologous cancer vaccine Bayer InnovationDusseldorf, GermanyStellar BiotechnologiesPort Hueneme, CA
follicular lymphoma (prevention of relapse)
Phase I(888) 842-2937(805) 488-2800
AVL-292(Btk inhibitor)
CelgeneSummit, NJ
second-line non-Hodgkin’s lymphoma, second-line Walden-ström’s macroglobulinemia(see also leukemia, unspecified)
Phase I(908) 673-9000
Bcl-2 inhibitor(ABT-199/GDC-0199)
Abbott LaboratoriesAbbott Park, ILGenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also leukemia)
Phase I(847) 937-6100(800) 626-3553
belinostat(orphan Drug)
Spectrum PharmaceuticalsHenderson, NV
peripheral T-cell lymphoma (PTCL) (Fast Track)(see also colorectal, leukemia, liver, lung, ovarian, other)
Phase II(702) 835-6300
Bexxar®
tositumomab and iodine I-131 tositumomab
GlaxoSmithKlineRsch. Triangle Park, NC
mantle cell lymphoma (combination therapy)
Phase II(888) 825-5249
BiovaxID®
B-cell lymphoma vaccine(personalized lymphoma vaccine)
BioVest InternationalTampa, FL
indolent follicular lymphoma (Fast Track)--------------------------------------------------mantle cell lymphoma
Phase III(813) 864-2554-------------------------------------------Phase II(813) 864-2554
CC-115(kinase inhibitor)
CelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also multiple myeloma, solid tumors)
Phase I(908) 673-9000
CC-122 CelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also multiple myeloma, solid tumors)
Phase I(908) 673-9000
CC-223(mTOR inhibitor)
CelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also lung, multiple myeloma)
Phase I(908) 673-9000
CEP-9722(PARP inhibitor)
CephalonFrazer, PA
mantle cell lymphoma (combination therapy)(see also lung)
Phase I(610) 344-0200
Medicines in Development for Cancer
Medicines in Development Cancer 2012 55
lympHoma
product Name Sponsor Indication Development Status
Clearazide™mechlorethamine gel(orphan Drug)
Ceptaris TherapeuticsMalvern, PA
cutaneous T-cell lymphoma(Fast Track)
application submitted(610) 975-9290
CT-011 CureTechYavne, Israel
diffuse large B-cell lymphoma, second-line follicular lymphoma (combination therapy)(see also colorectal, leukemia)
Phase IIwww.curetechbio.com
darinaparsin(ZIO-101)(orphan Drug)
ZIOPHARM OncologyNew York, NY
second-line peripheral T-cell lymphoma(see also liver, multiple myeloma, solid tumors)--------------------------------------------------first-line peripheral T-cell lymphoma (combination therapy), non-Hodgkin’s lymphoma
Phase II(646) 214-0700
-------------------------------------------Phase I(646) 214-0700
DCDS-4501A GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also leukemia)
Phase I(800) 626-3553
DCDT-2980S GenentechSouth San Francisco, CA
recurrent non-Hodgkin’s lymphoma(see also leukemia)
Phase I(800) 626-3553
DI-Leu16-IL2 Alopexx OncologyWaltham, MA
non-Hodgkin’s lymphoma Phase I(781) 497-9888
entinostat Syndax PharmaceuticalsWaltham, MA
Hodgkin’s disease(see also breast, colorectal, kidney, leukemia, lung)
Phase II(781) 419-1400
enzastaurin Eli LillyIndianapolis, IN
diffuse large B-cell lymphoma Phase III(800) 545-5979
epratuzumab(orphan Drug)
ImmunomedicsMorris Plains, NJUCBAtlanta, GA
diffuse large B-cell lymphoma (combination therapy), follicular lymphoma (combination therapy)(see also leukemia)
Phase II(973) 605-8200
epratuzumab Y-90 ImmunomedicsMorris Plains, NJ
diffuse large B-cell lymphoma
--------------------------------------------------recurrent non-Hodgkin’s lymphoma
Phase II(973) 605-8200-------------------------------------------Phase I/II(973) 605-8200
Medicines in Development for Cancer
Medicines in Development Cancer 201256
lympHoma
product Name Sponsor Indication Development Status
EZN-2968(HIF1-alpha inhibitor)
Enzon PharmaceuticalsPiscataway, NJ
(see also solid tumors) Phase I(973) 980-4500
Folotyn®
pralatrexate(orphan Drug)
Allos TherapeuticsWestminster, CO
peripheral T-cell lymphoma (first-line therapy)(see also bladder, breast, lung)--------------------------------------------------B-cell non-Hodgkin’s lymphoma, lymphoma (combination therapy)--------------------------------------------------cutaneous T-cell lymphoma
Phase III(303) 426-6262
-------------------------------------------Phase II(303) 426-6262-------------------------------------------Phase I(303) 426-6262
forodesine(orphan Drug)
BioCryst PharmaceuticalsDurham, NC
cutaneous T-cell lymphoma(see also leukemia)
Phase II(919) 859-1302
galiximab Biogen IdecCambridge, MA
non-Hodgkin’s lymphoma(combination therapy)--------------------------------------------------first-line non-Hodgkin’s lymphoma(monotherapy)
Phase II completed(617) 679-2000-------------------------------------------Phase I completed(617) 679-2000
GDC-0349(small molecule)
GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also solid tumors)
Phase I(800) 626-3553
GDC-0425(ChK1 inhibitor)
GenentechSouth San Francisco, CA
(see also solid tumors) Phase I(800) 626-3553
GDC-0575 GenentechSouth San Francisco, CA
(see also solid tumors) Phase I(800) 626-3553
GDC-0917(IAP antagonist)
GenentechSouth San Francisco, CA
(see also solid tumors) Phase I(800) 626-3553
GDC-0980(PI3 kinase/mTOR dual inhibitor)
GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also breast, solid tumors)
Phase I(800) 626-3553
GS-1101(PI3K delta inhibitor)
Gilead SciencesFoster City, CA
indolent non-Hodgkin’s lymphoma(see also leukemia)
Phase II(800) 445-3235
GSK461364(polio-like kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
non-Hodgkin’s lymphoma(see also solid tumors)
Phase I(888) 825-5249
GSK690693(AKT kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also solid tumors) Phase I(888) 825-5249
Medicines in Development for Cancer
Medicines in Development Cancer 2012 57
lympHoma
product Name Sponsor Indication Development Status
GSK2126458(PI3K/mTOR inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also solid tumors) Phase I(888) 825-5249
GSK2141795(protein kinase B inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also solid tumors) Phase I(888) 825-5249
iboctadekin GlaxoSmithKlineRsch. Triangle Park, NC
non-Hodgkin’s lymphoma (combination therapy)(see also ovarian)
Phase I completed(888) 825-5249
ibrutinib(PCI-32765)
Janssen BiotechHorsham, PAPharmacyclicsSunnyvale, CA
diffuse large B-cell lymphoma, mantle cell lymphoma(see also leukemia, multiple myeloma)
Phase II(800) 526-7736(408) 774-0330
IMGN529 ImmunoGenWaltham, MA
metastatic non-Hodgkin’s lymphoma Phase I(781) 895-0600
INK128(mTOR inhibitor)
IntellikineLa Jolla, CA
Waldenström’s macroglobulinemia(see also multiple myeloma, solid tumors)
Phase I(858) 768-6500
inotuzumab ozogamicin PfizerNew York, NY
aggressive non-Hodgkin’s lymphoma(see also leukemia)--------------------------------------------------diffuse large B-cell lymphoma, indolent non-Hodgkin’s lymphoma
Phase III(860) 732-5156-------------------------------------------Phase II(860) 732-5156
interleukin-12 gene therapy OncoSec MedicalSan Diego, CA
cutaneous T-cell lymphoma(see also skin)
Phase IIwww.oncosec.com
ISF35 MemgenSan Diego, CA
follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma(see also leukemia)
Phase II(858) 524-5400
JNJ-26481585(quisinostat)
Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
cutaneous T-cell lymphoma(see also leukemia)
Phase II(800) 817-5286
LEE011(CDK4/6 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also solid tumors) Phase I(888) 669-6682
LG740(activated T-cells)
LentigenGaithersburg, MDUniversity of PennsylvaniaPhiladelphia, PA
diffuse large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma(see also leukemia)
Phase I(301) 527-4200
Medicines in Development for Cancer
Medicines in Development Cancer 201258
lympHoma
product Name Sponsor Indication Development Status
lucatumumab(HDC122)
Novartis PharmaceuticalsEast Hanover, NJXOMABerkeley, CA
lymphoma
--------------------------------------------------follicular lymphoma
Phase I/II(888) 669-6682-------------------------------------------Phase I(888) 669-6682
Marqibo®
vincristine liposomalTalon TherapeuticsSan Mateo, CA
non-Hodgkin’s lymphoma(see also leukemia, skin, other)
Phase II(650) 588-6404
milatuzumab ImmunomedicsMorris Plains, NJ
non-Hodgkin’s lymphoma(see also leukemia, multiple myeloma)
Phase I/II(973) 605-8200
MK-7956(dinaciclib)
MerckWhitehouse Station, NJ
mantle cell lymphoma(see also leukemia)
Phase II(800) 672-6372
MK-8808 MerckWhitehouse Station, NJ
late-stage follicular lymphoma (combination therapy)
Phase I(800) 672-6372
MLN8237(alisertib)
Millennium PharmaceuticalsCambridge, MA
peripheral T-cell lymphoma (see also solid tumors)
Phase III(800) 390-5663
MLN9708(ixazomib)
Millennium PharmaceuticalsCambridge, MA
lymphoma, Waldenström’smacroglobulinemia(see also multiple myeloma, solid tumors)
Phase I(800) 390-5663
mocetinostat(MGCD0103, HDAC inhibitor)(orphan Drug)
MethylGeneMontreal, Canada
diffuse large B-cell lymphoma, follicular lymphoma(see also leukemia, solid tumors)
Phase II(514) 337-3333
mogamulizumab(orphan Drug)
AmgenThousand Oaks, CA
cutaneous T-cell lymphoma, peripheral T-cell lymphoma
Phase II(800) 772-6436
navitoclax(ABT-263)
Abbott LaboratoriesAbbott Park, IL
(see also leukemia, lung) Phase I/II(847) 937-6100
NPI-0052(marizomib)
Nereus PharmaceuticalsSan Diego, CA
(see also multiple myeloma, solid tumors)
Phase I(858) 587-4090
obatoclax(orphan Drug)
CephalonFrazer, PA
first-line follicular lymphoma (combination therapy)(see also leukemia, lung, multiple myeloma)--------------------------------------------------mantle cell lymphoma
Phase II completed(610) 344-0200
-------------------------------------------Phase I/II completed(610) 344-0200
Medicines in Development for Cancer
Medicines in Development Cancer 2012 59
lympHoma
product Name Sponsor Indication Development Status
obinutuzumab(GA101/RG7159)
Biogen IdecWeston, MAGenentechSouth San Francisco, CA
first-line non-Hodgkin’s lymphoma (combination therapy), second-line non-Hodgkin’s lymphoma (com-bination therapy), first-line B-cell lymphoma (combination therapy)(see also leukemia)--------------------------------------------------second-line non-Hodgkin’s lymphoma (monotherapy)
Phase III(781) 464-2000(800) 626-3553
-------------------------------------------Phase II(781) 464-2000(800) 626-3553
ON 013105 Onconova TherapeuticsNewtown, PA
(see also leukemia) Phase I(267) 759-3680
ONO-4059 ONO PharmaceuticalOsaka, Japan
B-cell lymphoma Phase Iwww.ono.co.jp
oral azacitidine CelgeneSummit, NJ
(see also leukemia, lung, solid tumors)
Phase I(908) 673-9000
OSI-027(TORC1/TORC2 inhibitor)
OSI PharmaceuticalsFarmingdale, NY
(see also kidney) Phase I(631) 962-0600
P 27600 Piramal Life SciencesMumbai, India
mantle cell lymphoma Phase IIwww.piramallifesciences.com
perifosine AEterna ZentarisBasking Ridge, NJ
lymphoma (combination therapy), Waldenström’s macroglobulinemia (see also brain, colorectal, kidney, leukemia, lung, multiple myeloma, sarcoma, solid tumors, stomach)
Phase II(908) 626-5428
PG11047 Progen PharmaceuticalsQueensland, Australia
(see also solid tumors) Phase Iwww.progen-pharma.com
pixantrone Cell TherapeuticsSeattle, WA
diffuse large B-cell lymphoma (see also breast)
Phase III(800) 215-2355
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
recurrent or refractory Hodgkin’s disease(see also brain, leukemia, solid tumors)
Phase II(510) 647-4000
Medicines in Development for Cancer
Medicines in Development Cancer 201260
lympHoma
product Name Sponsor Indication Development Status
Revlimid®
lenalidomideCelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also leukemia)
Phase III(908) 673-9000
RG7602 GenentechSouth San Francisco, CA
(see also solid tumors) Phase I(800) 626-3553
rigosertib Onconova TherapeuticsNewtown, PA
(see also leukemia, ovarian, pancreatic)
Phase II(267) 759-3680
Rituxan®
rituxumab(fast infusion)
Biogen IdecWeston, MAGenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma application submitted(781) 464-2000(800) 626-3553
SAR245409 (XL765)(PI3K/mTOR inhibitor)
Sanofi USBridgewater, NJExelixis South San Francisco, CA
non-Hodgkin’s lymphoma(see also breast)
Phase II(800) 981-2491(650) 837-7000
SGN-75(vorsetuzumab mafodotin)
Seattle GeneticsBothell, WA
non-Hodgkin’s lymphoma(see also kidney)
Phase I(425) 527-4000
SHP-141 Shape PharmaceuticalsCambridge, MA
cutaneous T-cell lymphoma Phase Iwww.shapepharma.com
sotrastaurin (AEB071)
Novartis PharmaceuticalsEast Hanover, NJ
diffuse large B-cell lymphoma Phase I(888) 669-6682
stem cell therapy Benitec BiopharmaSydney, AustraliaCity of Hope National Medical CenterDuarte, CA
AIDS-related lymphoma Phase Iwww.benitec.com
teglarinad CephalonFrazer, PA
(see also solid tumors) Phase I(610) 344-0200
telcyta™canfosfamide
TelikPalo Alto, CA
diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin’s lymphoma (see also lung, ovarian)
Phase II(650) 845-7700
thiarabine Access PharmaceuticalsDallas, TX
(see also leukemia) Phase I/II(215) 904-5100
Medicines in Development for Cancer
Medicines in Development Cancer 2012 61
lympHoma
product Name Sponsor Indication Development Status
tigatuzumab(anti-DR5 antibody)
Daiichi SankyoParsippany, NJ
(see also breast, colorectal, liver, ovarian, pancreatic)
Phase I completed(973) 944-2600
TKM-PLK1(RNAi)
Tekmira PharmaceuticalsBurnaby, Canada
(see also solid tumors) Phase I(604) 419-3200
trametinib GlaxoSmithKlineRsch. Triangle Park, NC
(see also leukemia, lung, multiple myeloma, pancreatic, skin)
Phase I(888) 825-5249
treanda®
bendamustineCephalonFrazer, PA
first-line non-Hodgkin’s lymphoma (combination therapy)(see also leukemia, multiple myeloma)--------------------------------------------------second-line mantle cell lymphoma (combination therapy)
application submitted(610) 344-0200
-------------------------------------------Phase II(610) 344-0200
TRU-016(humanized anti-CD37 therapeutic)
Emergent BioSolutionsRockville, MD
non-Hodgkin’s lymphoma(see also leukemia)
Phase I/II(301) 795-1800
UNBS-5162 Drais PharmaceuticalsBridgewater, NJ
(see also solid tumors) Phase I(908) 895-1200
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
first-line mantle cell lymphoma(see also leukemia, cancer-related, other)--------------------------------------------------non-Hodgkin’s B-cell lymphoma
--------------------------------------------------diffuse large B-cell lymphoma
Phase III(800) 390-5663
-------------------------------------------Phase III(800) 390-5663-------------------------------------------Phase II(800) 390-5663
veltuzumab ImmunomedicsMorris Plains, NJ
non-Hodgkin’s lymphoma(see also leukemia)
Phase I/II(973) 605-8200
Vidaza®
azacitidineCelgeneSummit, NJ
(see also leukemia) Phase III(908) 673-9000
VTX-2337 VentiRx PharmaceuticalsSeattle, WA
B-cell lymphoma(see also solid tumors)--------------------------------------------------lymphoma
Phase I/II(206) 689-2259-------------------------------------------Phase I(206) 689-2259
Medicines in Development for Cancer
Medicines in Development Cancer 201262
lympHoma
product Name Sponsor Indication Development Status
XmAb®2513(CD30-antigen inhibitor)
XencorMonrovia, CA
Hodgkin’s disease, T-cell lymphoma Phase I(626) 305-5900
YM155(sepantronium)
Astellas Pharma USDeerfield, IL
non-Hodgkin’s lymphoma(see also breast)
Phase II(800) 695-4321
zanolimumab(orphan Drug)
Emergent BioSolutionsRockville, MD
cutaneous T-cell lymphoma
--------------------------------------------------peripheral T-cell lymphoma
Phase II(301) 795-1800-------------------------------------------Phase I(301) 795-1800
Zevalin®
ibritumomab tiuxetanSpectrum PharmaceuticalsHenderson, NV
second-line diffuse large B-cell lymphoma--------------------------------------------------mantle cell lymphoma
Phase III(702) 835-6300-------------------------------------------Phase II(702) 835-6300
Zolinza®
vorinostatMerckWhitehouse Station, NJ
B-cell lymphoma(see also breast, leukemia, lung, multiple myeloma, other)
Phase II(800) 672-6273
multiple myeloma
product Name Sponsor Indication Development Status
ACE-041(dalantercept)
Acceleron PharmaCambridge, MA
(see also head/neck) Phase I(617) 649-9200
Actimid®
pomalidomide(orphan Drug)
CelgeneSummit, NJ
recurrent multiple myeloma(see also lung, lymphoma, pancreatic)
application submitted(908) 673-9000
ACY-1215(HDAC6 inhibitor)
Acetylon PharmaceuticalsBoston, MA
Phase I/II(617) 245-1300
ALXN6000(samalizumab)
Alexion PharmaceuticalsCheshire, CT
(see also leukemia) Phase I/II completed(203) 272-2596
Medicines in Development for Cancer
Medicines in Development Cancer 2012 63
multiple myeloma
product Name Sponsor Indication Development Status
Aplidin®
plitidepsin(orphan Drug)
PharmaMarMadrid, Spain
(see also lymphoma, solid tumors) Phase IIIwww.pharmamar.com
AR-42 Arno TherapeuticsFlemington, NJ
(see also leukemia, lymphoma) Phase I/II(862) 703-7170
ARRY-520(KSP inhibitor)
Array BioPharmaBoulder, CO
multiple myeloma(see also leukemia, solid tumors)--------------------------------------------------multiple myeloma (combination therapy)
Phase II(877) 633-2436-------------------------------------------Phase I(877) 633-2436
AT7519(CDK inhibitor)
Astex PharmaceuticalsDublin, CA
second-line multiple myeloma (see also leukemia, lymphoma, solid tumors)
Phase I/II(925) 560-0100
AT9283(aurora/Jak2 inhibitor)
Astex PharmaceuticalsDublin, CA
(see also leukemia, lymphoma, solid tumors)
Phase II(925) 560-0100
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, colorectal, lung, stomach)
Phase I/II(888) 669-6682
BHQ880(mAb)
Novartis PharmaceuticalsEast Hanover, NJ
(see also solid tumors) Phase II(888) 669-6682
BI-505(orphan Drug)
BioInvent InternationalLund, Sweden
second-line late-stage multiple myeloma
Phase Iwww.bioinvent.com
BIW-8962 Kyowa Hakko Kirin PharmaPrinceton, NJ
Phase I/II(609) 919-1100
carfilzomib(orphan Drug)
Onyx PharmaceuticalsSouth San Francisco, CA
third-line multiple myeloma (Fast Track)(see also solid tumors)--------------------------------------------------multiple myeloma (combination therapy)
application submitted(650) 266-0000
-------------------------------------------Phase I/II(650) 266-0000
CB3304 (noscapine)
Cougar BiotechnologyRaritan, NJ
Phase I/IIwww.cougarbiotechnology.com
CC-115(kinase inhibitor)
CelgeneSummit, NJ
(see also lymphoma, solid tumors) Phase I(908) 673-9000
CC-122 CelgeneSummit, NJ
(see also lymphoma, solid tumors) Phase I(908) 673-9000
CC-223(mTOR inhibitor)
CelgeneSummit, NJ
(see also lung, lymphoma) Phase I(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 201264
multiple myeloma
product Name Sponsor Indication Development Status
CP-18770(delanzomib)
CephalonFrazer, PA
Phase II(610) 344-0200
CX-4945(CK2 inhibitor)
Cylene PharmaceuticalsSan Diego, CA
(see also solid tumors) Phase I(858) 875-5100
daratumumab GenmabPrinceton, NJ
Phase I/II(609) 430-2481
darinaparsin(ZIO-101)
ZIOPHARM OncologyNew York, NY
(see also liver, lymphoma, solid tumors)
Phase II(646) 214-0700
DFRF-4539A GenentechSouth San Francisco, CA
refractory metastatic multiple myeloma
Phase I(800) 626-3553
elotuzumab (BMS-901608)
Bristol-Myers SquibbPrinceton, NJ
Phase III(800) 332-2056
ENMD-2076(orphan Drug)
EntreMedRockville, MD
relapsed or refractory multiple myeloma(see also ovarian, other)
Phase I(240) 864-2600
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
second-line multiple myeloma(see also breast, colorectal, leukemia, liver, lung, pancreatic, prostate, skin, stomach)
Phase I(781) 274-8200
GL-0817 GliknikBaltimore, MD
(see also head/neck) Phase IIwww.gliknik.com
GSK2110183(protein kinase B inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also leukemia) Phase I/II(888) 825-5249
GVAX® Myelomacancer vaccine
BioSante PharmaceuticalsLincolnshire, IL
Phase II(847) 478-0500
ibrutinib(PCI-32765)
Janssen BiotechHorsham, PAPharmacyclicsSunnyvale, CA
(see also leukemia, lymphoma) Phase II(800) 526-7736(408) 774-0330
imetelstat GeronMenlo Park, CA
second-line multiple myeloma (monotherapy)(see also breast, leukemia, lung)
Phase II(650) 473-7700
indatuximab ravtansine(orphan Drug)
BiotestDreieich, Germany
relapsed or refractory multiple myeloma
Phase I/IIwww.biotest.de
Medicines in Development for Cancer
Medicines in Development Cancer 2012 65
multiple myeloma
product Name Sponsor Indication Development Status
INK128(mTOR inhibitor)
IntellikineLa Jolla, CA
(see also lymphoma, solid tumors) Phase I(858) 768-6500
IPH-2101(anti-KIR mAb)
Innate PharmaMarseille, France
multiple myeloma (monotherapy)
--------------------------------------------------multiple myeloma (combination therapy)
Phase IIwww.innate-pharma.com-------------------------------------------Phase I/IIwww.innate-pharma.com
KW-2478 Kyowa Hakko Kirin PharmaPrinceton, NJ
multiple myeloma (combination therapy)
Phase I/II(609) 919-1100
LBH589 (panobinostat)
Novartis PharmaceuticalsEast Hanover, NJ
(see also kidney, leukemia, prostate, solid tumors)
Phase III(888) 669-6682
lorvotuzumab mertansine(IMGN901)
ImmunoGenWaltham, MA
(see also lung) Phase I(781) 895-0600
mapatumumab Human Genome SciencesRockville, MD
multiple myeloma (combination therapy)(see also liver, lung)
Phase II(301) 309-8504
melphalan intravenous(captisol-enabled)(orphan Drug)
CyDex PharmaceuticalsLenexa, KS
Phase IIwww.ligand.com/cydex
milatuzumab ImmunomedicsMorris Plains, NJ
recurrent multiple myeloma(see also leukemia, lymphoma)
Phase I/II(973) 605-8200
MLN9708(ixazomib)
Millennium PharmaceuticalsCambridge, MA
newly diagnosed multiple myeloma (combination therapy), second-line multiple myeloma(see also lymphoma, solid tumors)
Phase I/II(800) 390-5663
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, colorectal, head/neck, kidney, leukemia, liver, lung, ovarian, other)
Phase I/II(888) 842-2937
NPI-0052(marizomib)
Nereus PharmaceuticalsSan Diego, CA
(see also lymphoma, solid tumors) Phase I(858) 587-4090
obatoclax CephalonFrazer, PA
(see also leukemia, lung, lymphoma) Phase I completed(610) 344-0200
Medicines in Development for Cancer
Medicines in Development Cancer 201266
multiple myeloma
product Name Sponsor Indication Development Status
perifosine(orphan Drug)
AEterna ZentarisBasking Ridge, NJ
recurrent multiple myeloma (combination therapy)(Fast Track)(see also brain, colorectal, kidney, leukemia, lung, lymphoma, sarcoma, solid tumors, stomach)
Phase III(908) 626-5428
RG7444(MFGR-1877S)
GenentechSouth San Francisco, CA
refractory metastatic multiple myeloma(see also solid tumors)
Phase I(800) 626-3553
RG7598(antibody drug conjugate)
GenentechSouth San Francisco, CA
Phase I(800) 626-3553
samarium SM-153 lexidronaminjection
EUSA PharmaLanghorne, PA
(see also breast, prostate, sarcoma, other)
Phase I/II(800) 833-3533
SF1126 Semafore PharmaceuticalsIndianapolis, IN
(see also leukemia, solid tumors) Phase I(317) 876-3075
siltuximab Janssen BiotechHorsham, PA
(see also prostate, other) Phase II(800) 526-7736
SNS01-T(nano-encapsulated gene therapy)(orphan Drug)
Senesco TechnologiesBridgewater, NJ
second-line multiple myeloma Phase I/II(908) 864-4444
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
(see also brain, leukemia, pancreatic, sarcoma)
Phase I/II(650) 474-8200
TKI258(dovitinib)
Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, kidney, prostate, skin, other)
Phase II(888) 669-6682
trametinib GlaxoSmithKlineRsch. Triangle Park, NC
multiple myeloma (see also leukemia, lung, lymphoma, pancreatic, skin)
Phase I/II(888) 825-5249
treanda®
bendamustineCephalonFrazer, PA
second-line multiple myeloma (combination therapy)(see also leukemia, lymphoma)
Phase I/II(610) 344-0200
Xgeva™denosumab
AmgenThousand Oaks, CA
(see also cancer-related, other) Phase II(800) 772-6436
Zolinza®
vorinostat(orphan Drug)
MerckWhitehouse Station, NJ
metastatic multiple myeloma(see also breast, leukemia, lung, lymphoma, other)
Phase III(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012 67
ovarian CanCer
product Name Sponsor Indication Development Status
Å6 Angstrom PharmaceuticalsSolana Beach, CA
(see also other) Phase II(858) 314-2356
abagovomab(anti-idiotype mAb vaccine)(orphan Drug)
MenariniFlorence, Italy
Phase IIIwww.menarini.com
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ
(see also bladder, breast, lung, pancreatic, skin)
Phase II(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, colorectal, lung, lymphoma, prostate, skin, other)
Phase II(847) 937-6100
AE37 peptide vaccine Antigen ExpressWorcester, MA
(see also breast) Phase I(508) 852-8783
AEZS-108(orphan Drug)
AEterna ZentarisBasking Ridge, NJ
(see also bladder, prostate, other) Phase II(908) 626-5428
Avastin®
bevacizumab(orphan Drug)
GenentechSouth San Francisco, CA
relapsed, platinum-sensitive ovarian cancer(see also brain, breast, colorectal, lung, other)--------------------------------------------------first-line metastatic ovarian cancer
application submitted(800) 626-3553
-------------------------------------------Phase III(800) 626-3553
BC-819 (gene therapy)(orphan Drug)
BioCancell TherapeuticsJerusalem, Israel
late-stage ovarian cancer(see also bladder, pancreatic)
Phase I/IIwww.biocancell.com
belinostat Spectrum PharmaceuticalsHenderson, NV
late-stage ovarian cancer (combination therapy)(see also colorectal, leukemia, liver, lung, lymphoma, other)
Phase II completed(702) 835-6300
cabozantinib(XL184)
ExelixisSouth San Francisco, CA
(see also breast, kidney, lung, prostate, other)
Phase II(650) 837-7000
catumaxomab Fresenius Biotech North AmericaWaltham, MA
(see also other) Phase IIwww.fresenius-biotech.com
CVac™MUC-1 cancer vaccine
Prima BioMedSydney, Australia
Phase II/IIIwww.primabiomed.com.au
Medicines in Development for Cancer
Medicines in Development Cancer 201268
ovarian CanCer
product Name Sponsor Indication Development Status
DCVax®-ovariandendritic cell-based vaccine
Northwest BiotherapeuticsBethesda, MD
Phase I(240) 497-9024
DMUC-5754A GenentechSouth San Francisco, CA
second-line ovarian cancer (see also other)
Phase I(800) 626-3553
DPX-0907 ImmunovaccineHalifax, Canada
(see also breast, prostate) Phase I(902) 492-1819
DPX-survivac cancer vaccine ImmunovaccineHalifax, Canada
Phase I(902) 492-1819
E7850(irofulven)
EisaiWoodcliff Lake, NJ
(see also prostate, other) Phase II(888) 422-4743
EC20(technetium Tc-99m etarfolatide)
EndocyteWest Lafayette, IN
ovarian cancer (diagnosis)(see also lung)
Phase IIIwww.endocyte.com
EC145(vintafolide)
EndocyteWest Lafayette, INMerckWhitehouse Station, NJ
platinum-resistant ovarian cancer(see also lung)
Phase IIIwww.endocyte.com(800) 672-6372
EGEN-001(orphan Drug)
EGENHuntsville, AL
(see also colorectal, other) Phase II(256) 512-0077
elesclomol Synta PharmaceuticalsLexington, MA
(see also leukemia, lung) Phase II(781) 274-8200
ENMD-2076(orphan Drug)
EntreMedRockville, MD
platinum-resistant ovarian cancer(see also multiple myeloma, other)
Phase II(240) 864-2600
etirinotecan pegol (NKTR-102)(orphan Drug)
Nektar TherapeuticsSan Francisco, CA
platinum-resistant ovarian cancer(see also breast, colorectal, solid tumors)
Phase II(855) 482-6587
FANG™ Vaccineautologous tumor cell vaccine
GradalisCarrollton, TX
adjuvant ovarian cancer(see also colorectal, skin)
Phase II(214) 442-8100
folate binding protein (E39) vaccine
Galena BiopharmaLake Oswego, OR
(see also breast, other) Phase I/II(855) 855-4253
iboctadekin GlaxoSmithKlineRsch. Triangle Park, NC
(see also lymphoma) Phase I completed(888) 825-5249
Medicines in Development for Cancer
Medicines in Development Cancer 2012 69
ovarian CanCer
product Name Sponsor Indication Development Status
IMT-1012 immunotherapeutic vaccine
ImmunotopeDoylestown, PA
(see also breast) Phase I(215) 253-4180
iniparib(BSI-201)
Sanofi USBridgewater, NJ
(see also breast, lung) Phase II(800) 981-2491
Karenitecin®
cositecanBioNumerik PharmaceuticalsSan Antonio, TX
advanced ovarian cancer(see also lung, solid tumors)
Phase III(210) 614-1701
KHK-2866 Kyowa Hakko Kirin PharmaPrinceton, NJ
ovarian cancer (combination therapy)(see also solid tumors)
Phase I(609) 919-1100
MK-1775(Wee1 inhibitor)
MerckWhitehouse Station, NJ
second-line ovarian cancer Phase II(800) 672-6372
MORAb-003(farletuzumab)
EisaiWoodcliff Lake, NJ
platinum-sensitive ovarian cancer(see also lung)
Phase III(888) 422-4743
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
first-line ovarian cancer (see also breast, colorectal, head/neck, kidney, leukemia, liver, lung, multiple myeloma, other)
Phase II(888) 842-2937
OGX-427 OncoGenex PharmaceuticalsBothell, WA
(see also breast, lung) Phase I(425) 686-1500
olaratumab(LY3012207)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
(see also brain) Phase II(800) 545-5979
ombrabulin (AVE8062)
Sanofi USBridgewater, NJ
second-line ovarian cancer(see also lung, sarcoma)
Phase II(800) 981-2491
opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
(see also brain, lung, stomach, other) Phase III(800) 215-2355
oregovomab(orphan Drug)
Quest PharmaTechEdmonton, Canada
Phase I/II(780) 448-1400
OSI-906(IGF-1R/1R tyrosinase kinase inhibitor)
OSI PharmaceuticalsFarmingdale, NY
(see also lung, other) Phase II(631) 962-0600
oVax®
autologous cell vaccine(orphan Drug)
AVAX TechnologiesPhiladelphia, PA
Phase I/II(215) 241-9760
Medicines in Development for Cancer
Medicines in Development Cancer 201270
ovarian CanCer
product Name Sponsor Indication Development Status
phenoxodiol Marshall EdwardsSan Diego, CA
second-line late-stage ovarian cancer (Fast Track)(see also prostate, other)
Phase III(858) 792-6300
picoplatin Ponaird PharmaceuticalsSeattle, WA
(see also colorectal, lung, prostate) Phase II(206) 281-7001
Quinamed®
amonafideCephalonFrazer, PA
(see also breast, prostate) Phase II(610) 344-0200
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
ovarian cancer (combination therapy)(see also brain, colorectal, head/neck, lung, pancreatic, sarcoma, skin, solid tumors)--------------------------------------------------ovarian cancer (monotherapy)
Phase II(403) 670-7377
-------------------------------------------Phase I(403) 670-7377
RG7458 GenentechSouth San Francisco, CA
Phase I(800) 626-3553
RG7599(antibody drug conjugate)
GenentechSouth San Francisco, CA
(see also lung) Phase I(800) 626-3553
RG7600(antibody drug conjugate)
GenentechSouth San Francisco, CA
platinum-resistant ovarian cancer(see also pancreatic)
Phase I(800) 626-3553
rigosertib Onconova TherapeuticsNewtown, PA
(see also leukemia, lymphoma, pancreatic)
Phase II(267) 759-3680
rucaparib Clovis OncologyBoulder, CO
(see also breast) Phase II(303) 625-5000
sagopilone Bayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, prostate) Phase II completed(888) 842-2937
SAR256212 (MM-121)(anti-ErbB3 mAb)
Merrimack PharmaceuticalsCambridge, MASanofi USBridgewater, NJ
(see also breast, lung) Phase I(800) 981-2491
SG2000 SpirogenLondon, United Kingdom
Phase IIwww.spirogen.com
squalamine(orphan Drug)
OHR PharmaceuticalNew York, NY
resistant ovarian cancer Phase II(212) 682-8452
telcyta™canfosfamide
TelikPalo Alto, CA
(see also lung, lymphoma) Phase III completed(650) 845-7700
Medicines in Development for Cancer
Medicines in Development Cancer 2012 71
ovarian CanCer
product Name Sponsor Indication Development Status
tigatuzumab(anti-DR5 antibody)
Daiichi SankyoParsippany, NJ
(see also breast, colorectal, liver, lymphoma, pancreatic)
Phase II(973) 944-2600
topotecan liposomes injection Talon TherapeuticsSan Mateo, CA
(see also lung) Phase I(650) 588-6404
trabectedin(orphan Drug)
Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
second-line ovarian cancer(see also breast, prostate, sarcoma)
Phase III(800) 817-5286
TRC 105(ENG protein inhibitor)
TRACON PharmaceuticalsSan Diego, CA
(see also breast, prostate, other) Phase II(858) 550-0780
trebananib (AMG386)
AmgenThousand Oaks, CA
(see also breast, colorectal, kidney, liver, stomach, other)
Phase III(800) 772-6436
Vargatef™intedanib
Boehringer IngelheimPharmaceuticalsRidgefield, CT
first-line late-stage ovarian cancer (combination therapy)(see also lung)
Phase III(800) 243-0127
vosaroxin Sunesis PharmaceuticalsSouth San Francisco, CA
(see also leukemia) Phase II(650) 266-3739
Votrient™pazopanib
GlaxoSmithKlineRsch. Triangle Park, NC
(see also kidney, other) Phase III(888) 825-5249
Zybrestat™fosbretabulin(orphan Drug)
OXiGENESouth San Francisco, CA
(see also lung) Phase II(650) 635-7000
panCreatiC CanCer
product Name Sponsor Indication Development Status
Abraxane®
albumin-bound paclitaxel(orphan Drug)
CelgeneSummit, NJ
(see also bladder, breast, lung, ovarian, skin)
Phase III(908) 673-9000
Actimid®
pomalidomideCelgeneSummit, NJ
(see also lung, lymphoma, multiple myeloma)
Phase I/II(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 201272
panCreatiC CanCer
product Name Sponsor Indication Development Status
anti-MUC1 mAb Quest PharmaTechEdmonton, Canada
Phase I/II(780) 448-1400
anti-PSCA mAb AgensysSanta Monica, CAAstellas Pharma USDeerfield, IL
metastatic pancreatic cancer(combination therapy)
Phase II(800) 695-4321
apricoxib(TG01)
Tragara PharmaceuticalsSan Diego, CA
pancreatic (combination therapy)(see also lung)
Phase II(858) 350-6900
Archexin®
RX-0201(orphan Drug)
Rexahn PharmaceuticalsRockville, MD
metastatic pancreatic cancer (combination therapy)
Phase II(240) 268-5300
ASG-5ME AgensysSanta Monica, CASeattle GeneticsBothell, WA
metastatic pancreatic cancer(see also prostate)
Phase I(800) 695-4321(425) 527-4000
bavituximab Peregrine PharmaceuticalsTustin, CA
first-line pancreatic cancer (see also liver, lung)
Phase II(715) 508-6000
BAY 86-9766(MEK inhibitor)
Ardea BiosciencesSan Diego, CABayer HealthCare PharmaceuticalsWayne, NJ
first-line pancreatic cancer (combination therapy)(see also liver)
Phase I/II(888) 842-2937
BC-819 (gene therapy)(orphan Drug)
BioCancell TherapeuticsJerusalem, Israel
first-line late-stage pancreatic cancer(combination therapy) (Fast Track)(see also bladder, ovarian)
Phase IIwww.biocancell.com
Chk1 inhibitor(LY2603618)
Eli LillyIndianapolis, IN
(see also lung) Phase II(800) 545-5979
CO-101(lipid drug conjugate of gemcitabine)(orphan Drug)
Clovis OncologyBoulder, CO
first-line metastatic pancreatic cancer, second-line metastatic pancreatic cancer
Phase II(303) 625-5000
CO-101companion diagnostic(hENT1 IHC assay)
Clovis OncologyBoulder, COVentana Medical SystemsTucson, AZ
pancreatic cancer (diagnosis) in clinical trials(303) 625-5000
CPI-613(orphan Drug)
Cornerstone PharmaceuticalsCranbury, NJ
combination therapy(see also other)
Phase I/II(609) 409-7050
Medicines in Development for Cancer
Medicines in Development Cancer 2012 73
panCreatiC CanCer
product Name Sponsor Indication Development Status
CRS-207(cancer vaccine)
Aduro BioTechBerkeley, CA
metastatic pancreatic cancer(combination therapy)
Phase II(510) 848-4400
dalotuzumab(MK-0646)
MerckWhitehouse Station, NJ
(see also breast, lung, other) Phase I/II(800) 672-6372
encapsulated cell therapy(macrobeads)
Rogosin InstituteNew York, NY
refractory metastatic pancreatic cancer(see also colorectal, prostate)
Phase II(212) 746-1566
FG-3019(connective tissue growth factor)
FibroGenSan Francisco, CA
Phase II(415) 978-1200
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, prostate, skin, stomach)
Phase II(781) 274-8200
ganitumab(AMG 479)
AmgenThousand Oaks, CA
first-line metastatic pancreatic cancer(combination therapy)(see also breast, colorectal, lung, sarcoma)
Phase III(800) 772-6436
GI-4000 GlobeImmuneLouisville, CO
(see also colorectal, lung) Phase II(303) 625-2700
glufosfamide(orphan Drug)
Eleison PharmaceuticalsPrinceton, NJ
pancreatic cancer (Fast Track) Phase III completed(215) 554-3530
GS-6624(monoclonal antibody)
Gilead SciencesFoster City, CA
(see also colorectal) Phase II(800) 445-3235
GV1001 (hTERT RNA vaccine)
KAEL-GemVaxSeoul, South Korea
Phase Iwww.kaelgemvax.com
GVAX® pancreaticcancer vaccine(orphan Drug)
BioSante PharmaceuticalsLincolnshire, ILAduro BioTechBerkeley, CA
Phase II(847) 478-0500(510) 848-4400
HyperAcute® pancreasalgenpantucel-L(orphan Drug)
NewLink GeneticsAmes, IA
Phase III(515) 296-5555
IMP321 ImmutepChâtenay-Malabry, France
Phase Iwww.immutep.org
INNO-206(orphan Drug)
CytRxLos Angeles, CA
pancreatic ductal adenocarcinoma(see also sarcoma, solid tumors)
Phase II(310) 826-5648
Medicines in Development for Cancer
Medicines in Development Cancer 201274
panCreatiC CanCer
product Name Sponsor Indication Development Status
Istodax®
romidepsinCelgeneSummit, NJ
(see also kidney, prostate, other) Phase I/II(908) 673-9000
Jakafi™ruxolitinib
Incyte Wilmington, DE
(see also other) Phase II(855) 446-2983
KD032(ras/mTOR inhibitor)
Kadmon PharmaceuticalsWarrendale, PA
(see also lung) Phase I/II completed(724) 778-6100
LDE225(erismodegib)
Novartis PharmaceuticalsEast Hanover, NJ
neoadjuvant pancreatic cancer(see also leukemia, solid tumors, skin)
Phase I/II(888) 669-6682
LE-DT(liposomal docetaxel)
Insys TherapeuticsPhoenix, AZ
first-line pancreatic cancer Phase II(602) 910-2617
M402(low molecular weight heparin)
Momenta PharmaceuticalsCambridge, MA
metastatic pancreatic cancer Phase I/II(617) 491-9700
masitinib AB Science USAShort Hills, NJ
(see also stomach) Phase III(973) 218-2437
MM-398(nanotherapeutic)(orphan Drug)
Merrimack PharmaceuticalsCambridge, MA
metastatic pancreatic cancer Phase II(617) 441-1000
naptumomab estafenatox Active BiotechLund, Sweden
(see also kidney, lung) Phase I completedwww.activebiotech.com
NPC-1C(ensituximab)(orphan Drug)
Neogenix OncologyRockville, MD
late-stage, metastatic pancreatic cancer(see also colorectal)
Phase I(301) 917-6893
paclitaxel polymeric micelle formulation
Samyang BiopharmaceuticalsSeoul, South Korea
late-stage pancreatic cancer Phase IIwww.samyangpharm.com
pancAtak™gene therapy
AdvantageneAuburndale, MA
Phase I(617) 916-5445
PCI-27483(factor VIIa inhibitor)
PharmacyclicsSunnyvale, CA
metastatic pancreatic cancer (combination therapy)
Phase II(408) 774-0330
PEGPH20(pegylated recombinant human hyaluronidase)
Halozyme TherapeuticsSan Diego, CA
Phase I/II(858) 794-8889
Medicines in Development for Cancer
Medicines in Development Cancer 2012 75
panCreatiC CanCer
product Name Sponsor Indication Development Status
PHY906 PhytoCeuticaNew Haven, CT
(see also colorectal, liver, cancer-related)
Phase I/II(203) 777-3462
polyclonal antibody stimulator(orphan Drug)
Cancer AdvancesDurham, NC
(see also colorectal, stomach) Phase III(919) 361-2162
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
pancreatic cancer (combination therapy)(see also brain, colorectal, head/neck, lung, ovarian, sarcoma, skin, solid tumors)
Phase II(403) 670-7377
Rexin-G®
(orphan Drug)Epeius BiotechnologiesSan Marino, CA
metastatic pancreatic cancer(Fast Track)(see also breast, sarcoma)
Phase I/II(626) 441-6695
RG7600(antibody drug conjugate)
GenentechSouth San Francisco, CA
platinum-resistant pancreatic cancer(see also ovarian)
Phase I(800) 626-3553
rigosertib Onconova TherapeuticsNewtown, PA
(see also leukemia, lymphoma, ovarian)
Phase II/III(267) 759-3680
RP101 RESprotectDresden, Germany
Phase II/IIIwww.resprotect.de
SecreFlo™synthetic human secretin
RepligenWaltham, MA
pancreatic cancer (diagnosis) Phase 0(781) 250-0111
SpRYCeL®
dasatinibBristol-Myers SquibbPrinceton, NJ
(see also brain, breast, prostate, other)
in clinical trials(800) 332-2056
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
(see also brain, leukemia, multiple myeloma, sarcoma)
Phase II(650) 474-8200
tigatuzumab(anti-DR5 antibody)
Daiichi SankyoParsippany, NJ
(see also breast, colorectal, liver, lymphoma, ovarian)
Phase II completed(973) 944-2600
tivantinib (ARQ 197)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
(see also colorectal, kidney, liver, lung, sarcoma, other)
Phase I(781) 994-0300(973) 944-2600
trametinib GlaxoSmithKlineRsch. Triangle Park, NC
first-line pancreatic cancer (see also leukemia, lung, lymphoma, multiple myeloma, skin)
Phase II(888) 825-5249
uridine triacetate (PN401)
Wellstat TherapeuticsGaithersburg, MD
(see also stomach) Phase III(240) 631-2500
Medicines in Development for Cancer
Medicines in Development Cancer 201276
panCreatiC CanCer
product Name Sponsor Indication Development Status
Virulizin® Lorus TherapeuticsToronto, Canada
Phase III(416) 798-1200
Y-90 clivatuzumab(orphan Drug)
ImmunomedicsMorris Plains, NJ
first-line pancreatic cancer (Fast Track)
Phase I/II(973) 605-8200
prostate CanCer
product Name Sponsor Indication Development Status
99mTc-MIP-1405 Molecular Insight PharmaceuticalsCambridge, MA
prostate cancer (diagnosis) Phase I(617) 492-5554
ABI-008(nab®-docetaxel)
CelgeneSummit, NJ
first-line hormone-refractory prostate cancer
Phase I/II(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, colorectal, lung, lymphoma, ovarian, skin, other)
Phase I(847) 937-6100
AEZS-108 AEterna ZentarisBasking Ridge, NJ
(see also bladder, ovarian, other) Phase II(908) 626-5428
anti-OX40 mAb AgonOxPortland, OR
Phase I(800) 979-7202
AP1903 Bellicum PharmaceuticalsHouston, TX
(see also cancer-related) Phase I/II(713) 341-6472
Apatone®
ascorbic acid/menadioneIC-MedTechSan Diego, CA
Phase I/II(619) 749-6500
APC-100 Adamis PharmaceuticalsSan Diego, CA
Phase I/IIwww.adamispharmaceuticals.com
ARC-100 Archer BiosciencesNew York, NY
hormone-refractory prostate cancer(see also brain, breast, skin)
Phase II(646) 747-9090
ARN-509 Aragon PharmaceuticalsSan Diego, CA
hormone-refractory prostate cancer Phase I/II(858) 369-7600
Medicines in Development for Cancer
Medicines in Development Cancer 2012 77
prostate CanCer
product Name Sponsor Indication Development Status
ASG-5ME AgensysSanta Monica, CASeattle GeneticsBothell, WA
castration-resistant prostate cancer(see also pancreatic)
Phase I(800) 695-4321(425) 527-4000
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
hormone-refractory prostate cancer (combination therapy)(see also brain, leukemia, lung, lymphoma, stomach)--------------------------------------------------hormone-sensitive prostate cancer
Phase II(610) 408-0301
-------------------------------------------Phase I(610) 408-0301
AZD3514(androgen receptor down-regulator)
AstraZenecaWilmington, DE
Phase I(800) 236-9933
bafetinib CytRx Los Angeles, CA
second-line metastatic hormone-refractory prostate cancer(see also brain, leukemia)
Phase II(310) 826-5648
BPX-101(dendritic cell vaccine)
Bellicum PharmaceuticalsHouston, TX
Phase I/II(713) 341-6472
cabozantinib(XL184)
ExelixisSouth San Francisco, CA
castration-resistant prostate cancer (see also breast, kidney, lung, ovarian, other)
Phase III(650) 837-7000
CBLC102(mepacrine)
Cleveland BioLabsBuffalo, NYIncuronMoscow, Russia
hormone-refractory prostate cancer Phase II completed(716) 849-6810
CD1089 (seocalcitol)
Cougar BiotechnologyRaritan, NJ
Phase Iwww.cougarbiotechnology.com
cilengitide EMD SeronoRockland, MA
(see also brain) Phase III(800) 283-8088
custirsen(OGX-011/TV-1011)
OncoGenex PharmaceuticalsBothell, WATeva PharmaceuticalsTikva, Israel
first-line prostate cancer (combina-tion therapy), second-line hormone-refractory prostate cancer (combina-tion therapy) (Fast Track)(see also lung)
Phase III(425) 686-1500
CYT-500 EUSA PharmaLanghorne, PA
Phase I(800) 833-3533
DPX-0907 ImmunovaccineHalifax, Canada
(see also breast, ovarian) Phase I(902) 492-1819
Medicines in Development for Cancer
Medicines in Development Cancer 201278
prostate CanCer
product Name Sponsor Indication Development Status
DSTP-3086S GenentechSouth San Francisco, CA
metastatic hormone-refractory prostate cancer
Phase I(800) 626-3553
E7850(irofulven)
EisaiWoodcliff Lake, NJ
hormone-refractory prostate cancer(see also ovarian, other)
Phase II(888) 422-4743
EMD-525797(anti-integrin mAb)
EMD SeronoRockland, MA
metastatic castration-resistant prostate cancer
Phase II/III(800) 283-8088
emepepimut-S EMD SeronoRockland, MAOncothyreonSeattle, WA
newly-diagnosed prostate cancer(see also lung)
Phase II(800) 283-8088
encapsulated cell therapy(macrobeads)
Rogosin InstituteNew York, NY
refractory metastatic prostate cancer(see also colorectal, pancreatic)
Phase II(212) 746-1566
enzalutamide(MDV3100)
Astellas PharmaTokyo, JapanMedivationSan Francisco, CA
hormone-refractory prostate cancer(Fast Track)
Phase III(415) 543-3470
EPO-806(patupilone)
Novartis PharmaceuticalsEast Hanover, NJ
(see also brain) Phase II(888) 669-6682
EZN-4176(antisense oligonucleotide)
Enzon PharmaceuticalsPiscataway, NJ
Phase I(973) 980-4500
Firmagon®
degarelixFerring PharmaceuticalsParsippany, NJ
3-month formulation
--------------------------------------------------neoadjuvant therapy
Phase III(973) 796-1600-------------------------------------------Phase III(973) 796-1600
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
second-line hormone-refractory prostate cancer(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, skin, stomach)
Phase II(781) 274-8200
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
hormone-refractory prostate cancer(see also lung, skin, other)
Phase II(888) 669-6682
GRNVAC1(dendritic cell vaccine)
Argos TherapeuticsDurham, NCGeronMenlo Park, CA
(see also leukemia) Phase I/II(650) 473-7700
Medicines in Development for Cancer
Medicines in Development Cancer 2012 79
prostate CanCer
product Name Sponsor Indication Development Status
GTx-758(selective estrogen receptoralpha agonist)
GTxMemphis, TN
first-line advanced prostate cancer,second-line advanced prostate cancer
Phase II(901) 523-9700
GVAX® prostatecancer vaccine
BioSante PharmaceuticalsLincolnshire, ILAduro BioTechBerkeley, CA
(Fast Track) Phase III(847) 478-0500(510) 848-4400
Halaven®
eribulinEisaiWoodcliff Lake, NJ
(see also lung, sarcoma) Phase II(888) 422-4743
HE3235 Harbor TherapeuticsSan Diego, CA
hormone-refractory prostate cancer Phase I/II(858) 587-9333
intetumumab Janssen BiotechHorsham, PA
(see also skin) Phase II completed(800) 526-7736
IRX4204 Io TherapeuticsSanta Ana, CA
Phase IIwww.io-therapeutics.com
ISIS-EIF4ERx Isis PharmaceuticalsCarlsbad, CA
prostate cancer (combination therapy)(see also lung)
Phase II(800) 679-4747
Istodax®
romidepsinCelgeneSummit, NJ
(see also kidney, pancreatic, other) Phase II(908) 673-9000
J 591 Lu-177(anti-PMSA mAb)
BZL BiologicsNew York, NY
metastatic prostate cancer, non-metastatic prostate cancer
Phase II(212) 315-5575
JNJ-26854165(Hdm2 inhibitor)
Johnson & Johnson Pharmaceutical Research & DevelopmentRaritan, NJ
(see also lung, solid tumors) Phase I(800) 817-5286
KX2-391 Kinex PharmaceuticalsBuffalo, NY
(see also leukemia) Phase II(716) 898-8626
LBH589 (panobinostat)
Novartis PharmaceuticalsEast Hanover, NJ
(see also kidney, leukemia, multiple myeloma, solid tumors)
Phase II(888) 669-6682
LFA102(anti-prolactin receptor antibody)
Novartis PharmaceuticalsEast Hanover, NJXOMABerkeley, CA
(see also breast) Phase I(888) 669-6682
LOR-2040 Lorus TherapeuticsToronto, Canada
metastatic prostate cancer(see also breast, colorectal, kidney, leukemia)
Phase II(416) 798-1200
Medicines in Development for Cancer
Medicines in Development Cancer 201280
prostate CanCer
product Name Sponsor Indication Development Status
MER-104(GnRH antagonist)
Merrion PharmaceuticalsWilmington, DE
Phase I(910) 799-1847
MVA-BN® pRoantigen cancer vaccine
BN ImmunoTherapeuticsMountain View, CA
Phase I/II(650) 681-4660
NeuVax™cancer vaccine E75
Galena BiopharmaLake Oswego, OR
(see also breast) Phase I/II(855) 855-4253
nimotuzumab YM Biosciences USALehigh Valley, PA
(see also brain, breast) Phase II(610) 560-0600
NX-1207 Nymox PharmaceuticalQuebec, Canada
Phase II(800) 936-9669
ODM-201(androgen receptor antagonist)
Endo PharmaceuticalsChadds Ford, PAOrionEspoo, Finland
castration-resistant prostate cancer Phase II(800) 462-3636
oncolytic virus CZ BioMedTampa, FL
Phase I(813) 600-4088
Onyvax-105anti-idiotype cancer vaccine 105AD7
VaxOncoSeoul, South Korea
Phase IIwww.vaxonco.com
Onyvax-P(prostate cancer vaccine)
VaxOncoSeoul, South Korea
Phase II
ozarelix Spectrum PharmaceuticalsHenderson, NV
hormone-dependent prostate cancer Phase II(702) 835-6300
PEG arginine deiminase (ADI-PEG 20)
Polaris PharmaceuticalsSan Diego, CA
prostate cancer (combination therapy)(see also liver, skin, other)
Phase I(858) 452-6688
phenoxodiol Marshall EdwardsSan Diego, CA
prostate cancer (Fast Track)(see also ovarian, other)
Phase II completed(858) 792-6300
picoplatin Ponaird PharmaceuticalsSeattle, WA
(see also colorectal, lung, prostate) Phase II(206) 281-7001
prostAtak™gene therapy
AdvantageneAuburndale, MA
adjuvant prostate cancer(Fast Track)
Phase III(617) 916-5445
Medicines in Development for Cancer
Medicines in Development Cancer 2012 81
prostate CanCer
product Name Sponsor Indication Development Status
prostate cancer vaccine(anti-GnRH)
Novartis Vaccines & DiagnosticsCambridge, MA Pepscan TherapeuticsLelystad, Netherlands
Phase I/II(617) 871-7000
prostvac™rilimogene galvacirepvec
BM ImmunoTherapeuticsMountain View, CA
castration-resistant prostate cancer(Fast Track)
Phase III(650) 681-4660
provenge®
sipuleucel-TDendreonSeattle, WA
recurrent early-stage prostate cancer
--------------------------------------------------neoadjuvant early-stage prostate cancer
Phase III(877) 256-4545-------------------------------------------Phase II(877) 256-4545
PRX-302 Sophiris BioLa Jolla, CA
Phase II(858) 777-1760
PSMA ADC(anti-drug conjugate)
Progenics PharmaceuticalsTarrytown, NY
Phase I(914) 789-2800
PSMA protein vaccine(recombinant soluble)
Progenics PharmaceuticalsTarrytown, NY
Phase I(914) 789-2800
PSMA VRP therapeutic vaccine Progenics PharmaceuticalsTarrytown, NY
Phase I(914) 789-2800
PX-866 OncothyreonSeattle, WA
hormone-refractory prostate cancer(see also brain, head/neck, lung)
Phase II(206) 801-2100
Quinamed®
amonafideCephalonFrazer, PA
(see also breast, ovarian) Phase II(610) 344-0200
REIC gene therapy Momotaro-GeneOkayama, Japan
Phase Iwww.mt-gene.com
ridaforolimus ARIAD PharmaceuticalsCambridge, MAMerckWhitehouse Station, NJ
(see also breast, kidney, lung, sarcoma, other)
Phase II(800) 672-6372
sagopilone Bayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, ovarian) Phase II completed(888) 842-2937
samarium SM-153 lexidronam injection
EUSA PharmaLanghorne, PA
(see also breast, multiple myeloma, sarcoma, other)
Phase II(800) 833-3533
siltuximab Janssen BiotechHorsham, PA
hormone-refractory prostate cancer(see also multiple myeloma, other)
Phase I(800) 526-7736
Medicines in Development for Cancer
Medicines in Development Cancer 201282
prostate CanCer
product Name Sponsor Indication Development Status
SpRYCeL®
dasatinibBristol-Myers SquibbPrinceton, NJ
(see also brain, breast, pancreatic, other)
in clinical trials(800) 332-2056
TAK-448(KISS1R protein agonist)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
TAK-700 (orteronel)
Millennium PharmaceuticalsCambridge, MA
first-line metastatic prostate cancer (combination therapy), second-line metastatic prostate cancer(combination therapy)--------------------------------------------------prostate cancer
Phase III(800) 390-5663
-------------------------------------------Phase II(800) 390-5663
tasquinimod(TASQ)
Active BiotechLund, Sweden
metastatic prostate cancer
--------------------------------------------------second-line metastatic prostate cancer
Phase IIIwww.activebiotech.com-------------------------------------------Phase Iwww.activebiotech.com
teloB-Vaxtelomerase cancer vaccine
Adamis PharmaceuticalsSan Diego, CA
Phase Iwww.adamispharmaceuticals.com
tesetaxel GentaBerkeley Heights, NJ
(see also bladder, breast, skin, stomach)
Phase II(908) 286-9800
tigapotide Kotinos PharmaceuticalsNew York, NY
hormone-refractory prostate cancer Phase II(212) 935-3000
TKI258(dovitinib)
Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, kidney, multiple myeloma, skin, other)
Phase II(888) 669-6682
tNFerade™golnerminogene pradenovec
GenVecGaithersburg, MD
(see also head/neck, skin, stomach) Phase I(877) 943-6832
TOK-001 Tokai PharmaceuticalsCambridge, MA
castration-resistant prostate cancer Phase I(617) 225-4305
trabectedin Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
(see also breast, ovarian, sarcoma) Phase II(800) 817-5286
TRC 105(ENG protein inhibitor)
TRACON PharmaceuticalsSan Diego, CA
(see also breast, ovarian, other) Phase I/II(858) 550-0780
Medicines in Development for Cancer
Medicines in Development Cancer 2012 83
prostate CanCer
product Name Sponsor Indication Development Status
trofex™iofolastat I-124
Molecular Insight PharmaceuticalsCambridge, MA
prostate cancer (diagnosis) Phase I(617) 491-5554
troVax®
tumor-associated antigen vaccine
Oxford BioMedicaOxford, United Kingdom
hormone-refractory prostate cancer(combination therapy)
Phase IIwww.oxfordbiomedica.co.uk
VT-464 Viamet PharmaceuticalsMorrisville, NC
Phase I/II(919) 467-8539
YeRVoY®
ipilimumabBristol-Myers SquibbPrinceton, NJ
prostate cancer (post-hormonal therapy), prostate cancer (post-chemotherapy)(see also lung, skin)
in clinical trials(800) 332-2056
Zaltrap™aflibercept
Regeneron PharmaceuticalsTarrytown, NYSanofi USBridgewater, NJ
first-line androgen-independent prostate cancer(see also colorectal)
Phase III(914) 345-7400(800) 981-2491
Zytiga®
abirateroneJanssen BiotechHorsham, PA
first-line metastatic prostate cancer(see also breast)--------------------------------------------------neoadjuvant prostate cancer
Phase III(800) 526-7736-------------------------------------------Phase II(800) 526-7736
sarComa
product Name Sponsor Indication Development Status
8H9 I-131 mAb United TherapeuticsSilver Spring, MD
soft tissue sarcoma(see also brain, other)
Phase I(301) 608-9292
abexinostat(HDAC inhibitor)
PharmacyclicsSunnyvale, CA
sarcoma(see also lymphoma)
Phase I/II(408) 774-0330
brivanib(VEGFR/FGFR kinase inhibitor)
Bristol-Myers SquibbPrinceton, NJ
(see also colorectal, liver) Phase II(800) 332-2056
cancer vaccine MabVax TherapeuticsSan Diego, CA
(see also breast) Phase II(858) 259-9405
ganitumab(AMG 479)
AmgenThousand Oaks, CA
(see also breast, colorectal, lung, pancreatic)
Phase II(800) 772-6436
Halaven®
eribulinEisaiWoodcliff Lake, NJ
(see also lung, prostate) Phase III(888) 422-4743
Medicines in Development for Cancer
Medicines in Development Cancer 201284
sarComa
product Name Sponsor Indication Development Status
INNO-206(orphan Drug)
CytRxLos Angeles, CA
soft tissue sarcoma(see also pancreatic, solid tumors)
Phase II(310) 826-5648
Junovan™mifamurtide(orphan Drug)
Millennium PharmaceuticalsCambridge, MA
osteosarcoma Phase III(800) 390-5663
ombrabulin (AVE8062)
Sanofi USBridgewater, NJ
(see also lung, ovarian) Phase III(800) 981-2491
palifosfamide(ZIO-201)(orphan Drug)
ZIOPHARM OncologyNew York, NY
first-line soft tissue sarcoma (combination therapy)(see also lung, solid tumors)--------------------------------------------------second-line soft tissue sarcoma (combination therapy)--------------------------------------------------soft tissue sarcoma (monotherapy)
Phase III(646) 214-0700
-------------------------------------------Phase II(646) 214-0700-------------------------------------------Phase I/II(646) 214-0700
perifosine AEterna ZentarisBasking Ridge, NJ
(see also brain, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, solid tumors, stomach)
Phase II(908) 626-5428
PM-00104 PharmaMarMadrid, Spain
Ewing’s sarcoma(see also cervical, other)
Phase IIwww.pharmamar.com
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
(see also brain, colorectal, head/neck, lung, ovarian, pancreatic, skin, solid tumors)
Phase II(403) 670-7377
Rexin-G®
(orphan Drug)Epeius BiotechnologiesSan Marino, CA
osteosarcoma(see also breast, pancreatic)--------------------------------------------------soft tissue sarcoma
Phase II(626) 441-6695-------------------------------------------Phase I/II(626) 441-6695
ridaforolimus(orphan Drug)
ARIAD PharmaceuticalsCambridge, MAMerckWhitehouse Station, NJ
metastatic sarcoma (Fast Track)(see also breast, kidney, lung, prostate, other)--------------------------------------------------sarcoma
application submitted(800) 672-6372(626) 441-6695-------------------------------------------Phase II(800) 672-6372(626) 441-6695
robatumumab MerckWhitehouse Station, NJ
osteosarcoma, sarcoma(see also colorectal, solid tumors)
Phase II(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 85
sarComa
product Name Sponsor Indication Development Status
samarium SM-153 lexidronaminjection
EUSA PharmaLanghorne, PA
osteosarcoma(see also breast, multiple myeloma, prostate, other)
Phase I/II(800) 833-3533
saridegib(orphan Drug)
Infinity PharmaceuticalsCambridge, MA
chondrosarcoma (inoperable/unresectable)
Phase II(617) 453-1000
TH-302(orphan Drug)
Threshold PharmaceuticalsSouth San Francisco, CA
soft tissue sarcoma(see also brain, leukemia, multiple myeloma, pancreatic)
Phase III(650) 474-8200
tivantinib (ARQ 197)(orphan Drug)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
soft tissue sarcoma(see also colorectal, kidney, liver, lung, pancreatic, other)
Phase II(781) 994-0300(973) 944-2600
trabectedin(orphan Drug)
Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
soft tissue sarcoma(see also breast, ovarian, prostate)--------------------------------------------------soft tissue sarcoma (adolescents and children)
Phase III(800) 817-5286-------------------------------------------Phase II(800) 817-5286
skin CanCer
product Name Sponsor Indication Development Status
Abraxane®
albumin-bound paclitaxel(orphan Drug)
CelgeneSummit, NJ
malignant melanoma(see also bladder, breast, lung, ovarian, pancreatic)
Phase III(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
malignant melanoma(see also brain, breast, colorectal, lung, lymphoma, ovarian, prostate, other)
Phase II(847) 937-6100
Ad-IL-12 DNA therapeutic(INXN-2001)
ZIOPHARM OncologyNew York, NY
malignant melanoma Phase I(646) 214-0700
Allovectin®
velimogene aliplasmid(orphan Drug)
VicalSan Diego, CA
first-line malignant melanoma Phase III(858) 646-1100
Medicines in Development for Cancer
Medicines in Development Cancer 201286
skin CanCer
product Name Sponsor Indication Development Status
ALT-801 Altor BioScienceMiramar, FL
malignant melanoma(see also other)
Phase I/II(954) 443-8600
anti-PD1 (BMS-936558)
Bristol-Myers SquibbPrinceton, NJ
melanoma(see also kidney, lung)
Phase II(800) 332-2056
APN301(ch14.18 mAb/interleukin-2 fusion protein)
Apeiron BiologicsVienna, Austria
malignant melanoma(see also brain)
Phase IIwww.apeiron-biologics.com
ARC-100 Archer BiosciencesNew York, NY
malignant melanoma (combination therapy)(see also brain, breast, prostate)
Phase II(646) 747-9090
ARRY-162(MEK inhibitor)
Array BioPharmaBoulder, CO
malignant melanoma (BRAFV600E or NRAS mutations) (see also solid tumors)
Phase II(877) 633-2436
astuprotimut-R(MAGE-A3 antigen-specific cancer immunotherapeutic)
GlaxoSmithKlineRsch. Triangle Park, NC
malignant melanoma(see also lung)--------------------------------------------------inoperable/unresectable malignant melanoma
Phase III(888) 825-5249-------------------------------------------Phase II(888) 825-5249
autologous stem cell therapy California Stem CellsIrvine, CA
malignant melanoma Phase II(949) 534-9149
c31510 CytotechNatick, MA
basal cell cancer, squamous call cancer
Phase II(615) 515-5438
Cavatak™coxsackievirus A21(orphan Drug)
ViralyticsPymble, Australia
malignant melanoma Phase IIwww.viralytics.com
CB-10-01cancer vaccine
Cosmo PharmaceuticalsLainate, Italy
malignant melanoma Phase IIwww.cosmopharmaceuticals.com
CDX-011(glembatumumab vedotin)
Celldex TherapeuticsNeedham, MA
malignant melanoma(see also breast)
Phase II(781) 433-0771
CYT107(interleukin-7)
CytherisRockville, MD
malignant melanoma(see also kidney)
Phase I(301) 231-0451
DC-IL-12 DNA therapeutic(INXN-3001)
ZIOPHARM OncologyNew York, NY
malignant melanoma Phase I(646) 214-0700
DEDN-6526A GenentechSouth San Francisco, CA
malignant melanoma Phase I(800) 626-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012 87
skin CanCer
product Name Sponsor Indication Development Status
dendritic cancer cell vaccine EMD MilliporeBillerica, MA
malignant melanoma Phase I(781) 533-6000
E7050 EisaiWoodcliff Lake, NJ
late-stage malignant melanoma(see also brain, head/neck, liver, solid tumors, stomach)
Phase I/II(888) 422-4743
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
melanoma(see also brain, other)
Phase II(888) 422-4743
ecromeximab Life Science PharmaceuticalsDarien, CT
malignant melanoma (combination therapy)
Phase II(203) 656-2500
erivedge™vismodegib
GenentechSouth San Francisco, CA
early-stage basal cell cancer (resectable)
Phase II(800) 626-3553
FANG™ Vaccineautologous tumor cell vaccine
GradalisCarrollton, TX
malignant melanoma(see also colorectal, ovarian)
Phase II(214) 442-8100
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
malignant melanoma(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, stomach)
Phase II(781) 274-8200
GDC-0973(MEK inhibitor)
GenentechSouth San Francisco, CA
second-line metastatic malignant melanoma (combination therapy) (see also solid tumors)
Phase I(800) 626-3553
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also lung, prostate, other)
Phase II(888) 669-6682
GSK2118436(BRaf protein kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
first-line BRAF mutation-positive late-stage malignant melanoma(see also brain, lung)
--------------------------------------------------BRAF mutation-positive metastatic malignant melanoma (combination therapy)
Phase III(888) 825-5249
-------------------------------------------Phase II(888) 825-5249
GSK2241658A(cancer vaccine)
GlaxoSmithKlineRsch. Triangle Park, NC
metastatic malignant melanoma Phase I(888) 825-5249
GSK2302025A(cancer vaccine)
GlaxoSmithKlineRsch. Triangle Park, NC
first-line metastatic malignant melanoma
Phase I(888) 825-5249
Medicines in Development for Cancer
Medicines in Development Cancer 201288
skin CanCer
product Name Sponsor Indication Development Status
HyperAcute® Melanomamelanoma vaccine
NewLink GeneticsAmes, IA
malignant melanoma Phase II(515) 296-5555
IMC-gp100(cancer vaccine)
ImmunocoreOxon, United Kingdom
malignant melanoma Phase 0www.immunocore.com
Imprime pGG® BiotheraEagan, MN
malignant melanoma(see also colorectal, leukemia, lung)
Phase I(651) 675-0300
INCB24360 IncyteWilmington, DE
malignant melanoma(see also solid tumors)
Phase II(855) 446-2983
interleukin-12 gene therapy OncoSec MedicalSan Diego, CA
malignant melanoma, merkel cell carcinoma(see also lymphoma)
Phase IIwww.oncosec.com
intetumumab Janssen BiotechHorsham, PA
malignant melanoma(see also prostate)
Phase I/II(800) 526-7736
LDE225(erismodegib)
Novartis PharmaceuticalsEast Hanover, NJ
basal cell cancer(see also leukemia, pancreatic, solid tumors)
Phase II(888) 669-6682
LGK974(WNT signaling pathway inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also breast)
Phase I(888) 669-6682
LGX818(RAF inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
metastatic malignant melanoma(see also colorectal)
Phase I(888) 669-6682
Lymphoseek®
Tc-99m tilmanoceptNavidea PharmaceuticalsDublin, OH
malignant melanoma (diagnosis)(see also breast, head/neck)
application submitted(614) 793-7500
M-200 prophage cancer vaccine(vitespen)(orphan Drug)
AgenusLexington, MA
metastatic melanoma(Fast Track)
Phase III(781) 674-4400
Marqibo®
vincristine liposomal(orphan Drug)
Talon TherapeuticsSan Mateo, CA
malignant melanoma(see also leukemia, lymphoma, other)
Phase II(650) 588-6404
melanoma DNA vaccine Ichor Medical SystemsSan Diego, CAMemorial Sloan-Kettering Cancer CenterNew York, NY
malignant melanoma Phase I(858) 550-2022
MORAb-004 EisaiWoodcliff Lake, NJ
malignant melanoma Phase II(888) 422-4743
Medicines in Development for Cancer
Medicines in Development Cancer 2012 89
skin CanCer
product Name Sponsor Indication Development Status
muparfostat (PI-88)(orphan Drug)
Progen PharmaceuticalsQueensland, Australia
malignant melanoma(see also liver)
Phase IIwww.progen.com.au
MVax®
melanoma vaccineAVAX TechnologiesPhiladelphia, PA
malignant melanoma Phase III(215) 241-9760
NX-101 NexGenixNew York, NY
dermal neurofibromatoses Phase II(212) 974-3006
ontak®
denileukin diftitoxEisaiWoodcliff Lake, NJ
malignant melanoma Phase II(888) 422-4743
PEG arginine deiminase (ADI-PEG 20)
Polaris PharmaceuticalsSan Diego, CA
metastatic malignant melanoma (see also liver, prostate, other)
Phase II(858) 452-6688
picato®
ingenol mebutateLEO PharmaParsippany, NJ
basal cell cancer Phase II(877) 494-4536
POL-103A(melanoma vaccine)(orphan Drug)
PolynomaSan Diego, CA
malignant melanoma Phase III(858) 205-2501
PRAME antigen-specific cancer immunotherapeutic (recombinant)
GlaxoSmithKlineRsch. Triangle Park, NC
metastatic malignant melanoma(see also lung)
Phase I(888) 825-5349
PTI-188 Pain TherapeuticsAustin, TX
malignant melanoma Phase I completed(512) 501-2444
PV-10(rose bengal sodium)(orphan Drug)
Provectus PharmaceuticalsKnoxville, TN
malignant melanoma(see also liver)
Phase II completed(866) 594-5999
RAF265(raf kinase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also solid tumors)
Phase I(888) 669-6682
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
malignant melanoma(see also brain, colorectal, head/neck, lung, ovarian, pancreatic, sarcoma, solid tumors)
Phase II(403) 670-7377
RG7256(BRAF kinase inhibitor)
RocheNutley, NJ
malignant melanoma Phase I(973) 235-5000
RG7636(antibody drug conjugate)
RocheNutley, NJ
malignant melanoma Phase I(800) 626-3553
Medicines in Development for Cancer
Medicines in Development Cancer 201290
skin CanCer
product Name Sponsor Indication Development Status
talminogene laherparepvec AmgenThousand Oaks, CA
malignant melanoma Phase III(800) 772-6436
tasigna®
nilotinibNovartis PharmaceuticalsEast Hanover, NJ
malignant melanoma (c-Kit mutation)(see also leukemia, stomach)
Phase III(888) 669-6682
tesetaxel(orphan Drug)
GentaBerkeley Heights, NJ
malignant melanoma(see also bladder, breast, prostate, stomach)
Phase II(908) 286-9800
TKI258(dovitinib)
Novartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also breast, kidney, multiple myeloma, prostate, other)
Phase I/II(888) 669-6682
tNFerade™golnerminogene pradenovec
GenVecGaithersburg, MD
malignant melanoma(see also head/neck, prostate, stomach)
Phase II(877) 943-6832
trametinib GlaxoSmithKlineRsch. Triangle Park, NC
malignant melanoma (monotherapy)(see also leukemia, lung, lymphoma, multiple myeloma, pancreatic)--------------------------------------------------malignant melanoma (combination therapy)
Phase III(888) 825-5249
-------------------------------------------Phase II(888) 825-5249
veglin (VEGF antisense)
VasGene TherapeuticsLos Angeles, CA
Kaposi’s sarcoma(see also lung, kidney)
Phase I(323) 221-7818
YeRVoY®
ipilimumabBristol-Myers SquibbPrinceton, NJ
melanoma (adjuvant therapy),melanoma brain metastases(see also lung, prostate)
in clinical trials(800) 332-2056
Zadaxin®
thymalfasin alfa 1(orphan Drug)
SciClone PharmaceuticalsFoster City, CA
malignant melanoma(see also liver)
Phase II/III(650) 358-3456
solid tumors
product Name Sponsor Indication Development Status
AbGn-7 AbGenomicsLos Altos, CA
Phase I(650) 988-9912
ABI-009(sirolimus albumin bound)
CelgeneSummit, NJ
Phase I(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 2012 91
solid tumors
product Name Sponsor Indication Development Status
ABT-348(aurora kinase inhibitor)
Abbott LaboratoriesAbbott Park, IL
late-stage solid tumors(see also other)
Phase I(847) 937-6100
ABT-700(c-Met inhibitor)
Abbott LaboratoriesAbbott Park, IL
Phase I(847) 937-6100
ABT-767(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
Phase I(847) 937-6100
ABT-806(EGFR inhibitor)
Abbott LaboratoriesAbbott Park, IL
Phase I(847) 937-6100
AC220(quizartinib)
Ambit BiosciencesSan Diego, CAAstellas Pharma USDeerfield, IL
(see also leukemia) Phase I(858) 334-2100(800) 695-4321
AEZS-112 AEterna Zentaris Basking Ridge, NJ
(see also lymphoma) Phase I(908) 626-5428
AI-850 AcusphereLexington, MA
Phase I(617) 648-8800
ALB-109564(a)(tubulin inhibitor)
AMRIAlbany, NYBessor PharmaFramingham, MA
Phase Iwww.amriglobal.com
AlloStim™ Immunovative TherapiesShoham, Israel
(see also other) Phase I/IIwww.immunovative.co.il
Alocrest™vinorelbine liposomal
Talon TherapeuticsSan Mateo, CA
(see also lymphoma) Phase I(650) 588-6404
AMG 208(c-Met inhibitor)
AmgenThousand Oaks, CA
Phase I(800) 772-6436
AMG 337(c-Met inhibitor)
AmgenThousand Oaks, CA
Phase I(800) 772-6436
AMG 780(angioprotein inhibitor)
AmgenThousand Oaks, CA
Phase I(800) 772-6436
AMG 820(c-fms antagonist)
AmgenThousand Oaks, CA
Phase I(800) 772-6436
Medicines in Development for Cancer
Medicines in Development Cancer 201292
solid tumors
product Name Sponsor Indication Development Status
AMG 900(aurora kinase inhibitor)
AmgenThousand Oaks, CA
(see also other) Phase I(800) 772-6436
AMP-224 AmplimmuneGaithersburg, MD
Phase I(301) 309-9800
anti-CD137 (BMS-663513)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
anti-IGF-1R mAb GenentechSouth San Francisco, CA
Phase I(800) 626-3553
anti-PD-L1(BMS-936559)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
Aplidin®
plitidepsinPharmaMarMadrid, Spain
(see also lymphoma, multiple myeloma)
Phase Iwww.pharmamar.com
AR-12 Arno TherapeuticsFlemington, NJ
(see also lymphoma) Phase I(862) 703-7170
AR-67 Arno TherapeuticsFlemington, NJ
(see also brain, leukemia) Phase I(862) 703-7170
ARQ 092(AKT inhibitor)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
inoperable/unresectable late-stage solid tumors
Phase I(781) 994-0300(973) 944-2600
ARQ 621(Eg5 inhibitor)
ArQuleWoburn, MA
late-stage solid tumors(see also other)
Phase I(781) 994-0300
ARQ 736(BRAF inhibitor)
ArQuleWoburn, MA
late-stage solid tumors Phase I(781) 994-0300
ARQ 761(E2F1 stimulant)
ArQuleWoburn, MA
Phase I(781) 994-0300
ARRY-162(MEK inhibitor)
Array BioPharmaBoulder, CO
late-stage solid tumors(see also skin)
Phase I(877) 633-2436
ARRY-520(KSP inhibitor)
Array BioPharmaBoulder, CO
(see also leukemia, multiple myeloma)
Phase I(877) 633-2436
Medicines in Development for Cancer
Medicines in Development Cancer 2012 93
solid tumors
product Name Sponsor Indication Development Status
ASG-22ME AgensysSanta Monica, CASeattle GeneticsBothell, WA
Phase I(800) 695-4321(425) 527-4000
ASP3026 Astellas Pharma USDeerfield, IL
late-stage solid tumors(see also lymphoma)
Phase I(800) 695-4321
AT7519(CDK inhibitor)
Astex PharmaceuticalsDublin, CA
(see also leukemia, lymphoma, multiple myeloma)
Phase I(925) 560-0100
AT9283(aurora/Jak2 inhibitor)
Astex PharmaceuticalsDublin, CA
(see also leukemia, lymphoma, multiple myeloma)
Phase I(925) 560-0100
AT13387(Hsp90 inhibitor)
Astex PharmaceuticalsDublin, CA
refractory solid tumors(see also stomach)
Phase I(925) 560-0100
ATI-1123(docetaxel liposomal)
Azaya TherapeuticsSan Antonio, TX
Phase I(210) 341-6600
AZD1480(JAK1/JAK2 inhibitor)
AstraZenecaWilmington, DE
Phase I(800) 236-9933
AZD2014(TOR kinase inhibitor)
AstraZenecaWilmington, DE
Phase I(800) 236-9933
AZD4547(FGFR tyrosine kinase inhibitor)
AstraZenecaWilmington, DE
Phase II(800) 236-9933
AZD5363(AKT inhibitor)
Astex PharmaceuticalsDublin, CAAstraZenecaWilmington, DE
Phase I(800) 236-9933
AZD8330(ARRY-424704)(MEK inhibitor)
Array BioPharmaBoulder, COAstraZenecaWilmington, DE
Phase I(800) 236-9933
AZD8931(erbB kinase inhibitor)
AstraZenecaWilmington, DE
(see also breast) Phase II(800) 236-9933
BAY 10-00394(Pan-CDK inhibitor)
Bayer HealthCare PharmaceuticalsWayne, NJ
late-stage solid tumors Phase I(888) 842-2937
BAY 79-4620(antibody-drug conjugate)
Bayer HealthCare PharmaceuticalsWayne, NJ
Phase I(888) 842-2937
Medicines in Development for Cancer
Medicines in Development Cancer 201294
solid tumors
product Name Sponsor Indication Development Status
BAY 80-6946 Bayer HealthCare PharmaceuticalsWayne, NJ
Phase I(888) 842-2937
BAY 87-2243(HIF-1ἀ pathway inhibitor)
Bayer HealthCare PharmaceuticalsWayne, NJ
Phase I(888) 842-2937
BAY 94-9343(antibody drug conjugate)
Bayer HealthCare PharmaceuticalsWayne, NJ
Phase I(888) 842-2937
BBI503(stemness kinase inhibitor)
Boston BiomedicalNorwood, MA
late-stage solid tumors Phase I(781) 278-0900
BBI608(stemness inhibitor)
Boston BiomedicalNorwood, MA
late-stage solid tumors Phase I(781) 278-0900
belotecan OnKor PharmaceuticalsSeattle, WA
Phase II(206) 694-4424
BEZ235(kinase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I/II(888) 669-6682
BGJ398(FGF-R kinase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I(888) 669-6682
BGT226(MTOR/PI3K inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I/II(888) 669-6682
BHQ880(mAb)
Novartis PharmaceuticalsEast Hanover, NJ
(see also multiple myeloma) Phase I(888) 669-6682
BI-811283(aurora kinase B inhibitor)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
(see also leukemia) Phase I(800) 243-0127
BI-831266 Boehringer IngelheimPharmaceuticalsRidgefield, CT
Phase I(800) 243-0127
BI-836845(IgG1-lambda)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
Phase I(800) 243-0127
BI-847325 Boehringer IngelheimPharmaceuticalsRidgefield, CT
Phase I(800) 243-0127
Medicines in Development for Cancer
Medicines in Development Cancer 2012 95
solid tumors
product Name Sponsor Indication Development Status
BI-853520(TYK2 inhibitor)
Boehringer IngelheimPharmaceuticalsRidgefield, CT
Phase I(800) 243-0127
BIIB 015 Biogen IdecCambridge, MA
Phase I completed(617) 679-2000
BIIB 028 Biogen IdecCambridge, MA
Phase I completed(617) 679-2000
BIND-014(docetaxel nanopharmaceutical)
BIND BiosciencesCambridge, MA
Phase I(617) 491-3400
BMN-673(PARP inhibitor)
BioMarin PharmaceuticalsNovato, CA
(see also other) Phase I/II(415) 506-6700
BQS481(Eg5 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I(888) 669-6682
BYL719(PI3K-alpha inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
late-stage solid tumors Phase I(888) 669-6682
CA-18C3 XBiotechAustin, TX
(see also cancer-related, other) Phase I/II(512) 386-2900
CALAA 01(siRNA)
Calando PharmaceuticalsPasadena, CA
Phase I(626) 683-7200
carfilzomib Onyx PharmaceuticalsSouth San Francisco, CA
(see also multiple myeloma) Phase II(650) 266-0000
CBP-501(peptide mimetic)
CanBasShizouka, Japan
(see also lung) Phase Iwww.canbas.co.jp
CC-115(kinase inhibitor)
CelgeneSummit, NJ
(see also lymphoma, multiple myeloma)
Phase I(908) 673-9000
CC-122 CelgeneSummit, NJ
(see also lymphoma, multiple myeloma)
Phase I(908) 673-9000
CDX-1127 Celldex TherapeuticsNeedham, MA
(see also other) Phase I(781) 433-0771
CDX-1401(cancer vaccine)
Celldex TherapeuticsNeedham, MA
solid tumors expressing theNY-ESO-1 protein
Phase I/II(781) 433-0771
CEP-11981(VEGF-R/TIE2 kinase inhibitor)
CephalonFrazer, PA
Phase I completed(610) 344-0200
Medicines in Development for Cancer
Medicines in Development Cancer 201296
solid tumors
product Name Sponsor Indication Development Status
CG201(cancer vaccine)
CG TherapeuticsSeattle, WA
Phase II(206) 336-5604
CRLX101 Cerulean PharmaCambridge, MA
late-stage solid tumors Phase I/II(617) 551-9600
crolibulin EpiCeptTarrytown, NY
Phase I/II(914) 606-3500
CUDC-101 CurisLexington, MA
Phase I(617) 503-6500
CVX 060 (PF-04856884)(Ang2 antagonist)
PfizerNew York, NY
(see also kidney) Phase I(860) 732-5156
CX-4945(CK2 inhibitor)
Cylene PharmaceuticalsSan Diego, CA
(see also multiple myeloma) Phase I(858) 875-5100
CYC116(aurora kinase/VEGFR2 inhibitor)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
Phase I(908) 517-7330
CYT-6091(Aurimune)
CytImmune SciencesRockville, MD
Phase I(301) 825-3041
D-1MT NewLink GeneticsAmes, IA
(see also breast) Phase I(515) 296-5555
D-3263(TRPM8 protein stimulant)
DendreonSeattle, WA
Phase I(877) 256-4545
dacomitinib(PF-00299804)
PfizerNew York, NY
(see also lung) Phase II(860) 732-5156
darinaparsin(ZIO-101)
ZIOPHARM OncologyNew York, NY
(see also liver, lymphoma, multiple myeloma)
Phase I (646) 214-0700
DS-2248 Daiichi SankyoParsippany, NJ
Phase I(973) 944-2600
DS-7423 Daiichi SankyoParsippany, NJ
Phase I(973) 944-2600
Medicines in Development for Cancer
Medicines in Development Cancer 2012 97
solid tumors
product Name Sponsor Indication Development Status
E7050 EisaiWoodcliff Lake, NJ
metastatic solid tumors(see also brain, head/neck, liver, skin, stomach)
Phase I/II(888) 422-4743
EC17 EndocyteWest Lafayette, IN
Phase Iwww.endocyte.com
EC0489 EndocyteWest Lafayette, IN
Phase Iwww.endocyte.com
elsamitrucin Spectrum PharmaceuticalsHenderson, NV
late-stage solid tumors Phase I(702) 835-6300
EMD-1214063(c-Met kinase inhibitor)
EMD SeronoRockland, MA
Phase I(800) 283-8088
enavatuzumab Abbott LaboratoriesAbbott Park, IL
Phase I(847) 937-6100
EP-100 Esperance PharmaceuticalsBaton Rouge, LA
Phase I(225) 615-8944
ETBX-011cancer vaccine
EtubicsSeattle, WA
late-stage metastatic solid tumors Phase I(206) 838-5110
etirinotecan pegol (NKTR-102)
Nektar TherapeuticsSan Francisco, CA
combination therapy(see also breast, colorectal, ovarian)
Phase I(855) 482-6587
EZN-2208(PEG-SN38, firtecan pegol)
Enzon PharmaceuticalsPiscataway, NJ
solid tumors (pediatric)(see also breast, colorectal)--------------------------------------------------combination therapy
Phase I/II(973) 980-4500-------------------------------------------Phase I(973) 980-4500
EZN-2968(HIF1-alpha inhibitor)
Enzon PharmaceuticalsPiscataway, NJ
(see also lymphoma) Phase I(973) 980-4500
ficlatuzumab(AV-299)
AVEO PharmaceuticalsCambridge, MA
(see also lung) Phase I(617) 299-5000
fluciclatide F-18 GE HealthcareWaukesha, WINational Cancer InstituteBethesda, MD
solid tumors (diagnosis) Phase II(262) 513-4000
FP-1039/HGS1036 Five Prime TherapeuticsSouth San Francisco, CAHuman Genome SciencesRockville, MD
late-stage solid tumors Phase I(415) 365-5600(301) 309-8504
Medicines in Development for Cancer
Medicines in Development Cancer 201298
solid tumors
product Name Sponsor Indication Development Status
G-202 GenSperaSan Antonio, TX
Phase I(210) 479-8112
GC1008(fresolimumab)
GenzymeCambridge, MA
Phase I(617) 252-7500
GDC-0032(PI3 kinase inhibitor)
GenentechSouth San Francisco, CA
metastatic solid tumors Phase I(800) 626-3553
GDC-0068(Akt inhibitor)
GenentechSouth San Francisco, CA
Phase I/II(800) 626-3553
GDC-0349(small molecule)
GenentechSouth San Francisco, CA
(see also lymphoma) Phase I(800) 626-3553
GDC-0425(ChK1 inhibitor)
GenentechSouth San Francisco, CA
(see also lymphoma) Phase I(800) 626-3553
GDC-0575 GenentechSouth San Francisco, CA
(see also lymphoma) Phase I(800) 626-3553
GDC-0623(MEK inhibitor)
GenentechSouth San Francisco, CA
metastatic solid tumors Phase I(800) 626-3553
GDC-0917(IAP antagonist)
GenentechSouth San Francisco, CA
(see also lymphoma) Phase I(800) 626-3553
GDC-0973(MEK inhibitor)
GenentechSouth San Francisco, CA
(see also skin cancer) Phase I(800) 626-3553
GDC-0980(PI3 kinase/mTOR dual inhibitor)
GenentechSouth San Francisco, CA
(see also breast, lymphoma) Phase I(800) 626-3553
Genz644282(toposisomerase-1 inhibitor)
GenzymeCambridge, MA
Phase I(800) 981-2491
GGTI-2418 KiraxBonita Springs, FL
Phase I(239) 444-5400
GI-6301(brachyury peptide vaccine)
GlobeImmuneLouisville, CO
Phase I(303) 625-2700
GL-ONC1 GeneluxSan Diego, CA
Phase I(858) 483-0024
GO-203-2c Genus OncologyVernon Hills, IL
late-stage solid tumors Phase I(847) 549-6500
Medicines in Development for Cancer
Medicines in Development Cancer 2012 99
solid tumors
product Name Sponsor Indication Development Status
GSK461364(polio-like kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also lymphoma) Phase I(888) 825-5249
GSK690693(AKT kinase inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also lymphoma) Phase I(888) 825-5249
GSK1070916A(selective aurora kinase B/C inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
Phase I(888) 825-5249
GSK2126458(PI3K/mTOR inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also lymphoma) Phase I(888) 825-5249
GSK2141795(protein kinase B inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
(see also lymphoma) Phase I(888) 825-5249
GSK2256098(FAK inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
Phase I(888) 825-5249
GSK2636771(PI3K beta-selective inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
Phase I(888) 825-5249
HSP990(heat shock protein)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I(888) 669-6682
IGF-1R antagonist(BMS-754807)
Bristol-Myers SquibbPrinceton, NJ
Phase II(800) 332-2056
IMF-001(cancer vaccine)
ImmunoFrontierTokyo, Japan
NY-ESO-1 antigen-expressing solid tumors
Phase Iwww.immunofrontier.com
IMGN388 ImmunoGenWaltham, MA
Phase I(781) 895-0600
INC280(c-Met inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I/II(888) 669-6682
INCB24360 IncyteWilmington, DE
(see also skin) Phase I/II(855) 446-2983
indium-111 (ABT-806) Abbott LaboratoriesAbbott Park, IL
solid tumors (diagnosis) Phase I(847) 937-6100
INK128(mTOR inhibitor)
IntellikineLa Jolla, CA
(see also lymphoma, multiple myeloma)
Phase I(858) 768-6500
INK1117(PI3Kα inhibitor)
IntellikineLa Jolla, CA
Phase I(858) 768-6500
Medicines in Development for Cancer
Medicines in Development Cancer 2012100
solid tumors
product Name Sponsor Indication Development Status
INNO-206 CytRxLos Angeles, CA
(see also pancreatic, sarcoma) Phase I/II(310) 826-5648
INNO-305(WT-1 vaccine)
CytRxLos Angeles, CA
(see also leukemia) Phase I(310) 826-5648
JI-101(angiogenesis inhibitor)
Jubilant BiosysMalvern, PA
Phase I/II(610) 240-8690
JNJ-26854165(Hdm2 inhibitor)
Johnson & Johnson Pharmaceutical Research & DevelopmentRaritan, NJ
late-stage solid tumors(see also lung, prostate)
Phase I(800) 817-5286
JX-929 Jennerex BiotherapeuticsSan Francisco, CA
Phase I(415) 281-8886
Karenitecin®
BNP1350BioNumerik PharmaceuticalsSan Antonio, TX
solid tumors (adults and pediatric)(see also lung, ovarian)
Phase I(210) 614-1701
KHK-2866 Kyowa Hakko Kirin PharmaPrinceton, NJ
advanced solid tumors(see also ovarian)
Phase I(609) 919-1100
LBH589 (panobinostat)
Novartis PharmaceuticalsEast Hanover, NJ
(see also kidney, leukemia, multiple myeloma, prostate)
Phase I(888) 669-6682
LCI699(aldosterone synthase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase II(888) 669-6682
LCL161(IAP inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I(888) 669-6682
LDE225(erismodegib)
Novartis PharmaceuticalsEast Hanover, NJ
solid tumors (adults and pediatric)(see also leukemia, pancreatic, skin)
Phase I(888) 669-6682
LDK378(ALK inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I(888) 669-6682
LEE011(CDK4/6 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also lymphoma) Phase I(888) 669-6682
LEQ506(Smo antagonist)
Novartis PharmaceuticalsEast Hanover, NJ
Phase I(888) 669-6682
L-MDAM BioNumerik PharmaceuticalsSan Antonio, TX
Phase I(210) 614-1701
LOR 253(MTF-1 inhibitor)
Lorus TherapeuticsToronto, Canada
metastatic solid tumors Phase I(416) 798-1200
Medicines in Development for Cancer
Medicines in Development Cancer 2012 101
solid tumors
product Name Sponsor Indication Development Status
LP-261 Locus PharmaceuticalsBlue Bell, PA
Phase I(215) 358-2000
lurbinectedin PharmaMarMadrid, Spain
(see also leukemia) Phase Iwww.pharmamar.com
ME-143(NADH oxidase inhibitor)
Marshall EdwardsSan Diego, CA
refractory solid tumors Phase I(858) 792-6300
MEDI-565(anti-CEA BiTE)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
Phase I(800) 236-9933(301) 398-0000
MEDI-573(anti-IGF mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
Phase I(800) 236-9933(301) 398-0000
MEDI-0639(anti-delta-like 4 mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
Phase I(800) 236-9933(301) 398-0000
MEDI-3617(anti-ANG-2 mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
Phase I(800) 236-9933(301) 398-0000
MG-1102 Green CrossYongin, South KoreaMogam Biotechnology Research InstituteYongin, South Korea
second-line solid tumors Phase Iwww.eng.greencross.com
MGA271 (anti-B7-H3)
MacroGenicsRockville, MD
refractory metastatic solid tumors Phase I(301) 251-5172
MGAH22 (anti-HER2 mAb) MacroGenicsRockville, MD
Phase I(301) 251-5172
MINT1526A GenentechSouth San Francisco, CA
Phase I(800) 626-3553
MK-1496 MerckWhitehouse Station, NJ
Phase I completed(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012102
solid tumors
product Name Sponsor Indication Development Status
MK-3475 MerckWhitehouse Station, NJ
metastatic late-stage solid tumors Phase I(800) 672-6372
MK-4827(PARP inhibitor)
MerckWhitehouse Station, NJ
Phase I(800) 672-6372
MK-5108/VX-689(aurora kinase A inhibitor)
MerckWhitehouse Station, NJVertex PharmaceuticalsCambridge, MA
Phase I(800) 672-6372(617) 444-6100
MK-8242 MerckWhitehouse Station, NJ
(see also leukemia) Phase I(800) 672-6372
MLN0128 Millennium PharmaceuticalsCambridge, MA
(see also other) Phase I(800) 390-5663
MLN0518 (tandutinib)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
MLN1117 Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
MLN2480(raf kinase inhibitor)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
MLN4924(NEDD8 inhibitor)
Millennium PharmaceuticalsCambridge, MA
(see also other) Phase I(800) 390-5663
MLN8237(alisertib)
Millennium PharmaceuticalsCambridge, MA
(see also lymphoma) Phase II(800) 390-5663
MLN9708 (ixazomib)
Millennium PharmaceuticalsCambridge, MA
(see also lymphoma, multiple myeloma)
Phase I(800) 390-5663
MM-151(EGFR antagonist)
Merrimack PharmaceuticalsCambridge, MA
Phase I(617) 441-1000
mocetinostat(MGCD0103, HDAC inhibitor)
MethylGeneMontreal, Canada
(see also leukemia, lymphoma) Phase I/II(514) 337-3333
MPDL-3280A GenentechSouth San Francisco, CA
Phase I(800) 626-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012 103
solid tumors
product Name Sponsor Indication Development Status
MSC2015103B(MEK inhibitor)
EMD SeronoRockland, MA
Phase I(800) 283-8088
MTKi-328 BeiGeneBeijing, China
Phase Iwww.beigene.com
MTRN-2696 Spectrum PharmaceuticalsHenderson, NV
Phase I(702) 835-6300
NKP-1339 Niiki PharmaHoboken, NJ
Phase I(201) 710-5512
NKTR-105 (pegylated docetaxel)
Nektar TherapeuticsSan Francisco, CA
Phase I(415) 482-5300
NMS-1116354(CDC7 protein kinase inhibitor)
Nerviano Medical ServicesNerviano, Italy
Phase Iwww.nervianoms.com
NMS-1286937(PIK-1 inhibitor)
Nerviano Medical ServicesNerviano, Italy
Phase Iwww.nervianoms.com
NPI-0052(marizomib)
Nereus PharmaceuticalsSan Diego, CA
(see also lymphoma, multiple myeloma)
Phase I(858) 587-4090
olaparib(PARP inhibitor)
AstraZenecaWilmington, DE
Phase I(800) 236-9933
omapro™omacetaxine
CephalonFrazer, PA
(see also leukemia) Phase II(610) 344-0200
OMP-18R5(Wnt pathway)
Bayer HealthCare PharmaceuticalsWayne, NJOncoMed PharmaceuticalsRedwood City, CA
Phase I(888) 842-2837(650) 995-8200
OMP-21M18(DLL4 inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NCOncoMed PharmaceuticalsRedwood City, CA
Phase I(888) 825-5249(650) 995-8200
OMP-59R5(notch pathway)
GlaxoSmithKlineRsch. Triangle Park, NCOncoMed PharmaceuticalsRedwood City, CA
Phase I(888) 825-5249(650) 995-8200
omtriptolide PharmagenesisRedwood City, CAPierre Fabre PharmaceuticalsParsippany, NJ
Phase I(650) 842-7060www.pierre-fabre.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012104
solid tumors
product Name Sponsor Indication Development Status
ONT-10(cancer vaccine)
OncothyreonSeattle, WA
Phase I(206) 769-9219
ONX-0801 Onyx PharmaceuticalsSouth San Francisco, CA
Phase I(650) 266-0000
OPB-51602 Otsuka America PharmaceuticalRockville, MD
Phase I(800) 562-3974
oprozomib Onyx PharmaceuticalsSouth San Francisco, CA
Phase I(650) 266-0000
oral azacitidine CelgeneSummit, NJ
(see also leukemia, lung, lymphoma) Phase II(908) 673-9000
ortataxel Spectrum PharmaceuticalsHenderson, NV
taxane-refractory solid tumors Phase II(702) 835-6300
OSI-930(c-kit/VEGFR-2)
OSI PharmaceuticalsFarmingdale, NY
Phase I(631) 962-0600
p28 peptide CDG TherapeuticsChicago, IL
Phase Iwww.cdgti.com
paclitaxel liposomal Sun PharmaMumbai, India
Phase Iwww.sunpharma.com
palifosfamide(ZIO-201)
ZIOPHARM OncologyNew York, NY
(see also lung, sarcoma) Phase I(646) 214-0700
pbi-shRNA™ StMN1 Lp(anti-stathim gene therapy)
GradalisCarrollton, TX
Phase I(214) 442-8100
perifosine AEterna ZentarisBasking Ridge, NJ
solid tumors (pediatric)(see also brain, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, stomach)
Phase I(908) 626-5428
PF-00337210(VEGFR2 antagonist)
PfizerNew York, NY
Phase I completed(860) 732-5156
PF-03446962(ALK-1 mAb)
PfizerNew York, NY
Phase I(860) 732-5156
Medicines in Development for Cancer
Medicines in Development Cancer 2012 105
solid tumors
product Name Sponsor Indication Development Status
PF-04605412(anti-α5β1 integrin mAb)
PfizerNew York, NY
Phase I(860) 732-5156
PF-04691502(PI3K/mTOR inhibitor)
PfizerNew York, NY
(see also other) Phase I(860) 732-5156
PF-05212384(mTOR/PI3K inhibitor)
PfizerNew York, NY
(see also other) Phase I(860) 732-5156
PG11047 Progen PharmaceuticalsQueensland, Australia
(see also lymphoma) Phase Iwww.progen-pharma.com
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
metastatic solid tumors(see also brain, leukemia, lymphoma)
Phase I(510) 647-4000
PM-060184 PharmaMarMadrid, Spain
Phase Iwww.pharmamar.com
PNT2258(bcl-2 oncogene inhibitor)
ProNAi TherapeuticsAnn Arbor, MI
Phase I(269) 815-8098
PRI-724(CBP/catenin inhibitor)
PRISM BioLabYokohama, Japan
Phase Iwww.prismbiolab.com
PRLX93936 Prolexys PharmaceuticalsSalt Lake City, UT
Phase I
PTC299 PTC TherapeuticsSouth Plainfield, NJ
(see also breast, other) Phase II(908) 222-7000
purine nucleoside phosphorylasegene therapy
PNP TherapeuticsBirmingham, AL
Phase Iwww.pnptherapeutics.com
PWT33597(PI3K alpha/mTOR kinase)
Pathway TherapeuticsSan Francisco, CA
Phase Iwww.pathwaytx.com
QBI-139 Quintessence BiosciencesMadison, WI
Phase I(608) 441-2950
RAF265(raf kinase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also skin) Phase I/II(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012106
solid tumors
product Name Sponsor Indication Development Status
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
(see also colorectal, kidney, lung, stomach)
Phase I(888) 842-2837
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
solid tumors (pediatric)(see also brain, colorectal, head/neck, lung, ovarian, pancreatic, sarcoma, skin)
Phase I(403) 670-7377
RG7112(MDM2 antagonist)
RocheNutley, NJ
(see also other) Phase I(973) 235-5000
RG7116(ErbB-3 receptor antagonist)
Roche Nutley, NJ
Phase I(973) 235-5000
RG7155(anti-CSF-1R mAb)
RocheNutley, NJ
Phase I(973) 235-5000
RG7167(CIF/MEK inhibitor)
RocheNutley, NJ
Phase I(973) 235-5000
RG7304(MAP/raf inhibitor)
RocheNutley, NJ
Phase I(973) 235-5000
RG7321(PI3Kα inhibitor)
GenentechSouth San Francisco, CARocheNutley, NJ
Phase II(800) 626-3553(973) 235-5000
RG7347(NRP1 antagonist)
GenentechSouth San Francisco, CARocheNutley, NJ
Phase I(800) 626-3553(973) 235-5000
RG7356(CD44 antigen inhibitor)
RocheNutley, NJ
Phase I(973) 235-5000
RG7388(MDM2 inhibitor)
RocheNutley, NJ
(see also other) Phase I(973) 235-5000
RG7444(HFGR-1877S)
GenentechSouth San Francisco, CA
(see also multiple myeloma) Phase I(800) 626-3553
RG7446(mAb)
GenentechSouth San Francisco, CA
Phase I(800) 626-3553
RG7594(mAb)
GenentechSouth San Francisco, CA
advanced solid tumors Phase I(800) 626-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012 107
solid tumors
product Name Sponsor Indication Development Status
RG7602 GenentechSouth San Francisco, CA
(see also lymphoma) Phase I(800) 626-3553
robatumumab MerckWhitehouse Station, NJ
solid tumors (combination therapy)(see also colorectal, sarcoma)--------------------------------------------------solid tumors (pediatric)
Phase II(800) 672-6372-------------------------------------------Phase I(800) 672-6372
RRx-001 RadioRxMountain View, CA
Phase I(650) 681-9885
sapacitabine (CYC682)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
(see also leukemia, lung) Phase I(908) 517-7330
SAR125844(Met kinase inhibitor)
Sanofi USBridgewater, NJ
Phase I(800) 981-2491
SAR153192(anti-DLL4 mAb)
Sanofi USBridgewater, NJ
Phase I(800) 981-2491
SAR245408/MSC1936369Bcombination therapy(PI3K inhibitor/MEK inhibitor)
Merck SeronoGeneva, SwitzerlandSanofi USBridgewater, NJ
Phase I(800) 981-2491
SAR245409/MSC1936369Bcombination therapy(PI3K-mTOR inhibitor/MEK inhibitor)
Merck SeronoGeneva, SwitzerlandSanofi USBridgewater, NJ
Phase I(800) 981-2491
SAR256212 (MM-121) companion diagnostic
Merrimack PharmaceuticalsCambridge, MASanofi USBridgewater, NJ
solid tumors (diagnosis) Phase II(800) 981-2491
SAR307746 (REGN910)(anti-Ang2 mAb)
Regeneron PharmaceuticalsTarrytown, NYSanofi USBridgewater, NJ
Phase I(914) 347-7000(800) 981-2491
SAR566658(maytansin-loaded anti-DS6)
Sanofi USBridgewater, NJ
DS6-positive solid tumors Phase I(800) 981-2491
SB989 (pracinostat)
S*BIOOakland, CA
late-stage solid tumors(see also leukemia, other)
Phase I(650) 730-2860
Medicines in Development for Cancer
Medicines in Development Cancer 2012108
solid tumors
product Name Sponsor Indication Development Status
SCH-900353 MerckWhitehouse Station, NJ
Phase I(800) 672-6372
seliciclib (CYC202)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
(see also head/neck) Phase I(908) 517-7330
selumetinib (AZD6244/ARRY-142886)(MEK inhibitor)
AstraZenecaWilmington, DE
Phase II(800) 236-9933
selumetinib (AZD6244/ARRY-142886)/ MK2206 combination (MEK/AKT inhibitor)
AstraZenecaWilmington, DEMerckWhitehouse Station, NJ
Phase I(800) 236-9933(800) 672-6372
SF1126 Semafore PharmaceuticalsIndianapolis, IN
(see also leukemia, multiple myeloma)
Phase I(317) 876-3075
simotaxel IV TaxologFairfield, NJ
Phase I(866) 829-6564
solid tumor immunotherapy(mAb)
GenentechSouth San Francisco, CA
Phase I(800) 626-3553
sonepcizumab LpathSan Diego, CA
Phase I(858) 678-0800
SPI-1620(endothelin B receptor agonist)
Spectrum PharmaceuticalsHenderson, NV
Phase I(702) 835-6300
TAG vaccine GradalisCarrollton, TX
Phase I(214) 442-8100
TAK-385(gonadotrophin hormone-releasing hormone receptor antagonist)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
TAK-441(hedgehog signaling pathway inhibitor)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
TAK-701(HGF inhibitor)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
TAK-733(MEK inhibitor)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
Medicines in Development for Cancer
Medicines in Development Cancer 2012 109
solid tumors
product Name Sponsor Indication Development Status
TAK-960(Plk1 inhibitor)
Millennium PharmaceuticalsCambridge, MA
Phase I(800) 390-5663
teglarinad CephalonFrazer, PA
(see also lymphoma) Phase I(610) 344-0200
terameprocol Erimos PharmaceuticalsHouston, TX
solid tumors (IV-infusion)(see also brain, cervical, head/neck, other)
Phase I(713) 541-2000
TKM-PLK1(RNAi)
Tekmira PharmaceuticalsBurnaby, Canada
(see also lymphoma) Phase I(604) 419-3200
TL-32711(birinapant)
TetraLogic PharmaceuticalsMalvern, PA
(see also leukemia) Phase I/II(610) 889-9900
TLC-388 TLC BiopharmaceuticalsSouth San Francisco, CA
Phase I(650) 872-8816
TRC093(IgG1 mAb)
TRACON PharmaceuticalsSan Diego, CA
Phase I completed(858) 550-0780
TRC102(DNA repair inhibitor)
TRACON PharmaceuticalsSan Diego, CA
Phase I(858) 550-0780
tremelimumab(anti-CTLA4 mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
Phase II(800) 236-9933(301) 398-0000
TST-10088 CangeneWinnipeg, Canada
Phase I(204) 275-4200
U3-1565(anti-HB-EGF antibody)
AmgenThousand Oaks, CA Daiichi Sankyo USParsippany, NJ
Phase I(800) 772-6436(973) 944-2600
UNBS-5162 Drais PharmaceuticalsBridgewater, NJ
(see also lymphoma) Phase I(908) 895-1200
V934/V935 MerckWhitehouse Station, NJ
Phase I completed(800) 672-6372
V935(telomerase inhibitor vaccine)
GeronMenlo Park, CAMerckWhitehouse Station, NJ
Phase I(650) 473-7700(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012110
solid tumors
product Name Sponsor Indication Development Status
VGX-100(VEGF-C mAb)
Circadian TechnologiesVictoria, Australia
Phase Iwww.circadian.com.au
VTX-2337 VentiRx PharmaceuticalsSeattle, WA
(see also lymphoma) Phase I(206) 689-2259
VX15 VaccinexRochester, NY
Phase I(585) 271-2700
WX-UK1 WilexMunich, Germany
Phase Iwww.wilex.de
X-82(dual VEGFR/PDGFR inhibitor)
TyrogenexWest Palm Beach, FL
advanced solid tumors Phase I(561) 835-9356
Xalkori®crizotinib
PfizerNew York, NY
(see also lung) Phase I(860) 732-5156
XMT-1001 Mersana TherapeuticsCambridge, MA
Phase I(617) 498-0020
XMT-1107 Mersana TherapeuticsCambridge, MA
Phase I(617) 498-0020
stomaCH CanCer
product Name Sponsor Indication Development Status
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
late-stage esophageal cancer (combination therapy)(see also brain, leukemia, lung, lymphoma, prostate)
Phase I/II(610) 408-0301
AT13387(Hsp90 inhibitor)
Astex PharmaceuticalsDublin, CA
late-stage gastrointestinal stromal tumors (GIST) (second-line therapy) (see also solid tumors)
Phase II(925) 560-0100
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
second-line GIST(see also breast, colorectal, lung, multiple myeloma)
Phase II(888) 669-6682
BIIB 2024 Biogen IdecCambridge, MA
GIST(see also breast)
Phase II completed(617) 679-2000
Medicines in Development for Cancer
Medicines in Development Cancer 2012 111
stomaCH CanCer
product Name Sponsor Indication Development Status
crenolanib (CP-868-596)
AROG PharmaceuticalsDallas, TX
GIST(see also brain)
Phase II(214) 594-0002
E7050 EisaiWoodcliff Lake, NJ
gastric cancer (combination therapy)(see also brain, head/neck, liver, skin, solid tumors)
Phase I/II(888) 422-4743
eRBItUX® cetuximab
Bristol-Myers SquibbPrinceton, NJEli LillyIndianapolis, IN
gastric cancer(see also colorectal)
in clinical trials(800) 332-2056(800) 545-5979
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
esophageal cancer, gastric cancer, GIST(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin)
Phase II(781) 274-8200
masitinib(orphan Drug)
AB Science USAShort Hills, NJ
GIST(see also pancreatic)
Phase III(973) 218-2437
opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
esophageal cancer(see also brain, lung, ovarian, other)
Phase II(800) 215-2355
perifosine AEterna ZentarisBasking Ridge, NJ
GIST(see also brain, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors)
Phase II(908) 626-5428
polyclonal antibody stimulator(orphan Drug)
Cancer AdvancesDurham, NC
gastric cancer(see also colorectal, pancreatic)
Phase III(919) 361-2162
ramucirumab(IMC-1121B)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
gastric cancer(see also breast, colorectal)
Phase III(800) 545-5979
regorafenib(orphan Drug)
Bayer HealthCare PharmaceuticalsWayne, NJ
GIST (Fast Track)(see also colorectal, kidney, lung, solid tumors)
Phase III(888) 842-2837
S-1 Taiho Pharma U.S.A.Princeton, NJ
gastric cancer Phase III(609) 750-5300
tasigna®nilotinib(orphan Drug)
Novartis PharmaceuticalsEast Hanover, NJ
GIST (see also leukemia, skin)
Phase III(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012112
stomaCH CanCer
product Name Sponsor Indication Development Status
telatinib(orphan Drug)
ACT BiotechSan Francisco, CA
gastric cancer (combination therapy)(see also colorectal)
Phase II(415) 230-3900
tesetaxel(orphan Drug)
GentaBerkeley Heights, NJ
gastric cancer(see also bladder, breast, prostate, skin)
Phase II(908) 286-9800
tNFerade™golnerminogene pradenovac
GenVecGaithersburg, MD
esophageal cancer(see also head/neck, prostate, skin)
Phase II(877) 943-6832
trebananib (AMG386)
AmgenThousand Oaks, CA
esophageal cancer, gastric cancer(see also breast, colorectal, kidney, liver, ovarian, other)
Phase II(800) 772-6436
tykerb®
lapatinibGlaxoSmithKlineRsch. Triangle Park, NC
gastric cancer(see also breast, head/neck)
Phase III(888) 825-5249
uridine triacetate (PN401)
Wellstat TherapeuticsGaithersburg, MD
gastric cancer(see also pancreatic)
Phase II(240) 631-2500
Xeloda®
capecitabineGenentechSouth San Francisco, CA
esophageal cancer (see also brain, colorectal, liver)
Phase II(800) 626-3553
CanCer/CHemotHerapy-related Conditions
product Name Sponsor Indication Development Status
AG103 ActoGenixZwijnaarde, Belgium
oral mucositis associated with cancertreatment
Phase Iwww.actogenix.com
AP1903 Bellicum PharmaceuticalsHouston, TX
graft-versus-host disease(see also prostate)
Phase I(713) 341-6472
ARX-02 (sufentanil sublingual)
AcelRx PharmaceuticalsRedwood City, CA
breakthrough cancer pain Phase II(650) 216-3500
CA-18C3 XBiotechAustin, TX
cancer-related cachexia(see also other, solid tumors)
Phase I/II(512) 386-2900
Medicines in Development for Cancer
Medicines in Development Cancer 2012 113
CanCer/CHemotHerapy-related Conditions
product Name Sponsor Indication Development Status
CD1400(oltipraz)
Canopus BioPharmaStudio City, CA
chemotherapy- and radiation-inducedmucositis
Phase IIwww.canopusbiopharma.com
CLT-008 Cellerant TherapeuticsSan Carlos, CA
chemotherapy-related neutropenia(see also other)
Phase I/II(650) 232-2122
dronabinol oral solution INSYS TherapeuticsPhoenix, AZ
chemotherapy-induced nausea and vomiting
Phase III(602) 910-2617
E6014 EisaiWoodcliff Lake, NJ
oral mucositis Phase III(888) 422-4743
emend®
aprepitantMerckWhitehouse Station, NJ
chemotherapy-induced nausea and vomiting (pediatric)
Phase III(800) 672-6372
emend® IVaprepitant
MerckWhitehouse Station, NJ
chemotherapy-induced nausea and vomiting (pediatric)
Phase I(800) 672-6372
fentanyl inhalation Akela PharmaAustin, TX
cancer pain Phase II/III(512 834-0449
ferroportin mAb Eli LillyIndianapolis, IN
anemia associated with cancer Phase I(800) 545-5979
fulranumab Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
cancer pain (adjunctive treatment) Phase II(800) 817-5286
hepcidin mAb Eli LillyIndianapolis, IN
anemia associated with cancer Phase I(800) 545-5979
LG631 LentigenGaithersburg, MD
chemoprotection in patients undergoing treatment for glioblastoma
Phase I(301) 527-4200
mesenchymal stem cell therapy(orphan Drug)
MesoblastNew York, NY
for bone marrow regeneration in patients undergoing bone marrow transplantation
Phase III(212) 880-2060
morphine intranasal Marina BiotechBothell, WA
cancer pain Phase II(425) 908-3600
MultiStem®
stem cell therapy(orphan Drug)
Athersys Cleveland, OH
graft-versus-host disease in patients undergoing bone marrow transplant
Phase I(216) 431-9900
Medicines in Development for Cancer
Medicines in Development Cancer 2012114
CanCer/CHemotHerapy-related Conditions
product Name Sponsor Indication Development Status
nabiximols Otsuka America PharmaceuticalRockville, MD
cancer pain (adjunctive treatment) Phase III(800) 562-3974
netupitant/palonosetron Helsinn TherapeuticsBridgewater, NJ
chemotherapy-induced nausea and vomiting
Phase III(908) 231-1435
NP-2 gene therapy(intradermal)
Diamyd MedicalPittsburgh, PA
cancer pain Phase II(412) 770-1310
Nplate®
romiplostimAmgenThousand Oaks, CA
chemotherapy-associated thrombocytopenia
Phase II(800) 772-6436
PHY906 PhytoCeuticaNew Haven, CT
chemotherapy-induced gastrointestinal disorders(see also colorectal, liver, pancreatic)
Phase I/II(203) 777-3462
prochymal®remestemcel-L(orphan Drug)
Osiris TherapeuticsColumbia, MD
graft-versus-host disease Phase III(443) 545-1800
proDermaCel™norepinephrine topical
ProCertus BioPharmMadison, WI
prevention of oral mucositis, prevention of radiation-induced skin damage
Phase I/II(608) 273-8862
promacta®
eltrombopagGlaxoSmithKlineRsch. Triangle Park, NC
chemotherapy-induced thrombocytopenia
Phase II(888) 669-6682
RGI-2001 REGiMMUNESanta Clara, CA
graft-versus-host disease Phase I/IIwww.regimmune.com
rolapitant TESAROWaltham, MA
chemotherapy-induced nausea and vomiting
Phase III(339) 970-0900
SGX201 SoligenixPrinceton, NJ
acute radiation enteritis in patients with cancer
Phase I/II(609) 538-8200
sotatercept (ACE-011)
CelgeneSummit, NJ
chemotherapy-induced anemia(see also other)
Phase II/III(908) 673-9000
tanezumab PfizerNew York, NY
cancer pain (adjunctive treatment) Phase II (860) 732-5156
tavocept®dimesna
BioNumerik PharmaceuticalsSan Antonio, TX
chemoprotection(see also lung)
Phase III(210) 614-1701
Medicines in Development for Cancer
Medicines in Development Cancer 2012 115
CanCer/CHemotHerapy-related Conditions
product Name Sponsor Indication Development Status
T-cell replacement therapy Bellicum PharmaceuticalsHouston, TX
graft-versus-host disease in patients with late-stage cancer undergoing bone marrow transplantation
Phase I(713) 341-6472
TH-9402(orphan Drug)
Kiadis PharmaAmsterdam, Netherlands
graft-versus-host disease Phase I/IIwww.kiadis.com
TXA127 Tarix PharmaceuticalsCambridge, MA
chemotherapy-induced thrombocytopenia
Phase IIwww.tarixpharma.com
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
steroid-refractory graft-versus-host disease (see also leukemia, lymphoma, other)
Phase II(800) 390-5663
XEN-2174 XenomeQueensland, Australia
cancer pain Phase IIwww.xenome.com
Xgeva™denosumab
AmgenThousand Oaks, CA
prevention of cancer-related bone damage or malignant hypercalcemia(see also multiple myeloma, other)
Phase III(800) 772-6436
otHer CanCers
product Name Sponsor Indication Development Status
8H9 I-131 mAb United TherapeuticsSilver Spring, MD
peritoneal cancer(see also brain, sarcoma)
Phase I(301) 608-9292
Å6 Angstrom PharmaceuticalsSolana Beach, CA
gynecologic cancer(see also ovarian)
Phase I(858) 314-2356
ABT-348(aurora kinase inhibitor)
Abbott LaboratoriesAbbott Park, IL
hematological malignancies(see also solid tumors)
Phase I(847) 937-6100
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
fallopian tube cancer(see also brain, breast, colorectal, lung, lymphoma, ovarian, prostate, skin)
Phase II(847) 937-6100
AEZS-108 AEterna ZentarisBasking Ridge, NJ
late-stage endometrial cancer(see also bladder, ovarian, prostate)
Phase II(908) 626-5428
AlloStim™ Immunovative TherapiesShoham, Israel
hematological malignancies(see also solid tumors)
Phase I/IIwww.immunovative.co.il
Medicines in Development for Cancer
Medicines in Development Cancer 2012116
otHer CanCers
product Name Sponsor Indication Development Status
Alpharadin®
radium-223 chlorideBayer HealthCare PharmaceuticalsWayne, NJ
bone metastases from castration-resistant prostate cancer(see also solid tumors)
application submitted(888) 842-2837
ALT-801 Altor BioScienceMiramar, FL
urogenital cancer(see also skin)
Phase I/II(954) 443-8600
AMG 319(PI3K-delta inhibitor)
AmgenThousand Oaks, CA
hematological malignancies Phase I(800) 772-6436
AMG 900(aurora kinase inhibitor)
AmgenThousand Oaks, CA
hematological malignancies(see also solid tumors)
Phase I(800) 772-6436
anti-CD70 ADC(BMS-936561)
Bristol-Myers SquibbPrinceton, NJ
hematological malignancies Phase I(800) 332-2056
anti-CXCR4 (BMS-936564)
Bristol-Myers SquibbPrinceton, NJ
hematological malignancies Phase I(800) 332-2056
ARQ 621(Eg5 inhibitor)
ArQuleWoburn, MA
hematological malignancies(see also solid tumors)
Phase I(781) 994-0300
Avastin®
bevacizumabGenentechSouth San Francisco, CA
high-risk carcinoid tumor(see also brain, breast, colorectal, lung, ovarian)
Phase III(800) 626-3553
BAY 10-02670 Bayer HealthCare PharmaceuticalsWayne, NJ
uterine leiomyoma Phase I(888) 842-2937
belinostat Spectrum PharmaceuticalsHenderson, NV
peritoneal cancer, thymoma(see also colorectal, leukemia, liver, lung, lymphoma, ovarian)--------------------------------------------------first-line thymoma
--------------------------------------------------recurrent hematological malignancies(combination therapy)
Phase II(702) 835-6300
-------------------------------------------Phase I/II(702) 835-6300-------------------------------------------Phase I(702) 835-6300
BKM120(PI3K inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
second-line endometrial cancer, second-line urogenital cancer(see also brain, breast, lung)
Phase II(888) 669-6682
BMN-673(PARP inhibitor)
BioMarin PharmaceuticalsNovato, CA
hematological malignancies Phase I(415) 506-6700
Medicines in Development for Cancer
Medicines in Development Cancer 2012 117
otHer CanCers
product Name Sponsor Indication Development Status
BP-100-1-01 Bio-PathOgden, Utah
hematological malignancies Phase I(801) 580-2326
CA-18C3 XBiotechAustin, TX
hematological malignancies(see also cancer-related, solid tumors)
Phase I(512) 386-2900
cabozantinib(XL184)(orphan Drug)
ExelixisSouth San Francisco, CA
medullary thyroid cancer(see also breast, kidney, lung, ovarian, prostate)
Phase III(650) 837-7000
catumaxomab Fresenius Biotech North AmericaWaltham, MA
malignant ascites(see also ovarian)
Phase IIwww.fresenius-biotech.com
CDX-1127 Celldex TherapeuticsNeedham, MA
hematological malignancies(see also solid tumors)
Phase I(781) 433-0771
clodronic acid Bayer HealthCare PharmaceuticalsWayne, NJ
bone metastases Phase III(888) 842-2937
CLT-008 Cellerant TherapeuticsSan Carlos, CA
hematological malignancies(see also cancer-related)
Phase I(650) 232-2122
CPI-613(orphan Drug)
Cornerstone PharmaceuticalsCranbury, NJ
hematological malignancies(see also pancreatic)
Phase I(609) 409-7050
dalotuzumab(MK-0646)
MerckWhitehouse Station, NJ
neuroendocrine tumors(see also breast, lung, pancreatic)
Phase II(800) 672-6372
DMUC-5754A GenentechSouth San Francisco, CA
first-line fallopian tube cancer,second-line peritoneal cancer(see also ovarian)
Phase I(800) 626-3553
DN24-02(lapuleucel-T) dendritic cell vaccine
Dendreon Seattle, WA
high-risk, HER2-positive urogenitalcancer (adjuvant therapy)
Phase II(877) 256-4545
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
thyroid cancer(see also brain, skin)--------------------------------------------------endometrial cancer
Phase III(888) 422-4743-------------------------------------------Phase II(888) 422-4743
E7850(irofulven)
EisaiWoodcliff Lake, NJ
thyroid cancer(see also ovarian, prostate)
Phase II(888) 422-4743
efatutazone Daiichi SankyoParsippany, NJ
thyroid cancer(see also colorectal, lung)
Phase I/II(973) 944-2600
Medicines in Development for Cancer
Medicines in Development Cancer 2012118
otHer CanCers
product Name Sponsor Indication Development Status
EGEN-001 EGENHuntsville, AL
fallopian tube cancer, peritoneal cancer(see also colorectal, ovarian)
Phase II(256) 512-0077
elagolix Abbott LaboratoriesAbbott Park, ILNeurocrine BiosciencesSan Diego, CA
uterine leiomyoma Phase II(847) 938-6100(858) 617-7600
ENMD-2076 EntreMedRockville, MD
late-stage cancer(see also multiple myeloma, ovarian)
Phase I(240) 864-2600
Femara®
letrozoleNovartis PharmaceuticalsEast Hanover, NJ
recurrent, metastatic endometrial cancer (combination therapy)
Phase II(888) 669-6682
folate binding protein (E39) vaccine
Galena BiopharmaLake Oswego, OR
endometrial cancer(see also breast, ovarian)
Phase I/II(855) 855-4253
fostamatinib(SYK inhibitor)
AstraZenecaWilmington, DERigel PharmaceuticalsSouth San Francisco, CA
hematological malignancies Phase II(800) 236-9933(650) 624-1100
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
fibroma(see also lung, prostate, skin)
Phase II(888) 669-6682
Inlyta®
axitinibPfizerNew York, NY
thyroid cancer(see also kidney, liver)
Phase II(860) 732-5156
IPI-145 Infinity PharmaceuticalsCambridge, MA
hematological malignancies Phase I(617) 453-1000
Istodax®
romidepsinCelgeneSummit, NJ
hematological malignancies(see also kidney, pancreatic, prostate)
Phase I(908) 673-9000
IXeMpRA® ixabepilone
Bristol-Myers SquibbPrinceton, NJ
endometrial cancer in clinical trials(800) 332-2056
Jakafi™ruxolitinib
Incyte Wilmington, DE
hematological malignancies(see also pancreatic)
Phase II(855) 446-2983
KB004 KaloBios PharmaceuticalsSouth San Francisco, CA
hematological malignancies Phase I(650) 243-3100
Marqibo®
vincristine liposomalTalon TherapeuticsSan Mateo, CA
pediatric cancers(see also leukemia, lymphoma, skin)
Phase I/II(650) 588-6404
Medicines in Development for Cancer
Medicines in Development Cancer 2012 119
otHer CanCers
product Name Sponsor Indication Development Status
MEDI-551(anti-CD19 mAb)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
hematological malignancies Phase I(800) 236-9933(301) 398-0000
MER-101 (zoledronic acid oral)
Merrion PharmaceuticalsWilmington, NC
bone metastases Phase IIwww/merrionpharma.com
Mirena®
levonorgestrel-releasingintrauterine system
Bayer HealthCare PharmaceuticalsWayne, PA
endometrial cancer, endometrial hyperplasia
Phase II(888) 842-2937
MK-0752(notch signaling pathwayinhibitor)
MerckWhitehouse Station, NJ
central nervous system (CNS) cancer in patients ages 3-21(see also breast)
Phase I(800) 672-6372
MK-2206(c-akt inhibitor)
Merck Whitehouse Station, NJ
inoperable/unresectable neuroendocrine tumors(see also breast)
Phase II(800) 672-6372
MLN0128 Millennium PharmaceuticalsCambridge, MA
hematological malignancies(see also solid tumors)
Phase I(800) 390-5663
MLN4924(NEDD8 inhibitor)
Millennium PharmaceuticalsCambridge, MA
hematological malignancies(see aslo solid tumors)
Phase I(800) 390-5663
motesanib AmgenThousand Oaks, CA
thyroid cancer(see also breast, colorectal, lung)
Phase II(800) 772-6436
moxetumomab pasudotox(CAT-8015)
AstraZenecaWilmington, DEMedImmuneGaithersburg, MD
hematological malignancies Phase I(800) 236-9933(301) 398-0000
MSC1936369B EMD SeronoRockland, MA
hematological malignancies Phase I/II(800) 283-8088
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
thyroid cancer(see also breast, colorectal, head/neck, kidney, leukemia, liver, lung, multiple myeloma, ovarian)--------------------------------------------------neuroendocrine tumors
Phase III(888) 842-2937
-------------------------------------------Phase I(888) 842-2937
NiCord®
umbilical cord blood stem cell therapy
Gamida CellJerusalem, Israel
hematological malignancies Phase I/IIwww.gamida-cell.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012120
otHer CanCers
product Name Sponsor Indication Development Status
NTX-010 NeotropixMalvern, PA
neuroendocrine tumors(see also lung)
Phase Iwww.neotropix.com
opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
fallopian tube cancer, peritoneal cancer(see also brain, lung, ovarian, stomach)
Phase III(800) 215-2355
OPR-003 EUSA PharmaLanghorne, PAVaccinexRochester, NY
hematological malignancies Phase I(800) 833-3533(585) 271-2700
OSI-906(IGF-1R/1R tyrosinase kinase inhibitor)
OSI PharmaceuticalsFarmingdale, NY
adrenocortical carcinoma(see also lung, ovarian)
Phase III(631) 962-0600
PEG arginine deiminase (ADI-PEG 20)
Polaris PharmaceuticalsSan Diego, CA
pediatric cancer(see also liver, prostate, skin)
Phase I(858) 452-6688
PF-04691502(PI3K/mTOR inhibitor)
PfizerNew York, NY
endometrial cancer(see also solid tumors)
Phase II(860) 732-5156
PF-05212384(mTOR/PI3K inhibitor)
PfizerNew York, NY
endometrial cancer(see also solid tumors)
Phase II(860) 732-5156
PHA848125 Nerviano Medical ServicesNerviano, Italy
thymoma Phase IIwww.nervianoms.com
phenoxodiol Marshall EdwardsSan Diego, CA
fallopian tube cancer (combination therapy)(see also ovarian, prostate)
Phase I/II(858) 792-6300
PM-00104 PharmaMarMadrid, Spain
endometrial cancer(see also cervical, sarcoma)
Phase IIwww.pharmamar.com
PTC299 PTC TherapeuticsSouth Plainfield, NJ
central nervous system (CNS) cancer in children(see also breast, solid tumors)
Phase II(908) 222-7000
RG7112(MDM2 antagonist)
RocheNutley, NJ
hematological malignancies(see also solid tumors)
Phase I(973) 235-5000
RG7388(MDM2 inhibitor)
RocheNutley, NJ
hematological malignancies(see also solid tumors)
Phase I(973) 235-5000
RG7593(mAb)
RocheNutley, NJ
hematological malignancies Phase I(973) 235-5000
Medicines in Development for Cancer
Medicines in Development Cancer 2012 121
otHer CanCers
product Name Sponsor Indication Development Status
RG7596(antibody drug conjugate)
GenentechSouth San Francisco, CA
hematological malignancies Phase I(800) 626-3553
ridaforolimus ARIAD PharmaceuticalsCambridge, MAMerckWhitehouse Station, NJ
endometrial cancer(see also breast, kidney, lung, prostate, sarcoma)
Phase II(800) 672-6372
rintatolimod Hemispherx BiopharmaPhiladelphia, PA
cancer vaccine adjuvant Phase I/II(215) 988-0080
samarium SM-153 lexidronaminjection
EUSA PharmaLanghorne, PA
bone metastases(see also breast, multiple myeloma, prostate, sarcoma)
Phase III(800) 833-3533
SAR3419(maytansin-loaded anti-CD19 mAb)
Sanofi USBridgewater, NJImmunoGenNeedham, MA
B-cell malignancies Phase II(800) 981-2491(781) 895-0600
SAR245408 (XL147)(oral PI3K inhibitor)
Sanofi USBridgewater, NJExelixis South San Francisco, CA
endometrial cancer(see also breast)
Phase II(800) 981-2491(650) 837-7000
SAR650984(anti-CD38 naked mAb)
Sanofi USBridgewater, NJ
hematological malignancies Phase I(800) 981-2491
SB989 (pracinostat)
S*BIOOakland, CA
hematological malignancies(see also leukemia, solid tumors)
Phase I(650) 730-2860
siltuximab Janssen BiotechHorsham, PA
giant lymph node hyperplasia(see also multiple myeloma, prostate)
Phase II(800) 526-7736
SOM230 (pasireotide)
Novartis PharmaceuticalsEast Hanover, NJ
carcinoid tumors
--------------------------------------------------meningioma, neuroendocrine tumors
Phase III(888) 669-6682-------------------------------------------Phase II(888) 669-6682
sotatercept (ACE-011)
CelgeneSummit, NJ
cancer metastases(see also cancer-related)
Phase II(908) 673-9000
SpRYCeL®
dasatinibBristol-Myers SquibbPrinceton, NJ
pediatric cancer(see also brain, breast, pancreatic, prostate)
in clinical trials(800) 332-2056
Medicines in Development for Cancer
Medicines in Development Cancer 2012122
otHer CanCers
product Name Sponsor Indication Development Status
Stemex®
carlecortemcel-L(orphan Drug)
Gamida CellJerusalem, IsraelTeva North AmericaNorth Wales, PA
hematological malignancies(Fast Track)
Phase III(888) 838-2872
TAK-901(aurora kinase B inhibitor)
Millennium PharmaceuticalsCambridge, MA
hematological malignancies Phase I(800) 390-5663
tarceva®
erlotinibGenentechSouth San Francisco, CAOSI PharmaceuticalsFarmingdale, NY
gynecological cancer (see also brain, breast, head/neck, leukemia, liver, lung)
Phase II(800) 626-3553(631) 962-0600
telapristone Repros TherapeuticsThe Woodlands, TX
uterine leiomyoma Phase I/II(281) 719-3400
terameprocol Erimos PharmaceuticalsHouston, TX
hematological malignancies (intravenous)(see also brain, cervical, head/neck, solid tumors)
Phase I(713) 541-2000
TG02 S*BIOOakland, CATragara PharmaceuticalsSan Diego, CA
hematological malignancies Phase I(650) 235-5539(858) 350-6900
tivantinib (ARQ 197)
ArQuleWoburn, MADaiichi SankyoParsippany, NJ
germ cell and embryonal neoplasms(see also colorectal, kidney, liver, lung, pancreatic, sarcoma)
Phase II(781) 994-0300(973) 944-2600
TKI258(dovitinib)
Novartis PharmaceuticalsEast Hanover, NJ
second-line endometrial cancer, urothelial carcinoma(see also breast, kidney, multiple myeloma, prostate, skin)
Phase II(888) 669-6682
TRC 105(ENG protein inhibitor)
TRACON PharmaceuticalsSan Diego, CA
fallopian tube cancer, peritoneal cancer(see also breast, ovarian, prostate)
Phase II(858) 550-0780
trebananib (AMG386) AmgenThousand Oaks, CA
fallopian tube cancer, peritoneal cancer(see also breast, colorectal, kidney, liver, stomach)
Phase III(800) 772-6436
Medicines in Development for Cancer
Medicines in Development Cancer 2012 123
otHer CanCers
product Name Sponsor Indication Development Status
ulipristal Watson PharmaceuticalsParsippany, NJ
uterine leiomyoma Phase III(800) 900-1644
VB-111 VBL TherapeuticsOr Yehuda, Israel
thyroid cancer(see also brain)
Phase I/IIwww.vblrx.com
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
adenocarcinoma (combination therapy)(see also leukemia, lymphoma, cancer-related)
Phase II(800) 390-5663
volasertib Boehringer Ingelheim PharmaceuticalsRidgefield, CT
urogenital cancer Phase II(800) 243-0127
Votrient™pazopanib
GlaxoSmithKlineRsch. Triangle Park, NC
fallopian tube cancer, peritoneal cancer(see also kidney, ovarian)
Phase III(888) 825-5249
Xgeva™denosumab
AmgenThousand Oaks, CA
prevention of bone metastases in men with castrate-resistant prostate cancer(see also cancer-related, multiple myeloma)--------------------------------------------------prevention of bone metastases in women with early-stage breast cancer--------------------------------------------------giant cell tumor of bone
application submitted(800) 772-6436
-------------------------------------------Phase III(800) 772-6436
-------------------------------------------Phase II(800) 772-6436
Zelboraf®vemurafenib
GenentechSouth San Francisco, CAPlexxikonBerkeley, CA
inoperable/unresectable thyroid cancer(see also brain, colorectal)
Phase II(800) 626-3553(510) 647-4000
Zolinza®
vorinostatMerckWhitehouse Station, NJ
gynecological cancer, peritoneal cancer(see also breast, leukemia, lung, lymphoma, multiple myeloma)
Phase I/II(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012124
unspeCified CanCer
product Name Sponsor Indication Development Status
ABC294640 Apogee BiotechnologyHummelstown, PA
late-stage disease Phase I(843) 792-3420
ABI-011(nab®-5404)
CelgeneSummit, NJ
Phase I(908) 673-9000
AFX-9901 Afecta PharmaceuticalsIrvine, CA
in clinical trials(949) 253-4688
AGS-6MF AgensysSanta Monica, CAAstellas Pharma USDeerfield, IL
Phase I(800) 695-4321
AGS-16M8F AgensysSanta Monica, CAAstellas Pharma USDeerfield, IL
Phase I(800) 695-4321
ALT-836 Altor BioScienceMiramar, FL
Phase I/II(954) 443-8600
anti-KIR(BMS-986015)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
anti-LAG3(BMS-986016)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
ANX-514(docetaxel for injectable emulsion)
ADVENTRX PharmaceuticalsSan Diego, CA
Phase I(858) 552-0866
ARRY-300(MEK inhibitor)
Array BioPharmaBoulder, CONovartis PharmaceuticalsEast Hanover, NJ
Phase I(877) 633-2436(888) 669-6682
ARRY-382(c-fms antagonist)
Array BioPharmaBoulder, COCelgeneSummit, NJ
metastatic cancer Phase I(877) 633-2436(908) 673-9000
AVL-292(Btk inhibitor)
CelgeneSummit, NJ
(see also leukemia, lymphoma) Phase I(908) 673-9000
B7-2/GM-CSFcancer gene therapy vaccine
NuVax TherapeuticsTustin, CA
Phase I(714) 505-4461
BAY 94-9392(PET imaging)
Bayer HealthCare PharmaceuticalsWayne, NJ
cancer (diagnosis) Phase I(888) 842-2937
Medicines in Development for Cancer
Medicines in Development Cancer 2012 125
unspeCified CanCer
product Name Sponsor Indication Development Status
cancer vaccine Immunitor USAVancouver, Canada
Phase I/IIwww.immunitor.com
cancer vaccine(fibrocyte vaccine)
Cytokine PharmaSciencesKing of Prussia, PA
Phase I(610) 687-1776
carboxyamidotriazole orotate(CTO)
Tactical TherapeuticsNew York, NY
Phase I(212) 651-9653
CBLB502 Cleveland BioLabsBuffalo, NY
Phase I(716) 849-6810
CDK 4/6 inhibitor(LY2835219)
Eli LillyIndianapolis, IN
Phase II(800) 545-5979
CDX-301(Fms-like tyrosine kinase 3 ligand)
Celldex TherapeuticsNeedham, MA
Phase I(781) 433-0771
cell therapy Cell MedicaLondon, United KingdomCenter for Cell and Gene TherapyHouston, TX
Phase IIwww.cellmedica.co.uk
CEN-109 Centella TherapeuticsPalo Alto, CA
cancer (diagnosis) Phase IIwww.centellatx.com
Chk1 inhibitor Eli LillyIndianapolis, IN
Phase I(800) 545-5979
c-Met inhibitor Eli LillyIndianapolis, IN
Phase I(800) 545-5979
c-Met mAb(LY2875358)
Eli LillyIndianapolis, IN
Phase II(800) 545-5979
CSF-1R mAb(IMC-CS4)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
Phase I(800) 545-5979
curmucin Signpath PharmaQuakertown, PA
Phase I(267) 772-0107
CXCR4 peptide inhibitor(LY2510924)
Eli LillyIndianapolis, IN
Phase II(800) 545-5979
Medicines in Development for Cancer
Medicines in Development Cancer 2012126
unspeCified CanCer
product Name Sponsor Indication Development Status
cytotropic heterogeneous molecular lipids(CHML)
Glory PharmaceuticalsVienna, VA
Phase I(703) 204-1703
DM-CHOC-PEN Dekk-TecNew Orleans, LA
Phase I(504) 583-6135
EC0225 EndocyteWest Lafayette, IN
Phase Iwww.endocyte.com
EGFR/IGFR tandem adnectin(BMS-964210)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
eIF-4E ASO(LY2275796)
Eli LillyIndianapolis, IN
Phase II(800) 545-5979
fenretinide intravenous CerRxLubbock, TX
Phase Iwww.cerrx.com
FGF receptor inhibitor Eli LillyIndianapolis, IN
Phase I(800) 545-5979
fluorapacin ACEA BiosciencesSan Diego, CA
Phase I(866) 308-2232
gemcitabine prodrug Eli LillyIndianapolis, IN
Phase I(800) 545-5979
GI-6207(cancer vaccine)
GlobeImmuneLouisville, CO
Phase I(303) 625-2700
GSK3 inhibitor(LY2090314)
Eli LillyIndianapolis, IN
Phase II(800) 545-5979
HBI-8000 HUYA Bioscience InternationalSan Diego, CAQuintilesRsch. Triangle Park, NC
Phase Iwww.huyabio.com
hedgehog antagonist(LY2940680)
Eli LillyIndianapolis, IN
Phase II(800) 545-5979
hTERT plasmid DNA cancer vaccine
MerckWhitehouse Station, NJVicalSan Diego, CA
Phase I(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 127
unspeCified CanCer
product Name Sponsor Indication Development Status
IL-21 (BMS-982470)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
In-111-DACimaging agent
Mayo ClinicRochester, MNNaviscanSan Diego, CA
cancer (diagnosis) Phase Iwww.mayoclinic.org
ISIS-STAT3Rx Isis PharmaceuticalsCarlsbad, CA
Phase I(800) 679-4747
JAK2 inhibitor Eli LillyIndianapolis, IN
Phase I(800) 545-5979
masoprocol TriAct TherapeuticsSan Francisco, CA
Phase II(415) 602-7497
MK-8033(c-Met/RON protein inhibitor)
MerckWhitehouse Station, NJ
Phase I(800) 672-6372
new molecular entity Eli LillyIndianapolis, IN
Phase I(800) 545-5979
notch inhibitor Eli LillyIndianapolis, IN
Phase I(800) 545-5979
notch inhibitor (BMS-906024)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
OPB-31121 Otsuka America PharmaceuticalRockville, MD
Phase I(800) 562-3974
p38 MAP inhibitor (1) Eli LillyIndianapolis, IN
Phase I(800) 545-5979
p38 MAP inhibitor (2) Eli LillyIndianapolis, IN
Phase I(800) 545-5979
p70/AKT inhibitor Eli LillyIndianapolis, IN
Phase I(800) 545-5979
PB-357 Puma BiotechnologyLos Angeles, CA
Phase I(424) 248-6500
Medicines in Development for Cancer
Medicines in Development Cancer 2012128
unspeCified CanCer
product Name Sponsor Indication Development Status
PBI-05204 Phoenix BiotechnologySan Antonio, TX
Phase I(210) 828-4373
PD-0325901 PfizerNew York, NY
Phase I(860) 732-5156
PD-0332991 PfizerNew York, NY
Phase II(860) 732-5156
PF-03084014(gamma-secretase inhibitor)
PfizerNew York, NY
Phase I(860) 732-5156
PF-04449913(sonic hedgehog pathway inhibitor)
PfizerNew York, NY
Phase I(860) 732-5156
PF-05082566(CD137 antigen agonist mAb)
PfizerNew York, NY
Phase I(860) 732-5156
proleukin®
aldesleukin(subcutaneous)
Prometheus LaboratoriesSan Diego, CA
Phase II(888) 892-8391
PRT6207(Syk-specific inhibitor)
Biogen IdecCambridge, MAPortola PharmaceuticalsSouth San Francisco, CA
Phase I(781) 464-2000(650) 246-7000
RON mAb(IMC-RON8)
Eli LillyIndianapolis, INImClone SystemsBridgewater, NJ
Phase I(800) 545-5979
SB1578(JAK2 inhibitor)
S*BIOOakland, CA
Phase I(650) 235-5539
SCH-900776 MerckWhitehouse Station, NJ
Phase II(800) 672-6372
SMO antagonist (BMS-833923)
Bristol-Myers SquibbPrinceton, NJ
Phase I(800) 332-2056
SR13668 SRI InternationalMenlo Park, CA
cancer (prevention) Phase 0(650) 859-2000
V930/V932(plasmid DNA vaccine)
MerckWhitehouse Station, NJVicalSan Diego, CA
Phase I(800) 672-6372(858) 646-1100
Medicines in Development for Cancer
Medicines in Development Cancer 2012 129
unspeCified CanCer
product Name Sponsor Indication Development Status
VEGFR3 mAb(IMC-3C5)
Eli LillyIndianapolis, INImCloneBridgewater, NJ
Phase I(800) 545-5979
XmAb® anti-cancer mAb
Boehringer IngelheimPharmaceuticalsRidgefield, CTXencorMonrovia, CA
Phase I(800) 243-0127(626) 305-5900
Medicines in Development for Cancer
The content of this report has been obtained through industry sources and the Adis “R&D Insight” database based on the latest information. Report current as of May 16, 2012. The information may not be comprehensive. For more specific information about a particular product, contact the indi-vidual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA’s web site.
A publication of phRMA’s Communications & public Affairs Department. (202) 835-3460
www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info
Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.
Copyright © 2012 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.
Pharmaceutical Research and Manufacturers of America • 950 F Street, NW, Washington, DC 20004
Medicines in Development Cancer 2012130
Glossary
actinic keratoses—Roughness and thicken-ing of the skin caused by overexposure to the sun’s ultraviolet rays. It can degenerate into a skin cancer called squamous cell carcinoma.
adenocarcinoma—Malignant tumor derived from a gland or glandular tissue.
adjunctive treatment—An auxiliary treatment that is secondary to the main treatment.
adjuvant—A substance or drug that aids another substance in its action.
allogeneic—Refers to having cell types that are distinct and cause reactions in the immune system.
application submitted—An application for marketing has been submitted by the company to the Food and Drug Administration (FDA).
ascites—Excess fluid in the space between the tissues lining the abdomen and abdominal organs (the peritoneal cavity).
basal cell cancer—Cancer of the lower layers of the skin.
B-cell—A class of white blood cells important to the body’s immune system.
biliary—Relating to bile.
carcinoma—A malignant tumor that arises from epithelial tissues, such as skin.
cervical—Relating to the neck of the uterus.
chemoprotection—A therapeutic technique in which bone marrow cells are removed from an individual with cancer and are genetically modi-fied to withstand higher doses of chemotherapy before being returned to the donor.
cholangiocarcinoma—A malignancy of the biliary duct system that may originate in the liver and extrahepatic bile ducts. More than 90 percent are adenocarcinomas, and the remain-der are squamous cell tumors. Cholangiocarci-nomas tend to grow slowly and to infiltrate the walls of the ducts. Each year, approximately 2,500 cases occur, and the average incidence is 1 case per 100,000 people per year.
cutaneous—Pertaining to the skin.
dysplasia—Abnormal tissue development.
gastric—Of or relating to the stomach.
GISt—Gastrointestinal (GI) stromal cancer is an uncommon tumor of the GI tract. Not all GISTs are cancerous; some are benign. Although these cancers can arise anywhere in the GI tract, they occur most often in the stomach (60% to 70%) and less commonly in the small intestine (20% to 30%). The rest are found in the esophagus, large intestine, rectum, and anus. About 80% of people diag-nosed with GIST are older than 50. It is slightly more common in men. Blacks are more likely to develop GISTs than whites.
glioblastoma—A fast growing and highly malignant type of brain tumor arising from glial (supporting) cells within the brain. There are about five to 10 new cases per million popula-tion per year in the United States.
glioma—A type of brain tumor arising from the supporting glial cells within the brain. Gliomas make up about 60 percent of all primary brain tumors and are frequently malignant.
graft-versus-host disease (GVHD)—A complication in bone marrow transplants where immune system cells attack the transplant recipient’s tissues.
head and neck cancer—The term given to a variety of malignant tumors that develop in the mouth, throat, paranasal sinuses, nasal cavity, larynx, and salivary glands. Many authorities also include skin tumors of the face and neck and tumors of the cervical lymph nodes. There are more than half a million survivors of oral, head, and neck cancer living in the United States today.
hematological malignancies—Cancers of the blood or blood-forming tissues, such as leuke-mia, Hodgkin’s and non-Hodgkin’s lympho-mas, AIDS-related malignancies, multiple myeloma, myelodysplasia and myeloprolifera-tive disorders.
hepatocellular cancer/carcinoma—A cancer that begins in the liver cells.
hyperuricemia—An abnormally high uric acid level in the blood.
imaging agent—A substance used to enhance x-ray images of organs and spaces in the body.
intraepithelial neoplasia, anal (AIN) & cervi-cal (CIN)—AIN is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus. What is known of its natural history resembles that of cervical intraepithelial neoplasia. Dysplasia and cervi-cal intraepithelial neoplasia (CIN) are different terms or names for the same condition—it is a precursor to cervical cancer. CIN may be mild, moderate or severe.
Kaposi’s sarcoma—A rare, malignant skin tumor that occurs in some AIDS patients. It can be accompanied by fever, enlarged lymph nodes and gastrointestinal problems.
Leiomyoma—A benign neoplasm derived from smooth muscle.
leukemia—A form of cancer in which abnor-mally growing white blood cells are scattered throughout the body and bone marrow. They can take over the marrow and prevent it from making enough normal blood cells (white, red and platelets), leaving the patient highly susceptible to serious infections, anemia and bleeding episodes. The cells can also spill into the blood, infiltrating and interfering with the function of other organs. The four main types of leukemia are: acute lympho blastic leuke-mia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The acute types have a rapid onset, and overwhelming infection or blood loss can cause death. The chronic forms progress much more slowly.
lung cancer—The leading cause of cancer deaths in both men and women. There are several types of lung cancer, the most common being squamous cell carcinoma, small (oat) cell carcinoma, adenocarcinoma and large cell
Medicines in Development Cancer 2012 131
Glossary
carcinoma. Each has a different growth pattern and response to treatment. The squamous cell, small cell and large cell types are all strongly associated with tobacco abuse.
lymphoma—Cancers in which the cells of lym-phoid tissue, found mainly in the lymph nodes and spleen, multiply unchecked. Lymphomas fall into two categories: Hodgkin disease, char-acterized by a particular kind of abnormal cell, and non-Hodgkin lymphomas, which vary in their malignancy according to the nature and activity of the abnormal cells. Mantle cell lym-phoma is a type of non-Hodgkin lymphoma.
macroglobulinemia—A disorder in which plasma cells produce an excessive quantity of macroglobulins (large antibodies) that ac-cumulate in the blood. It results from a group of abnormal, cancerous lymphocytes and plasma cells. Men are affected more often than women, and the average age at onset is 65.
mastocytosis—A condition characterized by infiltration of mast cells into the tissues of the body. Mast cells are connective tissue cells which release chemicals including histamine that are very irritating and cause itching, swell-ing, and fluid leakage from cells.
medullary—Relating to the medulla (any soft marrow-like structure, especially the innermost part) or marrow.
melanoma—A cancer made up of pigmented (usually brown-colored) skin cells anywhere in the body.
mesothelioma—A tumor of the lining of the lung and chest cavity (the pleura).
metastases/metastatic—Areas of secondary cancer that have spread from the primary or original cancer site.
mucositis—The swelling, irritation, and ulcer-ation of the mucosal cells that line the digestive tract. Mucositis can occur anywhere along the digestive tract from the mouth to the anus. It can be a very troublesome and painful side effect of chemotherapy.
multiple myeloma—A malignant condition of middle to old age, characterized by the uncon-trolled proliferation and disordered function of plasma cells in the bone marrow. The condi-tion, which makes the patient particularly prone to infection, is rare, with about three new cases annually per 100,000 population.
myeloablation—A severe form of myelosup-pression, a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets. It is a side effect of some cancer treatments.
myelodysplastic syndromes (MDS)—Blood disorders that ultimately are fatal. Patients usually succumb to infections or bleeding. The term “preleukemia” has been used to describe these disorders.
neoadjuvant therapy—Chemotherapy, radia-tion therapy, or hormone therapy given before the primary or main treatment. Neo-adjuvant therapy, like chemotherapy and radiation therapy, is often given before surgery to reduce the size of a tumor or to make surgery less complicated.
neuroblastoma—A tumor of the adrenal glands or sympathetic nervous system (the part of the nervous system responsible for certain automatic body functions, such as the control of heart rate). Neuroblastomas are the most common extracranial (outside the skull) solid tumors of childhood.
osteosarcoma—Cancer of the bone that oc-curs predominantly in adolescents and young adults. It accounts for 5 percent of cancer in children.
peritoneal—Relating to the peritoneum, the membrane that lines the abdominal cavity and covers most of the abdominal organs.
phase 0—First-in-human trials conducted in accordance with FDA’s 2006 guidance on exploratory Investigational New Drug (IND) studies designed to speed up development of promising drugs by establishing very early on whether the agent behaves in human subjects as was anticipated from preclinical studies.
phase I—Safety testing and pharmacologi-cal profiling of new drugs in small numbers of humans.
phase II—Effectiveness testing and identifica-tion of side effects of new drugs in humans.
phase III—Extensive clinical trials in humans to verify effectiveness and monitor adverse reactions of new drugs.
prolactinoma—A noncancerous pituitary tumor that produces a hormone called prolac-tin, which results in too much prolactin in the blood.
refractory—Resistant to treatment or cure.
sarcoma—A malignant tumor that arises from deep body tissues, such as muscle, bone or fibrous tissue.
t-cell—One of two main classes of white blood cells called lymphocytes, which are important to the body’s disease-fighting immune system.
thrombocytopenia—A reduction in the number of platelet cells in the blood, which causes a tendency to bleed, especially from the smaller blood vessels.
thymoma—Although rare, thymomas are the most common tumor of the thymus, a small organ located in the upper chest just below the neck that produces certain types of white blood cells (lymphocytes) before birth and during childhood. Thymomas arise from thymic epithelial cells, which make up the covering of the thymus. Up to 40 percent of thymomas are invasive. They affect men and women equally and are usually diagnosed between the ages of 40 and 60. Thymomas are uncommon in children.
unresectable—Unable to be removed (re-sected) by surgery.
Medicines in Development Cancer 2012132
Selected Facts about Cancer in the United States
• Cancer is the second leading cause of death by disease—nearly 1 of every 4 deaths—in the United States, exceeded only by heart disease.
• Men have slightly less than a 1 in 2 lifetime risk of developing cancer; for women, the risk is a little more than 1 in 3. About 77 percent of all cancers are diagnosed in people ages 55 and older.
• This year alone, more than 1.6 million new cancer cases are expected to be diagnosed, and an estimated 577,190 people are expected to die of cancer. That’s more than 1,500 people a day.
• Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight or obesity, physical inactiv-ity, and poor nutrition, and thus could be prevented.
• The National Cancer Institute estimates that nearly 12 million Americans with a history of cancer were alive in January 2008. The 5-year relative survival rate for all cancers diagnosed between 2001 and 2007 is 67 percent, up from 49 percent in the mid-70s.
• Studies have shown that pain occurs in 30 percent of all cancer patients, regardless of the stage of the disease, and 90 percent of patients with advanced cancer experience severe pain. Half of patients may be undertreated for cancer pain.2
• The most common cause of cancer-related pain is from metastases to the bone. Up to 80 percent of cancer patients with bone metastases experience pain. The second most common cause of cancer pain is related to tumors infiltrating the nerve and hollow viscus. Tumors near neural structures may cause the most severe pain. The third most common cause of pain associated with cancer result from chemotherapy, radiation, or surgery.2
• Breakthrough pain—pain that occurs even when taking regular pain medication—is common in cancer patients. Breakthrough cancer pain occurs in 50 percent to 90 percent of oncology inpatient settings, 89 percent of home care and inpatient hospice settings, and 35 percent of community-based oncology practices. People with breakthrough pain have a significantly higher rate of hospitalization than those without break-through pain (36.9 percent vs. 22.5 percent, respectively) and dramatically higher estimated annual costs of care ($1.7 million compared with $192,000).3
• The National Institutes of Health estimates overall costs for cancer in 2007 at $226.8 billion: $103.8 billion for direct medical costs (total of all health expenditures) and $123 billion for indirect mortality costs (cost of lost productivity due to premature death).
overview1
pain
Costs1
Medicines in Development Cancer 2012 133
New Cancer Cases/Deaths1
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
All Sites .................................................................................. 1,638,910 ..................................................................................... 577,190 Male ............................................................................. 848,170 ..................................................................................... 301,820 Female ......................................................................... 790,740 ..................................................................................... 275,370
Acute Lymphocytic Leukemia .......................................................... 6,050 ......................................................................................... 1,440 Male ................................................................................. 3,450 ............................................................................................ 820 Female ............................................................................. 2,600 ............................................................................................ 620
Acute Myeloid Leukemia ............................................................... 13,780 ....................................................................................... 10,200 Male ................................................................................. 7,350 ......................................................................................... 5,790 Female ............................................................................. 6,430 ......................................................................................... 4,410
Bladder Cancer .............................................................................. 73,510 ....................................................................................... 14,880 Male ............................................................................... 55,600 ....................................................................................... 10,510 Female ........................................................................... 17,910 ......................................................................................... 4,370
Bone Cancer (and joints) ................................................................. 2,890 ......................................................................................... 1,410 Male ................................................................................. 1,600 ............................................................................................ 790 Female ............................................................................. 1,290 ............................................................................................ 620
Brain Cancer (and other nervous system) ..................................... 22,910 ....................................................................................... 13,700 Male ............................................................................... 12,630 ......................................................................................... 7,720 Female ........................................................................... 10,280 ......................................................................................... 5,980
Breast Cancer .............................................................................. 229,060 ....................................................................................... 39,920 Male ................................................................................. 2,190 ............................................................................................ 410 Female ......................................................................... 226,870 ....................................................................................... 39,510
Cervical and Uterine Cancers ........................................................ 59,300 ....................................................................................... 12,230 Male .......................................................................................— ...............................................................................................— Female ........................................................................... 59,300 ....................................................................................... 12,230
Chronic Lymphocytic Leukemia ..................................................... 16,060 ......................................................................................... 4,580 Male ................................................................................. 9,490 ......................................................................................... 2,730 Female ............................................................................. 6,570 ......................................................................................... 1,850
Chronic Myeloid Leukemia .............................................................. 5,430 ............................................................................................ 610 Male ................................................................................. 3,210 ............................................................................................ 370 Female ............................................................................. 2,220 ............................................................................................ 240
Colorectal Cancer ........................................................................ 143,460 ....................................................................................... 51,690 Male ............................................................................... 73,420 ....................................................................................... 26,470 Female ........................................................................... 70,040 ....................................................................................... 25,220
Selected Facts about Cancer in the United States
Medicines in Development Cancer 2012134
Selected Facts about Cancer in the United States
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
Esophageal Cancer ....................................................................... 17,460 ....................................................................................... 15,070 Male ............................................................................... 13,950 ....................................................................................... 12,040 Female ............................................................................. 3,510 ......................................................................................... 3,030
Kidney Cancer (and renal pelvis) .................................................. 64,770 ....................................................................................... 13,570 Male ............................................................................... 40,250 ......................................................................................... 8,650 Female ........................................................................... 24,520 ......................................................................................... 4,920
Leukemia (all types) ...................................................................... 47,150 ....................................................................................... 23,540 Male ............................................................................... 26,830 ....................................................................................... 13,500 Female ........................................................................... 20,320 ....................................................................................... 10,040
Liver Cancer .................................................................................. 28,720 ....................................................................................... 20,550 Male ............................................................................... 21,370 ....................................................................................... 13,980 Female ............................................................................. 7,350 ......................................................................................... 6,570
Lung Cancer (and bronchus) ....................................................... 226,160 ..................................................................................... 160,340 Male ..............................................................................116,470 ....................................................................................... 87,750 Female ......................................................................... 109,690 ....................................................................................... 72,590
Lymphoma (all types) .................................................................... 79,190 ....................................................................................... 20,130 Male ............................................................................... 43,120 ....................................................................................... 10,990 Female ........................................................................... 36,070 ......................................................................................... 9,140
Lymphoma (non-Hodgkin’s) ........................................................... 70,130 ....................................................................................... 18,940 Male ............................................................................... 38,160 ....................................................................................... 10,320 Female ........................................................................... 31,970 ......................................................................................... 8,620
Melanoma-Skin Cancer ................................................................. 76,250 ......................................................................................... 9,180 Male ............................................................................... 44,250 ......................................................................................... 6,060 Female ........................................................................... 32,000 ......................................................................................... 3,120
Multiple Myeloma ........................................................................... 21,700 ....................................................................................... 10,710 Male ............................................................................... 12,190 ......................................................................................... 6,020 Female ............................................................................. 9,510 ......................................................................................... 4,690
Ovarian Cancer ............................................................................. 22,280 ....................................................................................... 15,500 Male .......................................................................................— ...............................................................................................— Female ........................................................................... 22,280 ....................................................................................... 15,500
Pancreatic Cancer ......................................................................... 43,920 ....................................................................................... 37,390 Male ............................................................................... 22,090 ....................................................................................... 18,850 Female ........................................................................... 21,830 ....................................................................................... 18,540
New Cancer Cases/Deaths1 continued
Medicines in Development Cancer 2012 135
Selected Facts about Cancer in the United States
New Cancer Cases/Deaths1 continued
Sources:
1. Cancer Facts & Figures 2012, American Cancer Society (www.cancer.org)
2. Remedy Health Media, LLC (www.healthcommunities.com)
3. American Pain Foundation (www.painfoundation.org)
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
Prostate Cancer ........................................................................... 241,740 ....................................................................................... 28,170 Male ............................................................................. 241,740 ....................................................................................... 28,170 Female ...................................................................................— ...............................................................................................—
Stomach Cancer ............................................................................ 21,320 ....................................................................................... 10,540 Male ............................................................................... 13,020 ......................................................................................... 6,190 Female ............................................................................. 8,300 ......................................................................................... 4,350
the U.S. system of new drug approvals is perhaps the most rigorous in the world.It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.Once a new compound has been identified in the laboratory, medicines are usually devel-oped as follows:preclinical testing. A pharmaceutical com-pany conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the com-pound is evaluated for safety.Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug
Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.Clinical trials, phase I. These tests usually involve about 20 to 100 healthy volunteers. The tests study a drug’s safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabo-lized, and excreted as well as the duration of its action.Clinical trials, phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug’s effectiveness and determine the early side effect profile.Clinical trials, phase III. This phase usually involves 1,000 to 5,000 patients in clinics and
hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events. New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects. Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated $49.5 billion in research and development in 2011.
The Drug Discovery, Development and Approval Process
Developing a new medicine takes an average of 10-15 years; For every 5,000-10,000 compounds in the pipeline, only 1 is approved.
The Drug Development and Approval Process
top related